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 ABSTRACT  Migraine has been defined as a common disabling primary headache disorder by the International Headache Society (IHS).  The third edition of the International Classification of Headache Disorders (ICHD-III) drafted by the IHS classifies migraine into two major groups, migraine without aura (MO) and migraine with aura (MA).  MO is the most common form with headache attacks lasting between 4-72 hours.  MA sufferers, in addition, often experience aural symptoms preceding the headache phase of the migraine episode.    Among the most relevant epidemiological observations is the significant sexual dimorphism in the prevalence of migraine in men and women after puberty (3-4 times higher in women). The higher rates in women are thought to be hormonally-driven and numerous epidemiological and clinical studies support this theory. Additionally, genetic association studies in sex hormone receptor pathways and metabolism have provided some evidence supporting a hormonal role in migraine etiology, and mainly two genes, Estrogen Receptor 1 (ESR1) and Progesterone Receptor (PGR) have been investigated.    Other genetic variants have also been identified from studies undertaken in FHM (familial hemiplegic migraine) a monogenic form of MA.  These genes appear to be highly significant with large to moderate effects. Additionally, an increasing number of significantly associated genetic variants with the most common subtypes of migraine have been identified via genome-wide association studies (GWAS).  However, the replication of these variants in other populations has been challenging and the genetic role attributable to these variants remains controversial.  This research was aimed at identifying genes involved in migraine.  The study initially focused on the role of hormone related genes in the aetiology of migraine and subsequently aimed to 
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identify of novel genetic variants by investigating gene profiles, activated pathways and gene clusters in migraine patients.   The first aim of this research was to investigate the hormonal receptor genes, ESR1 and PGR in a large pedigree from Norfolk Island, a genetic isolated population located in the South Pacific Ocean.  143 SNPs in the ESR1 gene and 43 SNPs in the PGR gene were tested for migraine association in a sample of 285 individuals (76 cases and 209 controls).  SNPs were genotyped on the Illumina infinium High density (HD) Human 610 Quad DNA analysis BeadChip as part of a genome wide association study (GWAS).  The statistical analysis, performed using the GenABEL library in R, showed that 10 markers in the ESR1 gene had a significant association with migraine (p<0.05).  Among these markers, seven (rs9383939, rs851971, rs1048491, rs851967, rs851967, rs851988, rs9383938) are located upstream of the gene close to a promoter associated sequence.  This suggests a regulatory role on the expression of the ESR1 gene.  Interestingly, three associated SNPs (rs2813554, rs2813544 and rs7767143) are located in an intergenic region between the ESR1 and SYNE1 genes.  In summary, in this section we showed that association analysis in the ESR1 gene provided strong evidence to support a hormone mediated susceptibility model of migraine.  Additionally, results suggested that SYNE1 gene might also be playing a role in migraine susceptibility as some of the associated SNPs are located in an intergenic region between ESR1 and SYNE1.   To follow up the previous association of ESR1 and SYNE1 in the Norfolk cohort we performed an association study of these genes and other hormonal related genes in a menstrual migraine (MM) population consisting of 437 individuals (282 cases and 155 controls).  The MM diagnostic corresponds to individuals suffering migraine attacks during the menstrual cycle. There are two types of MM, to know, Menstrual Related Migraine (MRM) and Pure Menstrual Migraine (PMM).  In our population 68 cases correspond to a PMM diagnostic while 214 females suffer MRM.   34 SNPs, distributed in 14 genes (ESR1, FSHR, CGPR, RAMP1, LTA, TNF, SYNE1, 
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KCNK18, ESR2, CYP19A1, NRIP1, MIR890, MIR891A, MIR892A) were genotyped.  PCR-RFLP, TaqMan, Standard PCR and the Sequenom iPlex system were the methods selected for the genotyping.  The association was tested using a logistic regression analysis.  Results showed that SNPs rs3093664 (TNF) and rs9371601 (SYNE1) were associated with migraine in the total population (P-value=0.007 and P-value=0.009, respectively).  The strength of the association increased in the MRM sub-sample with respect to the total sample when the same SNPs, rs3093664 (P-value=0.007) and rs9371601 (P-value=0.003) were tested.  These findings provide additional validation of the role of SYNE1 in the development of migraine and supports the findings obtained in the Norfolk Island. This study also implicates the SYNE1 and TNF genes in susceptibility to menstrual migraine, more specifically MRM.    Another central aim of this research was to investigate the levels of expression of hormonally related genes.  For this study, expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) in blood tissue from a sub-sample of 335 individuals (79 cases and 256 controls) from the Norfolk Island population.  Statistical significance of differentially expressed genes between cases and controls was determined by both a standard t-test and a logistic regression analysis corrected by sex, age and kinship using the R software.  23323 probes were included in the analysis aimed at identifying significantly (P-value 1 x 10-7) expressed hormonal and/or hormonal related transcripts.  However, results indicated that there is no significant differential expression patterns in patients with migraine compared to controls (FDR>0.91).  These findings might also be an indication of subtle changes in levels of gene expression that do not reach significance when using traditional statistical methods.   A second gene expression analysis was also carried out in blood samples taken from a subset of 74 patients (41 cases and 33 controls) from the MM cohort.   All individuals from this sub-sample donated blood samples collected in Paxgene tubes in both the follicular (+1 - +3 menstrual cycle day) and luteal phase (-1 - -3 menstrual cycle day).  Gene expression analysis 
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was undertaken for the PGR, ESR1, SYNE1 and TNF genes using SYBR Green PCR Master Mix 1X (Life Technologies, Australia).  After comparing levels of gene expression using a simple logistic regression model, no significant difference in transcription levels between cases and controls and across the sub-populations in the studied genes was observed.  However, after completing a Pearson’s correlation analysis between the levels of expression of these transcripts, significant positive correlations in the follicular phase between the expression of TNF and SYNE1 (Rho=0.37, P-value=0.005), ESR1 and PGR (Rho=0.43, P-value=0.006) and ESR1 and SYNE1 (Rho=0.41, P-value=0.002) were found.  In contrast, in the luteal phase, we found a correlation between SYNE1 and PGR (Rho=0. 44, P-value= 0.006) and TNF and SYNE1 (Rho= 0.34, P-value=0. 015).  More interestingly, we detected significant differences in the correlations between gene expression in cases and controls.  This suggests that although there are no significant changes in the expression of genes that may influence migraine in PMM and MRM cases compared to controls, these genes interact in a different fashion both in the luteal and follicular stages of the menstrual cycle and in cases compared to controls.  These interactions have not previously been identified. They may serve as a reference to understand the relationship that hormones and cytokines might have in events that lead to migraine attacks, particularly in the transition from the luteal to follicular phase.    For the second part of this thesis we concentrated not only on hormonal genes but also on identifying other novel variants associated with migraine.  It is believed that the additive effect of multiple genes carrying modest effect is the key to the understanding of complex diseases.  In light of this, we also tested a migraine polygenic model where ranked groups of associated markers selected from previous GWASs were analysed by constructing, for each subject in the Norfolk Island population, a polygenic score consisting of the weighted sum of migraine-associated alleles.  Subsequently, using a logistic regression model we tested for association between the score and migraine status to determine whether associated markers reside within those contributing to the score. We also carried out an eQTL analysis in order to identify the 
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possible functional role of these variants in the proposed polygenic model.  A significant association (P-value =0.018) was found between the polygenic score and the migraine status. The eQTLs detected in this study include the rs1712517-USMG5, rs11172113-STAT6, 
rs11906854-CPNE1, rs3094117-HLA-C among 24 others, which according to the gene ontology analysis have mitochondrial, immunological and hormonal roles.  These functional categories have also been widely implicated in migraine pathophysiology.  These, our molecular genetic data strongly support a polygenic basis in migraine that involves common SNPs, some of them, with possible regulatory roles on the expression of mitochondrial, immunological as well as hormonal genes.   Using a GWAS data set, as outlined above, we have proven that the power of detecting association with migraine is affected by an add-on effect of multiple genes participating in the development of the disease.   However, the genotypic information from a GWAS gives us limited information about gene interactions taking place in the system, instead it considers only genes with possible genetic “errors”.  However, we know that proteins work in an orchestrated manner building a complex network of interactions between them, to an extent that the malfunctioning of one single element in the network will cause the dysregulation of the entire network.  These networks are called pathways or clusters, and the elements inside them are defined as highly correlated genes.  To investigate migraine related pathways, we used the levels of gene expression evaluated in a HumanHT-12 v.4 Expression BeadChip Kit (Illumina) in blood tissue a sub-sample of 335 individuals (79 cases and 256 controls) from the Norfolk Island population,  to explore groups of correlated genes that can be associated with migraine performing a pathway analysis, a supervised and an unsupervised clustering analysis. The detection of clubbed genes associated with migraine could lead to the identification of biomarkers to follow up the metabolic and immunological changes that occur as a consequence of suffering migraine, and may open the door to a “predictive”, “preventive”, “personalized”, and “participatory” (P4) medicine.   
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 We initially performed a pathway analysis using the Gene Set Enrichment Analysis software that suggests that cardiac muscle contraction, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease gene pathways are down-regulated in individuals suffering from migraine. Subsequently, we built a panel of 49 significantly associated (P-value<0.05) genes with the highest enrichment scores (ES) in the associated pathways. We found that genes in this panel were mostly represented by mitochondrial genes involved in the respiratory chain and Na+ and K+ pumps subunits genes.  Also, 7997 SNPs distributed in a range of 200kb either side of each gene in this panel were tested for association with migraine using the GenABEL package in R. Highly significant association was detected in SNPs rs6872379 (P-value < 0.001) in the NDUFS4 gene,  and in SNP rs12218075 (P-value < 0.001) in the NDUFB8 gene.  These genes are involved in mitochondria functioning.  To detect possible Expression Quantitative Trait Loci (eQTLs) involved in the modulation of under-regulated pathways a logistic regression analysis was then performed.  Results from this analysis showed, that SNPs rs1897139 and rs9810380 appear to be playing a role in the regulation of ATP1B3 expression (P-value=0.002). This gene encodes a Na+/K+ ATPase, an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na+ and K+ ions across the plasma membrane.  ATP1B3 is a determinant of pain variability and it modulates nociception.  Thus, according to this finding, it is possible that the migraine phenotype in Norfolk Islanders is being driven mainly by the influence of mitochondrial genes. This study has additionally identified 11 SNPs in 6 genes as being potentially implicated in migraine.  Subsequently we performed a supervised clustering consisting in the construction of  9 common axes of peripheral blood variation, represented by clusters of highly correlated genes. These Axes were previously constructed by other authors who also identified 10 of the genes most closely associated with each Axis, called Blood Informative Transcripts (BIT).  The BITs are used to differentiate immunological and metabolic status between healthy individuals and patients 
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suffering different types of diseases. We aimed to define these Axes of variation in the Norfolk Island population to see how they compare with others, and to explore the possible association of the BITs with migraine in NI. Probes were grouped together according to a list provided by the authors who previously defined the Axes.  Principal Component  (PC), logistic regression and correlation analysis were performed in  R in order to analyse the Axes.  Results indicated that when compared with other populations, NI was unique by showing a high correlated core of genes in Axes 2, 4, 6, 5 and 8. This suggested that this group of Axes are not independent of each other, as they appeared to be in the other populations.  We have also tested the association between BIT and migraine in affected individuals, but no significant association was found.  We hypothesized that according to these results the Norfolk Island genetic structure is different to other populations and genes are interacting in a different fashion.  Then, as follows, we decided to define gene clusters using an unsupervised clustering analysis, where no defined clusters are previously set, and instead genes are grouped together according to their correlation in the actual data set.  The unsupervised clustering analysis was carried out by constructing an eigengene network using the WGCNA package implemented in R. Modules or gene clusters were compared after calculating their eigengenes and applying Pearson’s correlation.  Principal component analysis was performed to visualize the distribution of the loadings and the scores in principal component 1 and principal component 2. After the analysis, 19 modules and 8 meta-modules consisting of 14164 (11692 genes) transcripts which account for approximately 61,25% of the total probe set in our microarray were identified.  Modules were colour coded. Approximately 85% of the transcripts included in the Axes of blood variation defined in the previous analysis were detected and they appeared distributed into the 19 modules.  The turquoise module shared 727 genes (37%) with axes 4, 6, 8 and 9, while the ME9 module shared 410 genes (23.3%) with axes 4, 7, 8 and 9.  Also, genes in axes which did not have a strong correlation in NI (Axes 1, 4, 5 and 9) are dispersed over different modules supporting the idea that genes were 
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interacting in different ways in the Norfolk Island population. Correlation between migraine and modules was tested but no significant results were obtained. Thus, in this research we demonstrates that gene interactions in Norfolk Island are different to other populations reflecting a special genetic configuration that we have delineated with the module construction.  Although the modules presented here were more robust than the modules defined in the Axes analysis, we still did not find association with migraine.    Overall, this study has validated a role for ESR1 in migraine susceptibility as well as implicating the novel gene SYNE1 in migraine particularly in menstrual migraine development.  In addition, this study has identified the NDUFS4, COX7A2L, NDUFB8, NDUFA10, NDUFA8 and ATP1B3 as other novel genes potentially playing a role in migraine development. We have also defined clusters of genes that that explain the gene interactions and the unique genetic structure of the Norfolk Island population.  Although gene clusters did not differentiate migraine cases from controls, they can be used in the future to evaluate gene interactions with environmental factors or other traits like CVD (Cardiovascular disease), also common in the Norfolk Island cohort.   In conclusion this research has added support to the migraine hormonal driven theory implicating hormonal and new hormonal related genes using genetic association studies.   It also provides new evidence for the role of mitochondrial genes through the implementation of different statistical methods and technical approaches that integrate genetic and transcription information.    
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                CHAPTER 1  INTRODUCTION                          

PREFACE  Migraine is a common disabling primary headache disorder [1] and it has a considerable burden in society [45, 46, 90]. The general mechanism of migraine is not well known and there are still an important number of questions to be answered.  That is why there is  still a current lack of preventive procedures  and  treatments are unsatisfactory in more than half of migraine patients [2]. In efforts to establish a better understanding of migraine pathophysiology, different genetic variants have been identified. [3-6] [6, 7] [8] [9] [10]   However, the difficulty in the replication of these gene associations in other populations, suggest that the disorder is not caused by a small number of genes with large effects on the phenotype.  Instead, the evidence suggests, that there might be a significant number of genes with small or moderate effects that together increase the disease susceptibility.   In this study we aimed to further investigate and validate previous gene associations with migraine but also to identify new pathways, genes clusters and eQTLs participating in the entangled network of reactions and biological processes that lead to the development of migraine.  Finding new genes involved in the pathophysiological migraine mechanism may allow a better understanding of the disease and will contribute to the development of new therapies and prophylactic treatments suitable for patients suffering from the most common types of migraine: migraine with aura, migraine without aura and menstrual migraine.  In this thesis, the background corresponds to chapter 1; while chapter 2 presents the methods used to achieve the proposed objectives, including a detailed description of the populations along with the techniques and the statistical methods used.  Chapters 3 to 8 correspond to the results section. These chapters have been formatted as journal articles as some of them have been already published and the rest are under a review stage.  At the beginning of each chapter 
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a prologue is presented in order to contextualize the investigation to be presented in relation to the previous chapter. Following the prologue, the next page presents the chapter number, the title and, at the bottom section, a bibliographic reference in the case of chapters published as journal articles; or a reference note indicating authors, title and the targeted scientific journal for chapters not yet published. Additionally, every chapter has a diagram depicting the work flow followed including general results and the main methods used. Subsequently, the reader will find the text divided into abstract, introduction, methods, results, discussion, conclusion, tables and figures. Finally, Chapter 9 presents a brief summary of results, the conclusions and future directions for this study.       
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RATIONALE  Migraine is a common neurovascular brain disorder that is characterised by attacks of severe unilateral pulsatile headache that is often accompanied by nausea, vomiting, photo- and or phonophobia [1].  Migraine has an enormous impact on society, as proven by the last General Burden Disease Study 2010 (GBDS2010)[11] .  For migraine, the estimated proportion of time spent in the ictal state (during attacks) was 5.3 percent, ranking as seventh highest among specific causes of disability globally. Migraine also ranked in the top ten causes of disability in fourteen of the twenty one world regions evaluated in the study [12].  Migraine has a strong genetic component. Population-based family studies have shown that the familiar risk of migraine is increased [13, 14].  A contribution of genetic factors in migraine was also apparent from twin studies that showed a concordance twice as high in monozygotic versus dizygotic twins [15, 16].  In fact, a large Dutch twin study revealed that genetic and environmental factors had an almost equally large contribution [17].  Different genetic variants have been identified, in particular, three genes, CACNA1A, ATP1A2 and SCNA1A, from studies undertaken in familial hemiplegic migraine (FHM), a monogenic form of MA [3-5].  These genes appear to be highly significant with large to moderate effects. Additionally, an increasing number of significantly associated genetic variants have been identified with the implementation of genome-wide association studies (GWAS)[6-8].    However, most variants identified so far from GWAS have not been yet replicated in other populations; they confer relatively small increments in risk, and explain only a small proportion of familial clustering [18, 19] .  This situation has slowed down the translation of migraine genetic studies into functional approaches and the application goal of genetic studies seems to be missing.  Indeed, after a decade of brilliant genetic evidence on rare forms of migraine, such as familial hemiplegic migraine, very little has been translated to therapeutic management for 
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the most common migraine forms [20-23]. Equally challenging in the case of most complex diseases [19], is the question of where and how to find the  “missing” heritability component of GWA studies with this often debated.    Among the explanations delivered for this missing heritability, a much larger number of variants of smaller effect, that are yet to be found, have been suggested [19].  This explanation seems to be suitable for the specific migraine scenario, whose polygenic nature has been highlighted by multiple studies [2, 18, 20, 21, 24]; it is accepted that multiple risk alleles exert modest individual effects rather than a few genes exerting large effects in migraine susceptibility.  Thus, the modest size of genetic effects detected so far confirms the multifactorial aetiology of this condition and suggests that greater research efforts are require to detect additional genetic influences.  The further mining of GWAS data and its integration to whole genome expression levels are tools believed to increase the power of the valuable information that lies behind thousands of genotypes coming from whole genome SNP arrays [19].  Other statistical methods, like pathway-based [25] and clustering analysis [26, 27] are alternative strategies to detect groups of genes associated that are associated with a particular trait.  Otherwise they are undetected by traditional analysis strategies which only look for high impact genes.    In this thesis, we aimed at the identification of new small effect genetic variants and clusters of highly correlated genes that confer susceptibility to migraine in individuals from the genetic isolate of the Norfolk Island population.  Due to historical reasons and geographical isolation events, phenomena like genetic drift and population bottleneck have had a great influence on the fixation of alleles that remain in a low frequency in the general population [16, 28].  Thus, individuals from this cohort represent an ideal genetic model for the investigation of a multifactorial disorder like migraine.     
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 We first implemented a classical candidate-gene associated study and a fine mapping strategy to evaluate the relation of diverse SNPs in ESR1 and PGR genes, previously associated with migraine in an independent population within our laboratory [29].  As a replication and perhaps more relevant sample we used a cohort suffering from menstrual migraine.  Individuals in this population suffer migraine attacks during their menstruation, which suggests an effect of hormonal influences taking part in the aetiology of this subtype of migraine.  Thus, the menstrual migraine population represents a suitable replication cohort to study hormonal genes.  Following this investigation of small effect hormonally related genes, we aimed at the implementation of modern statistical methods that combined information from GWAS and Genome wide expression analysis to detect new biological targets implicated in this disorder.  Polygenic modelling, eQTL analysis, pathway analysis, and clustering algorithms were performed to identify genetic profiles present in migraine sufferers.    Genomics plays a fundamental role in the implementation of a new type of medicine called Personalized Medicine [30], where the individual profile of a subject is evaluated before proceeding to a specific therapeutic strategy.  The identification of genetic variants able to explain consistently the heritability of migraine are urgently needed to achieve coupling of genetic and clinical studies that could lead to optimisation and personalisation of migraine therapies.  
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OBJECTIVES  
GENERAL OBJECTIVES  
• The main objectives of this study were to use a Caucasian menstrual migraine population and the genetic isolate of Norfolk Island population to identify novel susceptibility genes involved in migraine and further investigate previously identified gene associations. 
 
SPECIFIC OBJECTIVES  
• To undertake a genetic association analysis of ESR1 and PGR gene variants in a core pedigree from the Norfolk Island Population .  
• To undertake a follow up genetic association analysis of hormonal related gene variants in a menstrual migraine case-control population.  Specifically testing variants in the 
ESR1, FSHR, CGPR RAMP1, LTA, TNF, SYNE1, KCNK18, ESR2, CYP19A1, NRIP1,. MIR890, 
MIR891A, MIR892A genes for association. 
• To evaluate the expression of hormonal and cytokine genes, ESR1, PGR, SYNE and TNF in blood samples from a menstrual migraine population. 
• To investigate a polygenic model of migraine in the Norfolk Island population. 
• To identify pathways that are downregulated or upregulated in individuals suffering from migraine in the Norfolk Island population.  
• To identify eQTLs controlling the levels of expression of genes related to migraine pathophysiology. 
• To identify gene clusters that may help in the differentiation of migraine cases and controls using the Norfolk Island population.  
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                     CHAPTER 2   BACKGROUND                         
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2.1 GENERAL ASPECTS OF MIGRAINE 
 Migraine was first recognized around 81 A.D in Capadoccia, now a Turkish province by Arateus.  He described cephalalgia (severe but infrequent short-lasting headaches), cephalea (protracted but relatively mild headaches—presumably our chronic daily headache), and heterocrania, which we would now recognize as migraine [31]. Significant advances had been achieved since then, particularly in the 20th Century, when enormous number of papers and books full of theories, questions and answers have opened doors to a wide and rich field of research [32].  In 1962 migraine was first defined as: “Recurrent attacks of headache, widely varied in intensity, frequency, and duration.  The attacks are commonly unilateral in onset; are usually associated with anorexia, and sometimes with nausea and vomiting; and some are preceded by, or associated with, conspicuous sensory, motor, and mood disturbances; and are often familial” [33]. Since then, the definition and classification of migraine have undergone important changes to facilitate diagnosis by clinicians and scientists [34].  Migraine history has involved a process of trials and errors, and some major events are already part of the history.  Some of these have changed the direction of research, others have confirmed previous hypotheses, but all are important in delineating migraine research.  The discovery and clinical implementation of ergotamine [35, 36]; the studies in pain-sensitive structures in the head by Ray and Wolff in the 1930s [37]; the theory of cortical spreading depression proposed by  Leao in 1944 [38]; the proposal of the theory about the neurogenic in 1984 [39]; the introduction of sumatriptan [40]; and the demonstration with immunocytochemistry of the presence of Calcitonin Gene-related Peptide (CGRP) in perivascular nerves of cerebral arteries in 1983 [41], are all milestones in migraine and reflect an evolution in knowledge and the approaching of new 
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pathophysiological ideas on the basis of vascular, neurogenic, neurotransmitter, and genetic/molecular biological paradigms [32].   
2.2 CLASSIFICATION  In 1962 a migraine a committee classified headaches  for the first time [33].  Although the definitions presented were not very clear and they were susceptible of being  misinterpretated, this classification was used for the following 26 years.  In 1988, the Headache Classification Committee of the International Headache society (founded in 1981), published for the first time a headache classification with specific criteria to diagnose migraine [42].  A second edition was published in 2004 (International Classification of Headache Disorders II) [43] and months later a subsequent first revision is published separately [44].  Important progress, reflected in the newest  ICHD III edition  [1], have been made on the neurobiology of migraine since 2004.  The newest classification of migraine includes new categories, modern terminology and a wider range of subtypes of migraine that allows accurate diagnostics by physicians and researchers.  Some of the new changes include:   a) Migraine without aura remains as one of the main categories, while Migraine with aura is subdivided into four categories, including retinal migraine, previously classified as an independent entity; b) basilar-type migraine no longer exists and is now designated as  “migraine with brainstem aura”; c) four subtypes of familial hemiplegic migraine, according to the causative mutated gene,  have been included; d) chronic migraine is now one of the main categories and e) based on evidence that MA patients or MO suffer episodic symptoms related with migraine,  the “Childhood periodic syndromes that are commonly precursors of migraine” subtype has been replaced by the “Episodic syndromes that may be associated with migraine” subtype [1].    
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Previous studies developed  alternative classification systems to refine phenotypes and facilitate the detection of association or linkage [45], claiming a lack of specific  markers for migraine, co-occurrence of migraine subtypes and the low validity of inclusion criteria for identifying the differences between migraine and other headache subtypes [46, 47] in previous ICHD classifications. Thus,  Latent Class Analysis (LCA) and Trait Component Analysis (TCA) are systems based on the diagnostic criteria of the International Headache Society [48].  Throughout this thesis, the ICHD III will be used as it remains to be the most accepted headache classification in the scientific and medical community.  Table 2.1 shows the latest classification of headaches by the ICHD III.  In this classification, migraine is considered as part of the group of primary headaches with 13 other types of headache. There are two main subtypes of migraine: migraine without aura (MO) and Migraine with aura (MA). The former subtype is characterized by pulsating quality attacks lasting 4-72 hours.  This type of headache is generally aggravated by physical activity.  They can also be associated with nausea and/or sensitivity to light (photophobia) and to sound (phonophobia) [49].  On the other hand, MA attacks present reversible neurological symptoms or aura (visual disturbances, auditory changes, etc) that progress gradually over 5-20 minutes for a period of time less than 60 minutes[50].  2.3 EPIDEMIOLOGY  
2.3.1 INCIDENCE  The incidence of migraine in the general population has been investigated by only few studies.  Using the reported age of migraine onset from a prevalence study, Stewart and colleagues [51] found that among  MA in females adolescents 14.1 new cases per 1000 people per year were reported; On the other hand migraine with aura peaked in incidence 
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around 5 years of age (6.6/1000 person-years) in the male population; Similar findings were seen in Europe.  In a population from Denmark, the annual incidence of migraine in the middle age population (35 to 64 yo) was of 8%.  When stratification by gender was considered the incidence increased for females to a 15% and dropped in the male subgroup to a 3%.  Additionally, the peak of the prevalence in younger women was 20% [52].    
Table 2.1  Classification of migraine. The classification is given according to the International Headache Society 2013 3rd Edition.                      1.       Migraine            1.1.    Migraine without aura 
                1.1.1 Menstrual Migraine        1.2.    Migraine with aura        1.2.1.  Migraine with typical aura       1.2.1.1.  Typical aura with headache       1.2.1.2.  Typical aura without headache      1.2.2.  Migraine with brainstem aura       1.2.3.  Hemiplegic migraine        1.2.3.1.  Familial hemiplegic migraine (FHM)      1.2.3.1.1.  Familial hemiplegic migraine type 1 (FHM1)     1.2.3.1.2.  Familial hemiplegic migraine type 2 (FHM2)     1.2.3.1.3.  Familial hemiplegic migraine type 3 (FHM3)     1.2.3.1.4.  Familial hemiplegic migraine, other loci     1.2.3.2.  Sporadic hemiplegic migraine      1.2.4.  Retinal Migraine        1.3.     Chronic migraine         1.4.     Complications of migraine        1.4.1.  Status migrainosus        1.4.2.  Persistent aura without infarction       1.4.3.  Migrainous infarction        1.4.4.  Migraine-triggered seizure                          
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More recently, Stewart and colleagues [53] determined that the median age of onset was 20 and 19 year of age for females and males, respectively.  Further, they calculated the  lifetime incidence and reported it to be at 7.4% for males while the incidence for females was more than double (21% ) for females. These evidences together suggest that migraine is not a constant state, it is instead a dynamic phenomenon characterized by high percentages of remissions and onset in the general population.    
2.3.2 PREVALENCE  Although migraine is thought to be a more common disease in women, different studies have shown migraine have a higher prevalence in boys than in girls before the adolescence. The prevalence and incidence of migraine increases rapidly from childhood and it starts declining once the age of 40 is reached (Figure 2.1). In general, the prevalence peak of migraine occurs during the most productive year of live, in terms of economy, this is between 25 and 55 years of age.  [51-55].  The Global Burden of Disease Study 2010 (GBD2010) reported a 14,7% prevalence of migraine in general population, 10,68% in males and 18,79% in females. Migraine ranked as the third most common disease in the world, supporting the idea an increasing major public health disorder [56]  It has been also noted that migraine prevalence varies by race and geographic region. For instance a meta-analysis showed that prevalence is much lower in African and Asians populations while it is much higher in Europe [57] and North/Central/South America. It is interesting to note that the highest prevalence of migraine among Caucasian individuals was reported in North America [58].    16  Chapter 2: Background 
 
Figure 2.1.Prevalence of Migraine.  One year period prevalence of migraine by age and sex.  Adapted from [59]  
 These observations lead to the hypothesis of a genetic susceptibility to migraine determined by race [60].  However, other authors suggest that environmental factors and cultural behaviours should be taken into consideration as the symptom reporting may change and thus explain the observed race-specific variation [59].  
2.3.3 COMORBIDITY  Migraine is comorbid with a number of other diseases from clinical studies and in population samples (Table 2.2) [61, 62].  Next, is a brief discussion on the comorbidity of migraine with psychiatric, pain and vascular disorders.     
Psychiatric Disorders  Multiple studies have confirmed the association between migraine and different psychiatric conditions. For instance,  Patel et al., [63]  evaluated the prevalence of MDD in individuals with migraine, probable migraine, and controls. Results from this study 
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indicate that the prevalence of MDD was 28.1% in migraine patients while for the controls was about 10.3%. Further, the prevalence MDD was elevated in all migraine groups, that is MA and MO, when they were compared with controls.   
Comorbid Pain   Additionally, from cross-sectional studies, it has been noticed that other pain disorders considered also as chronic, are comorbid with migraine and possible shared mechanism behind this relationship have been proposed. For instance, a study carried out by El-Metwally et al.  [64] utilized Finnish children with a  diagnostic of non-traumatic musculoskeletal pain symptoms and hypermobility. They were re-evaluated after 14 years to stablish variables related to the musculoskeletal pain prognosis. Interestingly, the authors found that a negative prognosis was given to patients suffering headaches once or more a week.  Like this, other studies have been developed and confirmed the elevated risk of migraine in individuals with any other type of pain disorder [65-68].  
Vascular disorders  The most well document vascular comorbidity with migraine is ischemic stroke, as it has been demonstrated by multiple case-control as well as cross-sectional studies in patients selected from specialty care settings, registries, and from the general population. For instance,  a meta-analysis including a total of 14 studies  showed that migraineurs have an increased risk of stroke when compared to healthy individuals( (RR) = 2.16, 95%, CI = (1.9–2.5) [69].  Additionally, the Women’s Health Study compared individuals with any history of migraine or MO with healthy individuals and found that there is not increased risk to suffer stroke.  However, the study showed that individuals with an MA diagnosis had increased adjusted hazards ratios (HR= 1.53, 95% CI, 1.02–2.31) for all types of  stroke and almost and 1.71 (95% CI, 1.11–2.66) for ischemic stroke.[70].  The increased 
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risk for ischemic stroke was more than double (RR 2.25; 95% CI, 1.30 to 3.91) for 45–54 years old participants.   Furthermore, data analysis from the Atherosclerosis Risk in Communities Study, suggested that migraine patients have almost double the risk to suffer  ischemic stroke (RR = 1.84; 95% CI, 0.89–3.82) than their healthy counterparts [71]. However, in this study the risk was not statistically significant. The authors have suggested that this situation is probably due to the non-specific migraine classification used.  
Table 2.2. Comorbid disorders with migraine. Taken from Bigal, 2009.          Conditions comorbid with migraine   Psychiatric        Depression      
  Anxiety        Panic disorder       Bipolar       Neurologic        Epilepsy        Tourettes       Vascular         Raynaud’s phenomenon      Blood pressure (inconsistent)      Ischemic stroke, sub-clinical stroke, white matter       abnormalities  Heart         Patent foramen ovale       Mitral valve prolapsed      Atrial septal aneurysm     Other         Snoring/sleep apnea       Asthma/allergy       Systemic lupus erythematosus      Non-headache pain             
 
19  Chapter 2: Background 
Coronary heart disease has also been associated with migraine.  Until today a number fo studies have reported the strong connection between migraine, particularly MA, coronary disease. For instance, Rose and colleagues [72] evaluated the association between migraine and Rose angina. Participants were age 45 to 64 at baseline and were from the Atherosclerosis Risk in Communities study. The group of patients with migraine, particularly MA,  was twice as likely to have a suffer of Rose angina. Interestingly, results from the Women’s Health Study, showed that MA individuals have approximately double the relative risk to experience major cardiovascular disease[73].  Lastly, studies carried out in the male population showed that those suffering migraine, both MA and MO, were at higher risk of suffering major CVD [74]. 
2.3.4 BURDEN OF MIGRAINE  Migraine has an enormous impact on society, as proven by the last General Burden Disease Study 2010 (GBDS2010).  For migraine, the proportion of time spent during attacks or what is called the ictal state was 5.3%, ranking as 7th highest among specific causes of disability globally . The Disability Weight (DW) of migraine episodes was 0.433 (43.3% disability).  Migraine was responsible for 2.9% of all Years Lived with Disability (YLDs), and ranked in the top ten causes of disability [11, 75].  Previous studies have evaluated the costs of migraine [50, 76, 77].  In terms of indirect costs, like the effect of migraine on the paid (job) or unpaid (household) [50] it has been estimated that the decreased productivity while at work caused by migraineours costed 13 billion dollars per year only in the USA [78, 79].   Migraine is also one of the main reasons for patients visiting the emergency rooms [80].  A large amount of medications given over the counter OTC come from different headache disorders diagnosis and they have been calculated to cost over 3.2 billion dollars in 1999.    
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In another study, Stewart and colleagues as part of the American Migraine Prevalence and Prevention study, evaluated the Lost Productive Time (LPT). For individuals who suffer any type of headache the mean LPT per week was 1.8 hours.  Additionally, the 76.5% of the LPT related to headaches was by means of a reduction in performance.  [81].  
2.4 ENVIRONMENTAL FACTORS  Many migraine sufferers report that changes in the weather, high altitude, bright lights, smoke, and strong odors trigger their migraine headaches [82].  Additionally, the indoor environment, especially at the work place, further adds to the migraine disability.  Thus, the Job Accommodation Network’s Searchable Online Accommodation Resource (SOAR), a website maintained by the US Department of Labor, recommends modification of noise triggers, smell/fragrance triggers, lighting triggers, and other features of the work site for personnel suffering migraine. For instance, the addition of fluorescent light filters to generate a more natural lighting, deliver anti-glare filters for computer monitors, move employees away from convoluted traffic areas, implement sound absorption boards, apply a fragrance-free policy, among others [83]. Table 1.3, summarizes some of the most important environmental studies previously performed and the strength of correlation to migraine.  2.5 GENETIC FACTORS  Migraine has an undeniable strong genetic component that has been proven by multiple studies [84] . For instance, studies carried out in relatives of migraine patients suggest that they have a higher risk of suffer migraine than any other individual in the population who does not suffer the disorder [14, 85]. I has been determined that first-degree family members of MO patients were twice as susceptible to suffer migraine than individuals with no relatives suffering migraine.  Interestingly, results also suggested that the same 
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individuals had 40% more probabilities to suffer MA compared than their counterparts in the general population. Contrasting this results, are the findings from MA patients, whose  first-degree have approximately 4 times higher the risk to suffer MA.  The same individuals did not show any increased risk to suffer MO.   Another type of analysis are those carried out using mono- and di-zygotic twin pairs.  These methods represent a classical methodology to further explore the role that both genetic and environmental factors have on the development of a complex disease such as migraine.  From these studies different conclusions have been drawn.  Thus, the concordance rates in monozygotic twins are up to two times higher than in dizygotic twins when twins suffering both MA and MO were evaluated. [16, 86].  This gives some insight into the importance of the genetic factors in the aetiology of migraine. On the other hand, authors of a large twin study (30,000 twin pairs) reported that the contribution to the phenotype in migraine comes equally from genetic and environmental factors [17] and they also demonstrated that shared environmental factors do not exert  an outstanding role in the pathophysiology of migraine.  This theory was also previously suggested by others through the comparison of twins that grew up together with their counterparts raised apart from each other [87, 88]. 
 Although according to the official classification, MA and MO are subtypes of migraine, this issue still remains being polemic and studies supporting the theory of them being the same entity or different disorders have arouse.  In terms of genetic study designs, it is of vital importance to differentiate them properly as this impact directly the findings by increasing or decreasing association signals after the statistical analysis applied. One example comes from one study carried out in a population from Denmark which found that there was no a higher co-occurrence of MO and MA in comparison with the product of the prevalence of MO and MA in the general population [85, 89]  or in twins [90]. These 
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results suggest that MO and MA are the same entities. On the other hand, different authors argue in favour of the theory that these, are different manifestations of migraine and that in the spectrum of clinical expressions MA should be located at one end while MO should be in the other one[45, 91, 92]. This theory is further supported by clinical studies whose observations indicate that both MA and MO share headache symptomatology and not in rare occasions they are present in the same individual.  However, this fact is still uncertain and future studies should be focused on unveiling this relationship.  Although important progress has been made in regards to the identification of biological pathways behind the pathogenic process of rare Mendelian forms of migraine [24], the panoramic seem not be the same in the identification of genetic factor in common forms of migraine. According to the recent evidence it is suggested that the methylenetetrahydrofolate reductase gene (MTHFR) is one of the most promising candidate genes to explain a considerable amount of genetic variance leading to the susceptibility of migraine.  However, evidence in this respect remains inconsistent and more studies with bigger samples and better diagnostic tool should be performed to whether confirm or deny such asseveration [93, 94]. Other genes have been implicated in migraine and in the following paragraphs I intend the description of the most important ones. 
2.5.1 GENES FROM FHM   It is well known that familial hemiplegic migraine (FHM) is a form of migraine with aura with two main characteristics: it is rare and it is caused by mutations in one single gene.  Although FHM is seen as a different entity from general migraine it is still considered as a model to study the genetic aspects of the latter.  Thus, FHM have headaches and aura symptoms very similar to common migraine [95]. In addition, approximately 70%  of the FHM sufferers show FHM attacks together with characteristic attacks of common non-
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hemiplegic migraine [24]. Three main genes have been associated with FHM and the first one of them was CACNA1A or known as FHM1.  This gene is located on chromosome 19p13  and it [5]encodes the α1 subunit of the neuronal voltage-gated calcium channel protein whose expression is abundant in the central nervous system (CNS). [96]. A number of 21 missense mutations have been identified in the FHM1 gene.  They are all associated with a wide range of clinical features along with hemiplegic migraine [97],  cerebellar ataxia [98, 99]  and epilepsy, both during severe FHM attacks [100]  or independent of FHM attacks [101]  are not uncommon. The phenotype in for instance FHM1 S218L mutation carriers can be very severe, even lethal, after mild head trauma [102].   The ATP1A2 (FHM2), is the second gene associated with FHM and it is located on chromosome 1q23 [103]. It also encodes the α2 subunit of sodium–potassium pumps. Almost all FHM2 mutations (approximately 30) are amino acid changes, but there are also small deletions [104] and a mutation affecting the stop codon causing an extension of the ATP1A2 protein by 27 amino acid residues  [105] [103].  Although most of the FHM2 mutations have been associated with pure forms of FHM, varios mutations have been reported to be associated with FHM and cerebellar problems [106], childhood convulsions (BFIC)  [107], epilepsy [105] and permanent mental retardation [108].  
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Table 2.3. Environmental Factors.  Types of Studies on Various Environmental Factors. 
  Factor  Types of studies Types of refuting studies Confounding factors     Weather Interview Diary and ED studies using official weather data 
    
    Survey          Prospective cohort           Diary with metoeorological records         Air travel/altitude Questionnaire           Case report       
  Noise Retrospective studies   Stressful distractor during noise challenge study      Electromagnetic fields and sferics    Diary using official atomospheric data       Outdoor light exposure Survey            Prospective study            Case -control study         Seasonal variation and daily light exposure Questionnaire Retrospective ED study diary        Diary             Retrospective studies           Light threshold studies         Indoor lighting, fluorescent lights, computer screen  Case-control Diary  Head posture, office stres, noise, refractive error, bifocals, cervical disc disease, myopia, ergonomic factors 
      Diary Retrospective study        Survey  Questionnaire       Case report           Functional MRI         Busy visual environment Studies of sine grating patterns          Odors Interview           Survey            Population studies         Air pollution  With self report           Cross sectional study        
  Mold   Questionnaire Co-existing allergies, asthma, sensitivity to odors     ED, emergency department                 Finally, the SCN1A (FHM3) is the most recently identified gene in FHM. [4].  SCN1A a protein characterized as the 1 subunit of neuronal NaV1.1 voltage-gated sodium channels. It is also a gene associated with epilepsy, more specifically childhood epilepsy [109]. Only five FHM3 mutations have been identified that all change amino acid residues [135, [110, 111]. Missense mutations Q1489K and L1649Q were identified in large families and are associated with pure FHM. Notably, three out of five FHM carriers of the L263V mutation 
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had generalized tonic–clonic epileptic attacks, occurring independently from their hemiplegic migraine attacks.  
 Two more mutations in the SCN1A gene have been recently reported.  They are the  Q1489H and the F1499L [112] and they are tested in 5 individuals.  The findings indicate that out of five Q1489H carriers, four patients presented symptoms corresponding to hemiplegic migraine  plus a phenomenon that has been called  ‘elicited repetitive transient daily blindness’ (ERDB).  In this cases the occurrence of ERDB was not associated with either migraine or any other neurological symptom. On the other hand, the family whose members were carrying the F1499L mutation had also a linked with ERDB.  
SLC1A3 gene, encoding the glial glutamate transporter EAATI [113], and SLC4A4 gene, encoding the electrogenic sodium bicarbonate (Na+HCO3-) cotransporter NBCeI [114], were also associated with FHM in previous studies and might be considered as the fourth and fifth genes to be implicated in FHM.  So far we have mentioned cases where patients suffering hemiplegic migraine are always members of FHM families. However, there is another type of hemiplegic migraine whose presentation is sporadic.  This type of migraine is called sporadic hemiplegic migraine (SHM).  The symptoms that patients suffering SHM show are very alike to those show by hemiplegic migraine patients [115]. SHM patients, for example, can have experience hemiparesis independent attacks of common migraine.  To note is that in the population, the prevalence of familial and sporadic hemiplegic migraine is about 0.01% what shows how rare is this disease [116]. As these two disorders are closely related , it is not surprising that genetic studies aiming to the identification of variants in the different FHM genes in SHM individuals have been carried out [117-119]. Results are not concise and in a population from Holland, a clinical study found that approximately 15% of SHM patients 
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carry a different number of mutations in the gene mutations ATP1A2 gene [118].  However, when similar analysis was carried out in 100 individuals from a population from Denmark no mutations were identified in the FHM genes [119] .  
2.5.2 LINKAGE STUDIES  Classical linkage analysis is a genetic strategy focusing on the  identification of migraine susceptibility genes.  Thus, this method looks for chromosomal loci based on a family-based approach. Except for a few loci, replication successes have been scarce. For instance, a loss of functionality caused by mutation in the TRESK potassium channel gene, more specifically the KCNK18,, has  been associated by linkage studies with migraine with aura in a family.  However, no study has yet identified a particular variants causing this malfunctioning of this channel  [365];  Another linkage study using MA families from Finland determined a locus located on chromosome 4q24 [120]. Later an Icelandic study revealed the association of the 4q21 region, this time in MO patients. These two loci showed an overlap in their localization but it is unclear if they might harbour different genes for the subtypes of migraine MA and MO, or if in the other side, there is a unique gene underlying the onset of these two subtypes of migraine. Loci 18p11 and 3q also revealed suggestive linkage for a severe migraine phenotype on 92 Australian pedigrees [121].    As no causative mutation has been determined for any of the genes previously mentioned, it is well known in the scientific community  that the main reason behind it is the heterogeneity in the use of diagnostics tools across all the different studies. Thus, the modern methods to diagnose migraine are through the implementation of questionnaires and interviews with individuals suffering the disorder. There is not doubt that a better and more objective methodology for migraine diagnosis, perhaps a biochemical blood test, is  
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an urgent issue in order to obtain more homogenous samples that will impact directly the knowledge on the aetiology of migraine [24].  
2.5.3 ASSOCIATION STUDIES  Case–control association studies are another used strategy to determine genetic factors in a complex disorders scenario. The reasoning behind association studies is to identify any possible dissimilarities in the allele frequencies between individuals suffering an specific disorder (cases) and healthy individuals or also known as controls. An important number of studies using the candidate gene strategy have been performed in migraine. Most of these studies have focused so far in genes participating serotonin and dopamine metabolism. There are additionally, other genes that have also been considered and studied with the same strategy.  They are presented in Table 2.4. However, is it important to note that the majority of the reported associated variants could not be further replicated, suggesting that probably some of them are just a result of population structure or other bias ignored at the time of the analysis, and therefore they represent false positive findings.    Thus it is evident the lack of more systematic methodologies to infer if a given candidate gene or a group of genes have real effects on the migraine phenotype. This affirmation is supported by the fact that the gene associations detected so far have not been replicated and additionally, candidate genes that come from anatomical, pharmacological and clinical evidence could not be related to migraine based only in association studies [122].  Some authors have proposed different methodologies to address these type of difficulties and an example of it is an study performed in German population.  In this study, the authors were investigating different variants in dopamine genes by using a two-step design [123] where initially a haplotype analysis is performed to select 50 polymorphisms that will be further 
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investigated.  Using this methodology the selection of an adequate number of independent SNPs and a convenient sample size enable the authors to identify  several SNPs associated with migraine and participating in the dopamine-hydroxylase complex.   A second  example of a successful  association study is the project that lead to the implication of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene with migraine. Until today there is only one polymorphism, the MTHFR C677T, that has been investigated.  Interestingly, most of the studies agree on the exclusive association of the T allele with migraine [124-128], even though this association has also been contradicted by some others [128]. For instance, a meta-analysis utilizing 2,000 individuals with a migraine diagnostic, showed that the T-allele was only associated with MA but the no general migraine [93]. To note is that the T allele is thought to increase the levels of homocysteine and this in time, cause the pain in migraine via a dysfunctional endothelium effect.  However, this is just and hypothesis and more evidence is required [24]. Table 2.4 shows a summary of all the association studies performed until today and whose sample size is larger than 275 cases and controls.   
2.5.4. GENOME WIDE ASSOCIATION STUDIES  Techniques used for genotyping have suffer massive changes since they were reported for the first time.  Today, large numbers of SNPs in large sample sizes are feasible as new and more advance methods like SNPs arrays have been developed. These techniques represent great success for complex disorders, as the methods describe previously, linkage analysis and candidate genes associated studies are not enough to detect the effect of multiple variants with small effects as it is the case for genetic polymorphism involved in the aetiology of complex disorders   [129]. One of the advantages of the GWAS methodology is that it is more efficient on testing for the influence of common variants throughout the 
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genome in an unbiased fashion.  In this type of design, large study populations are needed to have sufficient power to detect genetic effects after correction for multiple testing.   A commonly used approach to correct by multiple testing is through the use of what has been called the genome-wide significance. This approach is based on the distribution of LD in the genome according to the population under investigation.  Thus, there are an ‘‘effective’’ number of independent regions in the genome, and consequently an effective number of statistical tests to correct. This threshold varies according to the population and, in the case of the European, an estimate of 7.2e-8 have been calculated [130]. Additionally, the gold standard for validation of GWA studies is the replication of results in an independent sample [131].   Until now, three major migraine GWA studies have been reported (Table 2.5).  Region 8q22.1 was identified in an study investigating 2748 European clinic-based MA cases and more than 10000 matched controls [132].  The SNP, rs1835740, is located between the MTDH and the PGCP genes; the second major GWAS involved 5122 migraine cases and more than 18000 controls from the general population [8].  From this study, three loci, 
TRPM8, LRP1 and PRDM16 were genome-wide significant.  A third GWAS was performed in 2326 MO patients and 5000 controls, and four novel migraine susceptibility genes were found : MEF2D, TGFBR2, PHACTR1 and ASTN2 [133].    Recently 5 new loci associated with migraine were reported in a meta-analysis across 29 genome-wide association studies (23285 migraine cases and 95425 population-matched controls). These variants are near genes AJAP1 (1p36), TSPAN2 (1p13),within FHL5 (6q16), c7orf10 (7p14), and near MMP16 (8q21).   
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2.5.5GENE EXPRESSION STUDIES  In recent years, there has been an increasing amount of literature on gene expression studies in different types of disorders.  Migraine is not the exception even though, the number of studies still remains limited by difficulties in obtaining brain samples from patients.  Available studies, report expression profiles from peripheral blood cells as it represents a readily available tissue whereas brain is not.    In addition, expression profiling from blood cells can also be used as a reflection of the complex biological networks and pathways taking place in the brain. Further, circulating immune cells expressed a different number of receptors and cascade signalling pathways that are activated by probable metabolic changes as a consequence of pathological events occurring in the brain [134].   
 
 In 2004 a study reported the investigation of genomic expression patterns from 22 blood samples of migraine patients during an acute migraine or chronic migraine were compared to 56 controls.  A group of platelet genes were upregulated in the two groups of migraine.  For instance, c-fos and cox-2 genes were expressed at higher levels in migraine, whereas specific mitochondrial genes were expressed at higher level in chronic migraine [134].  Later, in 2009, Nagata et al., reported 15 genes (SPTAN1, HPCAL1, FLJ22649, 
EFEMP2, LOC51316, POP4, ZNF281, FLJ11175, FLJ13993, LTA, MIR, COL27A1, PPL13) as being differentially expressed in lymphoblasts  originated from patients diagnosed as having migraine with aura.  Three of these genes were associated with cytoskeletal proteins [135].    More recently, a third study was performed in menstrually-related migraine in Adolescents from whole blood.  The study compared 36 patients (18 MRM and 18 non- 
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Table 2.4. Summary of association studies.  Studies performed on migraine that contained at least 275 cases and controls. 
 
 
 
 
 
 
 
Gene Variant Cases Migraine (MA/ Controls References5´, 10´-Methylenetetrahydrofolate reductase (MTHFR)MTHFR c.677C>T (C677T) 652 (465/187) 320 677T: NS (P = 0.017/–) Lea et al. 2004MTHFR c.677C>T (C677T) 413 (187/226) 1212 677T: – (P < 0.006/NS) Scher et al 2006MTHFR c.677C>T (C677T) 898 (898/–) 900 677T: – (NS/–) Kaunisto et al. 2006MTHFR c.677C>T (C677T) 2,961 (2,170/791) 3844 677T: NS (P = 0.0005/NS) Rubino et al. 2007MTHFR c.677C>T 4,577 (1,275/1951) 20424 677T: P = 0.03 (P = 0.02/NS) Schurks et al. 2008
Dopaminergic system; catechol-O-methyltransferase (COMT), dopamine -hydroxylase (DBH), dopamine transporter (DAT1)COMT c.472A>G (Val158Met) 305 NS Hagen et al. 2006DBH 1021C>T 830 (588/242) 1021T: P = 0.004 (P = 0.011/NS) Fernandez et al. 20091603C>T NS (NS/NS)DBH c.1434 + 1579A>G (rs2097629; intr  650 (650/-) c.1434 + 1579G: – (P = 0.01/–) Todt et al. 2009DRD2 c.-32+16024T>:G (rs7131056; intron 1) c.-32 + 16024T – (P = 0.006/–)SLC6A3 c.1840-204G>A (rs40184; intron 14) c.1840-204A: – (P = 0.03/–)SLC6A3 VNTR in intron 8 550 (401/149) NS (NS/NS) McCallum et al. 2007Serotonergic systemHTR2C c.69G>C (Cys23Ser) 275 NS Johnson et al. 2003c.2831T>G (T2831G) NSHTR2C c.69G>C (Cys23Ser) 335(184/151) NS Oterino et al. 2007HTR2C c.69G>C (Cys23Ser) 561 (561/-) NS Oterino et al. 2007Gamma- aminobutyric acid type A (GABA-A) receptor syst                     GABRA5 Multiple variants tested 898(898/-) 900 NS Oswell et al. 2008GABRB3 Multiple variants tested NSGABRG3 Multiple variants tested NSGABRA5 Multiple variants tested 649 (649/-) 652 NS Netzer et al. 2008GABRB3 Multiple variants tested NSGABRG3 Multiple variants tested NSGABRE Multiple variants tested 384 (254/130) 275 NSGABRQ c.1432T>A (I478F) NSHormone receptor system; estrogen receptor 1 and 2 (ESR1 and ESR2), follicle stimulating hormone receptor (FSHR), androgen receptor (AR), CYP19 (CYP19A1), nuclear receptor-interacting protein 1 (NRIP1), progesterone receptor (PGR)ESR1 c.594G>A (G594A) 484 (360/124) 484 594A: P = 0.003 (P = 0.01/P = 0.02) Colson et al. 2004ESR1 c.2014G>A (G2014A) 898 (898/–) 900 – (NS/–)ESR1 c.325G>C (G325C) 356 (198/158) 374 325C: P = 0.03 (P = 0.045/NS) Kaunisto et al. 2006ESR2 c.2100A>G (A2100G) 2100A: NS (P = 0.03/NS) Oterino et al. 2008FSHR c.2039G>A (Ser680Asn) 2039G: NS (p = 0.01/NS)CYP19A1 c.1672C>T (C1672T) NS (NS/NS)NR1P1 c.225G>A (Gly75Gly) NS (NS/NS)AR CAG repeat in exon 1 509 (371/138) 454 NS (NS/NS)PGR PROGINS ins in intron 7        0.008) Colson et al. 2004
Inflammation related genes; tumor necrosis factor- and - (TNFA and TNFB) and lymphotoxin  (LTA)TNFA c.308G>A (G308A) 299 (38/261) 306 308G: P < 0.001 (NS/P < 0.001) Rainero et al. 2004TNFA Multiple variants tested 439 (65/327) 382 NSLTA 294T>C (rs2844482; promoter) 294C: P = 0.0002 Asuni et al. 2009TNFA c.308G>A (G308A) 299 (–/299) 278 – (–/NS)TNFB c.252G>A (G252A) 252A: – (–/P = 0.018)Insulin receptor gene (INSR)INSR c.2946-713C>A 827 (377/450) 765 c.2946-713A: NS McCallum et al. 2001(SNP84; intron 15) (P = 0.002/NS)c.2842 + 1451T>A c.2842 + 1451A: NS(SNP90; intron 14) (P = 0.007/NS)c.3255C>T (SNP274) c.3255T: NS (P = 0.008/NS)INSR c.2842 + 1451T>A 1,278 (1,278/–) 1337 c.2842 + 1451T: –(rs2860174; intron 14) (P = 0.005/–)Angiotensin converting enzyme (ACE), angiotensin receptor 1 (AGTR1) and angiotensin (AGT) Tronvik et al. 2008ACE Ins/del (rs1799752; intron 15) 342 (187/155) 403 NS Schurks et al. 2009ACE Ins/del (rs1799752; intron 15) 3,226 (1,275/1951) 20, 423 NSAGTR1 c.1166A>C (A166C) 3,226 (1,275/1,951) 20, 423 NSAGT c.803T>C (Met235Thr) NSAssociation studies with other genesNOS3 c.-51-898G>A 337 (188/149) 341 NS Toriello et al. 2008(rs1800779; intron 1) NSc.894T>G (rs1799983) NSIon transporter genesMultiple variants tested 3676 3624 NS Nyholt et al. 2008
Associated allele with 
phenotype (P vlue)
Association studies performed for migraine 
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Table 2.5.  GWA studies on migraine. Summary of recent GWAS in migraine. The name of the SNP.  (*) SNPs that have been replicated and reached the genome-wide significance threshold (7.2e-8) .  The gene, cohort and the P-value are also indicated for every study.  
      
 SNP Gene Cohort /Reference P-value(OR(CI 95%))   rs1835740* MTDH Clinic-based MA [136] 1,69 x 10-11 (1,18(1,13-1,24))   rs17862920 TRPM8 Clinic-based MA [8] 1,26 x 10-5 (0,78(0,69-0,87))   rs10166942* TRPM8 Clinic-based MO [137] 5,97 x 10-9 (0,77(0,70-0,84))     Population-based migraine [8] 5,50 x 10-12 (0,85(0,82-0,89))   rs11172113* LRPI Population -based migraine [8] 4,30x 10-9 (0,90(0,78-0,93))     Population -based migraine [137] 2,97 x 10-8 (0,86(0,81-0,91))   rs2651899* PRDM16 Population-based migraine [8] 3,8 x 10-9 (1,11(1,07-1,15))   rs3790455 MEF2D Clinic-based MO [137] 7,6 x 10-11 (1,20(1,14-1,27))   rs9349379 PHACTR1 Clinic-based MO [137] 3,20 x 10-8 (0,86(0,81-0,91))   rs7640543* TGFBR2  Clinic-based MO [137] 1,17 x 10-9 (1,19(1,13-1,26))   rs6478241 ASTN2  Clinic-based MO [137] 3,86 x 10-8 (1,16(1,11-1,23))   rs10915437 AJAP1 Meta-analysis[7]  2.81 x 10-8 (1,16(1,11-1,23))   rs12134493 TSPAN2 Meta-analysis [138] 6.71 × 10−14(1.14 (1.10-1.18))   rs13208321 FHL5 Meta-analysis [7] 2.15 × 10−12(1.18 (1.13-1.24))   rs4379368 c7orf10 Meta-analysis [7] 1.46 × 10−9(1.11 (1.08-1.15))               MRM) to 20 controls.  Conclusions from this study revealed that 77 genes were unique in MRM, while 61 genes were commonly expressed for MRM and non MRM and 127 genes had a unique expression pattern for non-MRM.  Gene ontology indicated functional categories of mitochondrial function, immunomodulation/inflammation and DNA homeostasis [139]. Finally, The most recent study comes from an study in brains of familial hemiplegic migraine type I knock-in mice where a tyrosine hydroxylase marker appeared strongly upregulated in mice with the S218L in the CACNA1A gene in cerebellum [28].   2.6 BIOLOGY OF MIGRAINE  Migraine is considered to be a neurovascular disorder given the important influence of vascular and neuronal components in its pathophysiology.  However, throughout the 20th century, two independent theories, the vascular and the neuronal theory were the central 
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topic of an agitated debate on the migraine pathophysiology.  The vascular theory, which viewed migraine as a vasculopathy, assumed that the aura symptoms were due to the vasoconstriction caused by induced hypoxemia. The vascular theory, also attributed the migraine headache to the vasodilation of blood the vessels in the brain, which in turn, resulted in a mechanical depolarization of primary nociceptive neurons.  This theory was consistent with the inducing effects of vasodilators like nitroglycerin contrasting with the relieving effect that ergotamine, a potent vasoconstrictor had. observed headache Reports of no efficacy from the non-vasoconstrictive substance P antagonist in acute migraine also seemed to favour the vasogenic hypothesis [140].  However, by imaging analysis we now know that when nitroglycerin is administered to provoke migraine, the headache starts just when the blood vessels area at a normal calibre, that is after the vasodilation episode. [141, 142].  In addition, other vasodilation substances, like vasoactive intestinal peptide, do not induce migraine headache [143].  The alternative neurogenic theory conceived migraine as a disorder of the brain whose vascular manifestations were passive phenomena consequence of neuronal dysfunction. This theory was supported by the fact that the neurologic symptoms occurring during the aura phase are difficult to localize within a unique neurovascular territory.   Additionally, neuroimaging studies indicated that the decreases in brain blood flow observed during aura was not sufficient to cause ischemia, and that the headache phase occurs before the later vasodilation take place [144, 145].  Furthermore, multiple non-vasoconstrictive treatments are known to be effective in migraine [146]. AAs it was mentioned previously, As it was mentioned previously, migraine is known to be caused by both vascular and neuronal process.  Although the debate is now focused on whether the former or the latter is the mechanism leading to the activation of nociceptors in the brain [147], different factors have been proposed as triggers of the pain headache Among them, the ovarian hormones have been widely considered.  As it is the purpose of this thesis the evaluation 
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of hormonal genetic factors involved with the susceptibility of migraine, the next sections are dedicated to the possible role of hormones in migraine and the studies that support its participation in the aetiology of migraine.   2.7 MIGRAINE AND HORMONES  The central nervous system (CNS) is highly influence by ovarian hormones which orchestrate many of the biochemical reactions taking place in the brain.  The two more important hormones are the estrogen and progesterone.  Even though they are not segregated in the brain, they act on it by means of hormone receptors widely distributed in cortical and sub-cortical areas of the brain. For instance, when these hormones bind to their respective receptors they can cause the alteration of the gene transcription via exerting genomic or non-genomic mechanism to activate specific action in the neurons. Different neurotransmitter systems like serotonergic, dopaminergic and GABAergic modulate pain processing, hence considered as of vital importance in the pathogenesis of migraine, are regulated by estrogen and progesterone levels. There are, however, some differences in their action.  On one hand estrogen is mostly an enhancer of the neurotransmission system while progesterone seems to have a inhibitory effect.  Investigation of ovarian hormones is a growing research field and its importance lay of the fact that the understanding of the process behind hormonal activation and neurotransmission will bring light into the molecular aspects of migraine [148, 149]. In the following paragraph I will describe the endocrinology of the menstrual cycle to give the reader an understanding of another subtype of migraine, menstrual migraine, related with changes in the hormonal levels during the menstrual cycle.    
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2.7.1 ENDOCRINOLOGY OF THE FEMALE REPRODUCTIVE CYCLE   The menstrual cycle is an intricate of endocrine and neurologic events taking place in the hypothalamic, pituitary, and ovarian axes [150].  Firstly, neurons from the arcuate nucleus in the hypothalamus synthesize the Gonadotropin releasing hormone (GnRH) which is later release into the circulation in progressive way. Then, once in the anterior pituitary gland, GnRH binds to its receptors to trigger the discharge of two hormones, the follicle stimulating hormone (FSH) and leutinizing hormone (LH). The pulsating released of these two hormones will allow the development of the follicles occurring during the early to mid follicular phases of the menstrual cycle. In turn, the development of the follicles precipitates the synthesis of more estrogen into the circulation.  Thus, the concentrations of serum estrogen increase and once a peak in met a signal is send to the anterior pituitary to relaease more LH.  As a consequence, a dominant follicle is developed and with this, the next ovulation cycle [149].   Once ovulation takes place, the remaining of what was before the dominant follicle turns into the corpus luteum which during the luteal phase, produces estradiol and progesterone. When fertilization does not occur the corpus luteum degenerate and consequently, the levels of estrogen and progesterone in serum decrease, precipitating the menstrual bleeding by means of the endometrium removal [148].  
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Figure 2.2. Hormonal changes during the menstrual cycle. Higher peaks of migraine incidence occur when progesterone and estrogen levels in blood fall at the end of the luteal phase and the beginning of the follicular phase.    
2.7.2 INFLUENCE OF ESTROGEN IN MIGRAINE  According the different studies the levels of serum estrogen  are associated with modulating among other aspects,  the severity, disability and frequency of a migraine headache. Thus, low levels of estrogen (below 45 to 50 pg/mL) like those present in the perimenstruation stage, cause migraine. On the other side, high serum levels of estrogen like for example those experienced during pregnancy have the ability to worsen MA, although this situation does not happen for all patients. For instance, moderate to high levels of estrogen act as preventive biomolecules of migraine headaches in patients with MO.  Meanwhile the same high levels can also be a trigger in individuals suffering MA. An study [151] analyse whether migraine patients were more sensitive to estrogen levels using a transdermal estradiol patch.  A number of interesting observations were found.  The authors detected that the levels of estradiol were 45–50% higher in the migraine group.  Within this group, it was noted that the levels of estradiol were constant for the 
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first 2 days when the patch was wore but then they notably vary when compared to the fifth and seventh day measurements.  In conclusion, this study shows how that some migraine patients are extremely sensitive to minor changes in the levels of serum estrogen. Additionally, these study also support the theory that different mechanisms are behind the precipitation of MA and MO migraine headaches. Thus, MO headaches seem to associate better with low levels of estrogen and MA are mostly influenced by increased levels of the same hormone, however, the specific mechanisms are unknown [149].  
2.7.3 PROGESTERONE AND MIGRAINE  Although studies have mainly focused on the role of estrogen in migraine, the role of progesterone has also been investigated.  Clinical studies suggest that the increased levels of progesterone during the mid luteal phase can prevent headaches compared to other tiems during the cycle [152]. Other reports [153] have shown that the intake of oral progestins in a daily fashion could also prevent headaches particularly in women experiencing the premenopausal stage.  However, these kind of therapies are of a restrictive use as different side effects like breakthrough bleeding and mastalgia have been observed.  Contrasting to the preventative effect of progesterone, is the precipitation effect of some contraceptive agents such as injectable depot medroxyprogesterone and levonorgestrel implants in some susceptible patients [154]. Other studies have reported that the administration of  progestins and estrogen replacement therapy together may trigger migraine in postmenopausal women [155, 156]. Thus, it can be seen that progesterone and progestin can have opposite effects depending on the clinical background.  It is important to note that to draw more conclusive affirmations, larger experiments with better designs are require to overcome the uncertainty at the moment of the treatment prescription in the clinical environment.   
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2.7.4 EFFECTS OF OVARIAN HORMONES ON NEUROTRASNMITER SYSTEMS  Ovarian hormones have multiple effects on the neurotransmitter systems which in turn control a diverse number of tasks in the brain.  However, the effect of hormones is modulated by different variables which are listed in the following sentences. One of the most important factors in the modulation of neurotransmitters by hormones is the specificity of region and the neurons where they exert its effects. Thus, estrogen or progesterone may be able to increment the expression of genes encoding determined enzymes in one brain area while in a different area; the effect could be the opposite that is, decreasing the release or the action of specific molecules. A second variable consist of the activation or inhibition of different systems.  For instance, higher levels of estrogen during the menstrual cycle activates the release of  GnRH whereas lower levels inhibit its released.  Additionally, the joined action of estrogen and progesterone produces different consequences of when they act separately [148].   
2.7.5 GENETICS OF OVARIAN HORMONES RECEPTORS  Different studies have focused candidate gene association studies to the role of hormone variants in migraine.  The variants studied include polymorphisms in hormonal pathways and metabolism. Among the most well studied variants are the ESR-1 594G>A [157-160], ESR-1 325C>G  [158-162], ESR-1 Pvu II C>T [163] and ESR-1 30T>C [158, 160].  The first variant, was found to be migraine associated in a recent meta-analysis [164] as it aslo was the 325C>G polymorphism. This study indicates that carriers of these two variants have 40–60% higher risk to suffer MA or MO when dominant and recessive genetic models were investigated. On the other hand, a 306 base pair insertion within intron 7 (PROGINS allele) has been widely investigated in the PGR gene.  Further studies indicate that this 
39  Chapter 2: Background 
variant is overrepresented in migraine sufferers, however, the evidence is largely speculative and more studies are necessary to reach a definite conclusion [29].  Interestingly, when variants from ESR1 and PGR genes where investigated using a gene interaction analysis, a  synergistic relationship between the G594A and the PROGINS was found.  Thus, carriers of both risk alleles were almost three times more susceptible to experience migraine headache than PROGINS only carriers, whose risk was calculated to be about 1.8.    The ESR-1 gene possess 8 exons and it localizes at  the chromosomal region 6q25.1 [165]. Although there is another beta receptor, the alpha protein is the most abundantly expressed in diverse human brain areas [166] implicated in different ways in pain processing and the modulation of other symptoms present in migraine like the aura symptoms. It is also interesting to note that the two most studied polymorphisms in the ESR1 gene, the 594G>A and the 325C>G are synonymous.  This means that they do not change the amino acid sequence, hence not changing the structure of the ESR-1 protein. It is then possible that , if well these variants are not causing the disease, they might be in high linkage disequilibrium with the real causative variant or they might exert their effects through other mechanisms.  As an example, the Pvu II C>T polymorphism is located in an intronic region and it does not encode any sequence that will be translated into a protein.   However, this polymorphism may have a strong influence on the splicing, thus changing the protein structure and production [167].    PGR is the gene encoding the progesterone receptor protein located on chromosome 11 region q22 [168]. Similarly than estrogen receptors, the progesterone receptors are also widely distributed in different human grain regions [169]. The action of the progesterone receptors is modulated by estrogen and progesterone levels and this is where their strong relationship lay [170]. As it was mentioned previously, the PROGINS polymorphism, a 
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306-bp long Alu insertion is one of the most studied variants in the PGR gene and it is located in intron 7.  It has been hypothesised carriers of the PROGINS polymorphism have lower levels of expressed PGR [171] and that at the same time it increases the risk of migraine although this was only showed for  only individuals with Caucasian ancestry [164].Other polymorphism have been studies in the ESR-1 [158, 159], AR [29] , FSHR  [162], ESR-2 [160], CYP19A1 [162], and NRIP1 [162] genes.  However, they lack of replication studies and thus their association with migraine is still unclear. A summary of the most interesting studies performed on migraine in relation to hormones are presented in Table 2.6.    
          
  Author (P-value)  
 Polymorphism 
Corominas et 
al., 2009 
Oterino et 
al. 2006 
Kaunisto et 
al. 2006 
Oterino et 
al. 2008 
Joshi, et 
al 2009 
Colson et 
al. 2005 
Colson et 
al. 2005 
 
 325 C > G 0.25 0.09 0.005 0.01 0.88    
 594 G >A 0.92 0.57 0.26 - - 0.008 4x10-5  
 Pvu II C > T - - - - 0.02    
 PROGINS 0.86    0.0004 0.039 0.019  
          
 
Table 2.6 Candidate Gene Studies.  Studies investigating polymorphisms in the hormonal genes ESR1 (estrogen receptor 1) and PGR (Progesterone Receptor).   
2.7.6 MENSTRUAL MIGRAINE  Menstrual migraine has an overall prevalence of 3% in the general population and it is divided into two subcategories according to the time in the menstrual cycle where the headaches attacks occur.  The first subtype is known as “pure menstrual MO”. In this subtype of MM the headache attacks exclusively take place 2-3 days before or after the first day of the menstrual cycle. It has been calculated that the prevalence of PMM among migraineours oscillate from 7% to 19%.  The second subtype is the “menstrually related 
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MO”(MRM)  in which attacks are present during the peri-menstrual period in addition to attacks during any other stage of the menstrual cycle [1]. This is the most common subtype of MM with a prevalence that goes 35% to 51% among females in the general population. According to different population-based studies it has been demonstrated that the attacks in PMM and MRM are very similar to those occurring in general migraine and little discrepancy has been reported between them [172]. However, clinical studies suggest that menstrual migraine attacks can be more severe than those happening outside the menstrual cycle [173].  The difference between these results can be explained by possible bias in the recruitment of the samples as clinical studies might have a bigger number of hormonally sensitive individuals than those carry out in the general population.    The implication of menstrual migraine with hormones has been studied in previous studies. For instance, an study comparing the levels of estrogen and progesterone in serum different timelines during the menstrual cycle of females suffering menstrual migraine, non-menstrual migraine and controls, could not stablish any difference in the concentrations of hormones in the blood stream among these groups [149]. Similarly, Epstein and colleagues [174], showed that the concentrations of estrogen during the follicular and luteal phases do not change between females suffering general migraine and menstrual related migraine.  Interestingly, the same authors found that blood concentrations of progesterone were much higher during early stages of the follicular phase in patients whose diagnostic was menstrual migraine.  There is, however, scepticism about the veracity of these findings as the levels of progesterone are usually very low at this specific time of the menstrual cycle.  As per these results, the evidence suggest that there is not fluctuation of the levels of hormones between MM and general migraine sufferers.  Thus, the difference must rely on the sensitivity to the response to changes in the hormonal concentrations.   Thus, different theories have been proposed to explain the menstrual migraine pathophysiology however, the most plausible, based on the available 
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evidence is without doubts, the estrogen withdrawal theory. This theory was proposed my Somerville et al., after an experiment in which the administration of an intramuscular estradiol injection before the menstrual cycle in female patients suffering menstrual migraine, caused the delay of the headache attack by increasing the levels of serum estradiol [175]. Similar experiments were performed in order to determine whether progesterone could have the same effect than estrogen, but no effect was detected [176]. In further studies, Lignieres and colleagues, [177] showed that when a group a cohort of menstrual migraine individuals were administered injections of estradiol only 31% of them experience migraine compared to 96% of the patients developed a migraine attack in the placebo group.  Pradalier et al., replicated these findings and they additionally reported that the levels of estradiol should remain above 45 pg/mL in order to avoid menstrual migraine attacks [178].   2.8 GENETIC DATA CONCEPTS   The following paragraphs are dedicated to the definition of common concepts in genetic studies that will be used through the body of this dissertation, the linkage disequilibrium and the Hardy Weinberg equilibrium concepts.  
2.8.1 LINKAGE DISEQUILIBRIUM (LD)  Many times gene variations detected to be associated with a trait may not have a causal effect on such phenotype because the polymorphism is located in an intronic or intergenic region or because the mutation is of a synonymous type, that is it does not affect the amino-acidic sequence in the coded protein.   However, the association signal reported for these type of variants may be the result of the physical closeness with the real causative variant or what is commonly known as to be in high linkage disequilibrium with a 
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functional variant.   Linkage disequilibrium is defined as the tendency of alleles at linked loci to be inherited together [179] .  Populations with an African ancestry are, in terms of evolutionary aspects, the primeval human populations. Thus, they have experienced more generations for LD to decay than European or Asian populations. Further, bottleneck events associated with migrations out of Africa have led to the reduction of the haplotypic variety in European and Asian populations relative to African- populations.  Therefore, individuals with an African ancestry have a tendency to harbour shorter segments of linked alleles than European or Asian ancestry individuals.  LD is of vital importance in evolutionary biology and human genetics. For instance, genetic drift, natural selection and changes in population size can affect LD. It is said that LD in the genomic context provides information about the natural selection history and other influences that cause evolutive changes in terms of gene frequency. The way these factors affect LD in between a particular pair of loci is dependent on recombination rates taking place in that specific genomic region [180, 181].  
2.8.2 HARDY WEINBERG EQUILIBRIUM  The Hardy-Weinberg equilibrium (HWE) refers to independence of alleles in a single locus.  Thus, given one allele whose genotypes are AA, Aa and aa, the HWE will be achieved if the odds of the A allele on one homolog chromosome is independent on the a allele occurring in the second homolog chromosome. To test whether an variant is in HWE, a method called the Pearson’s χ2-test and the Fisher’s exact test have being develop. Usually the Fisher’s exact test is used when the allele counts are less than five, otherwise the χ2-test is generally used [182].     
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2.9 GENETIC ASSOCIATION STUDIES  Genetic Association Studies aim to correlate genetic information from individuals in the general population or families to a trait. There are a number of statistical methods that have been described to achieve the identification of genes or variants with a determined trait, generally a disease status.  In the following paragraphs these methods have been divided into three categories (candidate gene, fine mapping and whole genome-wide scans are described) aiming the description and better understanding of such techniques.  [182].  
2.9.1 CANDIDATE GENE STUDIES   Candidate gene studies investigate different variants in the same gene that has previously being selected based on the biological function and the possible role that it could exert on the trait under investigation [182].  The investigated SNPs or variants are called markers as since the beginning the investigator knows that they are not possible the real causal disease mutation, instead they are in high LD with it. Candidate genes have become more popular nowadays as they require small sample sizes and the penalty by multiple comparisons in less than the one applied when high trough put techniques like GWAS are implemented. Candidate gene studies are used to validate the findings from GWAS [182].   
2.9.2 FINE MAPPING STUDIES   With a high level of precision, fine mapping studies target the identification, of the genetic location of a disease-causing variant or as it is normally denominated, a mutation. Knowledge about this location can be of great scientific value as it excludes the need for studies based on marker loci, thus decreasing the error and variability in associated tests.   
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2.9.3 GENOME-WIDE ASSOCIATION STUDIES (GWAS)   Similar to the previous studies, GWASaim to identify associations between SNPs and a trait. However, they are less hypothesis driven and also implicate the characterization of a large number of SNPs. The data preprocessing in GWAS studies is more comprehensive and the analysis are computationally speaking more challenging than the previous studies described in this section.  Additionally,  they are implemented in order to explore the interactions between genes and other risk factors like age, diet or gender in complex diseases  [182].  2.10 GENE EXPRESSION ANALYSIS 
 Oligonucleotide and cDNA microarrays are designed to simultaneously measure the levels of expression of thousands of mRNAs. This high-throughput technique is used to predict the biological role of genes that has not been annotated.  It is also used to  infer networks from the analysis of interactions between genes and to investigate the mechanisms by which the gene expression and cell function are affected by an specific disease, drug, mutation and environmental condition [183]. From these analysis, wide datasets are always the result and in order to make them publicly available, different databases specialize in store and classify them.  In this way the scientific community takes advantage of the substantial amounts of gene-expression information provided by every single experiment [184-186]. The challenge now, is to interpret and manage appropriately such information to make the most of these freely available information [183].  The analysis of microarray data begins with a normalization process. In this step the experimental variability across different array spots is reduced while the biological variability is maintained [187]. To address this process, several statistical methods have 
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been designed [188-191] enabling the further statistical analyses considering only the biological variability. Some of these methods include the t tests, non-parametric tests and Bayesian models [192]. They are univariate statistical methods which determine either the (relative) expression of a gene from normalized microarray data.  These analyses generate a list of genes differentially expressed among two or more groups of samples. Caution needs to be taken when selecting the method to use as it has been noticed that different statistical procedures generate non-identical lists[183].  The next step in the analysis of normalized data can be the   grouping or classification of samples and genes according to similarities in their expression patterns.  This methods are called unsupervised clustering analysis and some examples include hierarchical and K-means clustering [193]; Additionally, methods to reduce the dimensionality of the data are also available and they aim to reduce the high-dimension in the expression datasets based on either structure of (co) variance matrix, like principal component analysis [194], or based on local similarity like self-organizing maps [195]).  Pathway analysis, is another alternative to reduce the dimensionality in a given data set; This type of analysis are able to recognize small variations in expression than gene lists resulting from the previously described univariate statistical analysis. Pathway analysis is appropriate for detecting low gene expression levels [183].  
2.11 ISOLATED POPULATION GENETICS  Population genetics is the quantitative study of genetic variation in populations and how allele and genotype frequencies are maintained or changed over time  [196] Population genetics is concerned with genetic, environmental and societal factors that dictate the frequency and distribution of alleles and genotypes in families and communities. When a 
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small number of individuals are separated from the parent population due to factors such as migration or population bottlenecks and sustain isolation, marked changes in allele and genotype frequencies may result. Such communities are commonly referred to as isolated populations. In population genetics, isolated populations are a unique resource to study Mendelian and complex inherited human traits as genetic and non-genetic heterogeneity is expected to be limited or even reduced due to the presence of genetic, environmental and societal factors.  Many isolated populations exist worldwide including the Island of Kosrae, Federated States of Micronesia [197], the European Island country of Iceland  [198], the Islands of Dalmatia, Croatia, Old order Amish of Lancaster County, Pennsylvania, USA [199], Hutterite communities of Canada [200], Bedouin isolates of South Sinai [201],  Paisa Community of Antioquia, Colombia [202],  Pima Indians of Arizona, USA [203] and the European country of Finland [204] to name a few. Isolated populations are defined as having a small number of founding individuals and geographical or linguistic, religious or other cultural barriers that prohibit migration and interbreeding with other groups, thus restricting genetic diversity. One such example is the Ashkenazi Jewish population, which has remained separate from surrounding European populations due to religious and cultural practices of endogamy [205]. Over 20 rare recessive diseases are reported in this isolate.  Genetic drift and founder effect are commonly present in isolated populations, both major evolutionary forces that determine the fluctuation in allele frequencies [196]. The magnitudes of these effects depend on population size, mating and the time elapsed since the initial founding event. Consequently, the genetic structure of each isolated population may differ depending on the evolutionary history of the population and extent of genetic drift and founder effect. In summary, isolated populations may be characterised by one or 
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more of the following characteristics: limited number of initial founders, prolonged isolation, limited immigration and/or migration, high levels of endogamy and consanguineous unions, large genealogies, uniform environment and lifestyle factors, and presence and frequency of population bottlenecks. All of these factors impact upon allelic diversity and linkage disequilibrium (LD), forging unique genetic profiles that may enhance positional cloning of Mendelian and complex human disorders.   
Norfolk Island Population 
 Norfolk Island is a small, volcanic Island located almost 1,500 kilometres west of Brisbane, Australia in the South Pacific Ocean. The island lies between New Caledonia, New Zealand, and Australia along the Norfolk Ridge and has an area of 34.6 square kilometres. Captain James Cook discovered Norfolk Island on October 10, 1774 and claimed it under the British Crown. The first penal settlement was established in 1788, but was abandoned in 1814 due to convict uprisings. In 1825 the then uninhabited Island of Norfolk was re-occupied as a convict station under the British Empire for the most violent felons. Once more, murder, convict uprising and prisoner brutality forced the station to be closed. All inhabitants were relocated to Hobart, Tasmania. Norfolk remained uninhabited until June 1856 [206].   The tale of the Bounty is truly captivating. Originally commissioned for a breadfruit expedition to Tahiti from England, the voyage ended when 24 seamen (from Isle of Man, today a self-governing British Crown dependency) led by Acting Lieutenant Fletcher Christian revolted against Captain William Bligh in the early hours of April 28th, 1789. The mutineers seized control of the Bounty and returned to Tahiti. Upon reaching their destination, 16 crewmen deserted the ship to inhabit Tahiti. Now fugitives of the British crown, Acting Lieutenant Fletcher Christian along with 8 more seamen 12 Tahitian 
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women, 6 Tahitian men and a baby girl fled Tahiti to seek refuge in Pitcairn Island in January 1790[206] . 
 The early years of the Pitcairn settlement were extremely violent. All the Tahitian men and 7 of the mutineers met brutal deaths. And then due to the limited number of founders and extreme geographical isolation, early stages of population growth were characterised by complex relationships with high levels of endogamy and consanguineous unions.  During expansion the already small population suffered bottlenecks in the form of epidemics, drought, and food shortages. Eventually the Island’s natural resources diminished, population growth became unsustainable and relocation was required. To aid the population, Queen Victoria gifted the people Norfolk Island (then uninhabited).  On the morning of June 8th 1856, 194 settlers landed at Kingston, Norfolk Island. The population included 40 men, 47 women, 53 boys, 53 girls and a baby boy born on the relocation voyage (27 islanders left Norfolk to resettle Pitcairn Island in 1863). In 1913 Norfolk Island became an Australian territory. Today about 40 per cent of the close to 2,200 inhabitants on Norfolk are descendents of the Bounty mutineers [207]. The anniversary of the landing on Norfolk Island is celebrated to this present day as a public holiday, known as Norfolk Bounty Day. Strict immigration laws allowing only those of Pitcairn descent to occupy Norfolk Island were established [206].  The islanders live a relatively homogeneous lifestyle due to their isolation, strict quarantine and immigration laws, and community centred culture. Given lifestyle, geographic location and population history, environmental and genetic variation between individuals should be limited.  
Previous studies in the Norfolk Island Population 
 As a consequence of the homogeneity in the Norfolk Island population in terms of genetic and environmental factors, multiple studies have been carried out and invaluable insight 50  Chapter 2: Background 
into the aetiology of different complex disorders has been achieved.  For instance, Bellis et al. demonstrated the potential of this genetic isolate for identifying cardiovascular diseases (CVD) risk factor quantitative trait loci (QTL) [208]. In their study, the investigators  reported a higher prevalence of obesity, CVD risk factors and hypertension in islanders. Additionally, the heritability for traits like triglycerides, cholesterol, and blood pressures was calculated as 0.2 in this specfic population. Furthermore, results from a genome-wide linkage scan showed a LOD score of 2.01 in the 1p36 chromosomal region when the systolic blood pressure trait was analyzed.  Also a region on chromosome 5q35 segregating with weight, waist circumference, HDL-c and total triglyceride levels when different CVD risk traits was detected [209, 210]; Later in 2008, the same authors reinforced the idea of the Norfolk isolate as a powerful resource for the mapping of complex disease genes, when results from a linkage analysis in the Xq13.3 chromosomal region showed that LD in samples from 56 islanders (males) extends up to 9.5-11 Mb [28]. In regards to migraine studies, a heritability of 0.53 and a prevalence of 25% was estimated in the 377-member core pedigree indicating  a significant genetic component for migraine in this population [211].  These findings point towards the conclusion that individuals in the Norfolk Island population possess a high risk to suffer migraine. Further, different studies have shown the association of different gene variants with migraine in individuals from the Norfolk Island.  Thus, Cox et al, provided evidence for association of variants  rs73532286 (beta= 0.286) and rs6426929 (beta=0.315), in the calcium-activated potassium ion channel gene (KCNN3) [212]; A genome wide association analysis was performed in 2012 and SNP rs4807347 (P = 9.6 × 10(-6)), located in the zinc finger protein 555 (ZNF555) showed evidence of statistical association. This association was successfully replicated in a large independent and unrelated cohort with >500 migraineurs [213]. Additionally, another study evaluating variants in the X chromosome, provided evidence for the association of a locus located in the Xq12 chromosomal region with migraine.  The associated SNP rs102834 (P = 1.63 × 10-5) is specifically located in the 
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5'UTR of HEPH gene [10]. More recently an expression quantitative trait loci (eQTLs) was carried out resulting in the identification of 200 cis-acting 70 trans-acting eQTLs (p < 1.84 × 10-7).  In addition, four genes: NAAA, PAPSS1, NME1, and PRDX1 were implicated as possible candidate genes in CVD [121].    
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                   CHAPTER 3  METHODS 
            

OVERVIEW  This research is aimed at identifying migraine susceptibility genes.  Initially, the research was focused on using the genetic isolate of Norfolk Island population to evaluate the genetic association of ESR1 and PGR genes with migraine.  These two genes have been widely investigated and previous studies suggest an strong association with the etiology of general migraine.  Additionally, a Caucasian menstrual migraine population was used as a follow up population to replicate the results found in the Norfolk Island cohort.   The group of evaluated genes in the menstrual migraine cohort was ESR1, FSHR, CGPR, RAMP1, 
LTA, TNF, SYNE1, KCNK18, ESR2, CYP19A1, NRIP1, MIR890, MIR891A and MIR892A.  We have also aimed to identify new migraine genes with moderate effect whose detection is potentiated by using statistical strategies that include polygenic modelling, pathway analysis and clustering methods.   To achieve these goals, DNA, phenotypic data and genealogical information for each participant was required. Clinical diagnostic criterion and empirically derived statistical methods were employed to define phenotypes. A genome wide scan of SNPs previously undertaken in the Norfolk Island population was analyzed by association methods especially suited to large and complex genealogies.  Other genotyping techniques used in this study include standard polymerase chain reaction (PCR), Restriction fragment length polymorphism (RFLP), TaqMan® assay and the MALDI-TOF mass spectrometry based method commercially available as Sequenom®.  Genotypic information was analysed using association test and logistic regression.  To evaluate the expression of genes in cases and controls from the menstrual migraine population we used a SYBR® Green real-time PCR technique.  Subsequently, the levels of expression were compared with the  ΔΔCt method. Correlation between levels of transcription was measured using Pearson’s correlation.  A genome wide expression analysis performed in the Norfolk Island cohort 
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was analysed using diverse statistical methods including pathway analysis using the GSEA software and clustering methodologies.    The objective of this chapter is to describe all methods, techniques and analysis used to obtain the results presented in this thesis.  The first section corresponds to the description of methods and techniques applied to obtain qualitative or quantitative data.  The second section, describes the statistical methods used to perform the analysis of the data acquired using the techniques describe in the earlier section.  Further information about the methodology employed in this thesis are given at the “methods” section of every results chapter, that is from chapter 4 through chapter 9.  
 
3.1 POPULATION ASCERTAINMENT  
3.1.1 NORFOLK ISLAND POPULATION The study protocol was approved by the Griffith University Human Research Ethics Committee. All subjects provided signed, informed consent prior to participation. In brief, subjects were ascertained according to permanent resident status (not selected on phenotypes of interest), to ensure sampling of individuals from the same genealogical background. In the first instance phenotypic data and biological specimens were obtained from 600 subjects (261 males, 339 females) with a mean age of 50.8 years (SD = 16.4 years). Venous blood specimens were available for 600 individuals from their visit to a temporary research clinic on Norfolk Island, carried out during 2000. Blood samples were collected in EDTA tubes. DNA was isolated from a 10-20ml sample using a standard salting-out procedure [214]. DNA concentration (ng/µl) and purity (260nm:280nm) were determined spectrophometrically using the NanoDrop ND-1000 (NanoDrop Technologies, Inc.).  Phenotypic data were obtained via a comprehensive medical questionnaire that 
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included a section specific to migraine. Detailed questions regarding family history, symptoms, triggers, and medication were obtained. Migraine diagnosis was established in accordance with current IHS guidelines [43].   
3.1.3 MENSTRUAL MIGRAINE POPULATION  Menstrual migraine is a population of 437 females recruited by the City of London Migraine Clinic, including both Pure Menstrual Migraine (PMM) and Menstrual Related Migraine (MRM) cases and controls. Migraine diagnosis was in accordance with ICHD-II [215]. The inclusion criteria for cases selection was the occurrence of attacks on day 1 ± 2 of menstruation in at least two out of three menstrual cycles. Diagnosis of PMM and MRM  was confirmed by diary evidence from at least three menstrual cycles.  Controls were women with no personal or family history of migraine, age and ethnicity matched to cases. Biological specimens were collected and transported to the Genomics Research Centre for further processing. Saliva samples were obtained from the 437 females (282 cases: 68 PMM and 214 MRM; and 155 controls (median age 45.0; range 21-60 vs. 39.5; 22-61 years). Saliva samples were collected and DNA isolated using Oragene (Australia) Saliva DNA extraction kits. 74 patients (41 cases and 33 controls (median age 42.0; range 21-49 vs. 35.5; 24-49 years) with paired follicular and luteal phase samples available for 30 cases and 29 controls from the same population, who had not taken any hormonal treatment (including dietary isoflavone supplements) within the previous three months, were asked to donate blood samples at both luteal and follicular menstrual cycle stages. A total number of 134 samples were collected in Paxgene tubes for expression analysis purposes. mRNA extraction was carried out using Qiagen  PAXgene blood miRNA kits (Catalog # 763134).  Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, medication use and contraceptive use.  The study protocol was originally approved by the Griffith University Human Research Ethics 
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Committee and subsequently by the Queensland University of Technology Human Ethics Committee (Australia), and the East London and the City Research Ethics Committee (UK). All subjects provided signed, informed consent prior to participation.  3.2 GENOTYPING TECHNIQUES  
3.2.1 GENOME-WIDE SCAN OF SINGLE NUCLEOTIDE POLYMORPHISMS 
This study also undertook a genome wide scan of autosomal SNPs markers to identify genomic regions involved in the predisposition of migraine in the extended Norfolk Island pedigree. All genotyping for this genome wide association study (GWAS) was undertaken at the Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas 78245-0549, USA. DNA samples were genotyped according to the manufacturer’s instructions on Illumina Infinium High Density (HD) Human610-Quad DNA analysis BeadChip version 1. This method was selected for having a high genomic coverage of common SNPs and CNV regions. A total of 620,901 genome wide markers were genotyped in a sub-sample of 285 related individuals (135 males; 150 females). Markers had a median spacing of 2.7kb (mean = 4.7kb) throughout the genome.   
Each Human610-Quad DNA analysis BeadChip employed a four-sample format requiring 200ng of DNA per sample. Samples were scanned on the Illumina BeadArray 500GX Reader. The infinium HD assay protocol utilises single-tube sample preparation and whole-genome amplification without PCR or ligation steps. The whole-genome genotyping method using the single-base extension assay has 4 steps: a single-tube whole-genome amplification, an array-based hybridization capture, an ‘on array’ enzymatic allele-specific primer extension and lastly, an amplified-signal detection [216, 217]. The unlabelled DNA is fragmented and hybridised to 50-mer oligo probes on the BeadChip. Second is the allele 
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detection, which involves an enzymatic single base extension with labelled nucleotide. The samples are then washed, stained and scanned. Using a 4-sample format, each sample can be scanned in 9 minutes.  
Raw data was obtained using Illumina BeadScan image data acquisition software (version 2.3.0.13). Preliminary analysis of raw data was undertaken in Illumina BeadStudio software (version 1.5.0.34) with the recommended parameters for the Infinium assay and using genotype cluster files provided by Illumina. Individuals with a call rate below 95% and SNPs with a call rate below 99%, deviating from Hardy-Weinberg equilibrium  (PHWE<1x10-7) or with a minor allele frequency of less than 1% were excluded from analysis.  
3.2.2 G594A GENOTYPING   Genotyping of the G594A variant in ESR1 gene was carried out by using PCR-RFLP.  DNA samples (20ng/uL) were incubated in a 20 uL reaction with dNTPs (0.2mM),  5X buffer, MgCl2 (3.75mM), reverse primer (5’GCC ATT GGT GTT GGA TGC ATG C3’) and forward primer (5’GAG GAG ACG GAC CAA AGC CAC3’) (0.25uM), 5U of Taq Polymerase and water under the following cycling conditions: an initial step at 94°C for 2 min followed by 5 cycles of 94°C for 45 s, 69°C for 1 min, and 72°C for 2 min; then 30 cycles of 94°C for 30 s, 67°C for 30 s and 72°C for 45 s and a final step of 72°C for 5 min.  The restriction enzyme BtgI (New England Biolabs, Australia) was used for the determination of the SNP genotype.   
3.2.3 PROGINS GENOTYPING 
 PROGINS insertion/deletion was tested with a standard PCR. DNA samples (20ng/uL) were incubated in a 25 uL reaction with dNTPs (0.2mM), 5X buffer, MgCl2 (1.4 mM), 
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reverse primer -5'-AAA GTA TTT TCT TGC TAA ATG TC-3'- and forward primer -5'-GGC AGA AAG CAA AAT AAA AAG A-3'-(0.24uM), 6U of Taq Polymerase (Invitrogen)  and  water under the following cycling conditions: an initial step at 94°C for 4 min followed by 30 cycles of 94°C for 30 s, 51°C for 30 s, and 72°C for 45 s and a final step of 72°C for 2 min. Samples were then observed on a 2% agarose gel to detect the presence of the PROGINS insert. 
3.2.3 SEQUENOM PLEX  A total of 34 SNPs were selected from 14 different genes on nine chromosomes as the research panel for the study. Selected SNPs were located in genes involved in neuronal, hormonal and immunologic pathways previously associated with migraine. The SNPs were tested by using the Sequenom genotyping platform (Sequenom®, San Diego, CA, USA), which uses MALDI-TOF mass spectroscopy and MassARRAY technology with an iPlex system.  Primers for polymerase chain reaction (PCR) amplification and single base extension were designed by Sequenom Assay Design 3.1 software (Sequenom, San Diego, CA, USA) according to the manufacturer’s instructions.  3.3 GENE EXPRESSION TECHNIQUES  
3.3.1 GENOME WIDE EXPRESSION STUDY  For gene expression analysis, blood was collected and stored at −20°C in PAXgene tubes (QIAGEN). PAXgene Blood miRNA Kits (QIAGEN) were used for extracting total RNA according to the manufacturer’s instructions, and RNA was assessed for quality with the Bioanalyzer 2100 (Agilent Technologies). A total of 250 ng of RNA was amplified and labeled with the Illumina TotalPrep-96 RNA Amplification Kit (Life Technologies) 
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according to the manufacturer’s instructions. Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) with 750 ng of amplified RNA according to the Whole-Genome Gene Expression Direct Hybridization Assay Guide. Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1). Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the number of expressed probes (at detection p values ≤ 0.05), mean raw expression values across probes, and correlations (across probes) between samples, all samples provided high-quality data, except for one sample that was of questionable quality (this was removed). Significantly expressed probes were then determined at a false-discovery rate of 5% on the basis of p values generated in a binomial test on the counts of samples in which a probe generated detection p values ≤ 0.05 (success) and > 0.05 (failure). Subsequently, the raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization. 
 
3.3.2 PGR, ESR1, SYNE1 AND TNF GENES EXPRESSION    A two-step quantitative reverse transcription PCR (qPCR) was performed. An amount of 100ng of RNA was converted into cDNA by adding  9.2ng/uL Invitrogen Random Hexamers, dNTPs (500uM), and free-RNAse H2O to a final volume of 32.5ul. The reaction was incubated at 65°C for 10 minutes in a thermocycler to disrupt secondary structures, followed by a second incubation on ice for at least 5 minutes.  In the second step of the reaction, 1st Strand Buffer (1X), DTT (2mM), SuperScript® III Reverse transcriptase (100U) and RNase-free H2O were added to the previous reaction product for a final volume of 50 ul. The cDNA synthesis reaction was carried out with an initial incubation of 25°C for 5 minutes, followed by a 50°C for 60 minutes and a final step of reaction 
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inactivation at 70°C for 15 min. Stock cDNA was stored at -80°C and 1:2 diluted cDNA working samples were stored at -20°C.     To scan levels of expression of PGR, ESR1, SYNE1 and TNF genes we used SYBR Green PCR Master Mix 1X (Life Technologies, Australia), 200 nM reverse and forward primers (Additional file 2), Rox (reference probe) 2X, 100 ng of cDNA and free RNase-H2O to a final volume of 10 ul.  Fifty cycles of 50°C-2min, 95°C-3min, 95°C – 3 s, and 60°C–30 s were carried out in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Australia).  In order to allow for relative quantitation of gene expression, we used the reference genes 18S and GADPH.  Efficiency tests for all primers sets to be used (Appendix 2) were performed and amplification efficiencies were found to be comparable.   
3.4 DATA ANALYSIS  
3.4.1 ASSOCIATION TESTS  
Norfolk Island population To evaluate genetic association of SNPs in the Norfolk Island population we used the GenABEL package [218]. Originally GenABEL-package was developed to facilitate GWA analysis of quantitative traits using data coming from extended families and/or collected form genetically isolated populations. At the same time GenABEL-package implements a large number of procedures used in analysis of population-based data; it supports analysis of binary and quantitative traits, and of survival data. GeneABEL is implemented as a library in R [219].  As a default, GenABEL first checks the data for SNPs and samples with low call rate (<95%), SNPs with Minor Allele Frequency (MAF) (<0.87%); SNPs out of HWE, samples with extreme autosomal heterozygosity (FDR at 0.01) and those which have 
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genome wide Identity by State (IBS) ≥ 0.95; GeneABEL estimates  residuals of the trait and the inverse of the variance-covariance matrix for further use in analysis with the common “mmscore”.  The MM score is score test for association between a trait and genetic polymorphism, in samples of related individuals.  The Score test is calculated by the following formula  
𝑚𝑚𝑚𝑚 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = ((G − E[G])𝑉𝑉−1𝑆𝑆𝑆𝑆𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑌𝑌)2(G − E[G])𝑉𝑉−1(𝐺𝐺 − 𝐸𝐸[𝐺𝐺])   where G is the vector of genotypes (coded 0, 1, 2) and E[G] is a vector of (strata-specific) mean genotypic values; V−1 is the InvSigma and residual Y are residuals from the trait analysis.  The mm score is similar to that implemented by Abecasis et al [220].  
Menstrual Migraine Population We initially performed a basic case/control association test  implemented in PLINK [221]. The basic association test is for a disease trait and is based on comparing allele frequencies between cases and controls (asymptotic and empirical p-values are available). In order to minimize the effect of having a dissimilar number of cases and controls in our study, we implemented a logistic regression analysis in R [219] for only those SNPs with  p-values < 0.01 in the previous association test.  A Wald test was applied to fit the logistic regression model.    
3.4.2 GENE EXPRESSION ANALYSIS  
Norfolk Island population 
 
(Equation 3.1) 
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Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1)[222]. Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the 
number of expressed probes (at “detection p values” ≤ 0.05), mean raw expression values across probes, and correlations (across probes) between samples, all samples provided high-quality data, except for one sample that was of questionable quality (this was removed). Significantly expressed probes were then determined at a false-discovery rate of 5% on the basis of p values generated in a binomial test on the counts of samples in which a probe generated “detection p values” ≤ 0.05 (success) and > 0.05 (failure). Subsequently, the raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization.   
Pathway analysis 
 Pathway analysis was performed using GSEA [223] . GSEA assess gene set enrichment of  KEGG (c2.kegg.v4.0.symbols.gmt) pathways that show an overrepresentation of up- or downregulated genes between cases  and controls.  Each gene is ranked by their expression difference using weighted Kolmogorov-Smirnov global statistic.  GSEA reports two main scores: the enrichment score (ES), which reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes and the normalized enrichment score (NES) which normalizes the enrichment score in order to be comparable between gene sets. Detail information on the parameters used is provided in chapter  6.      
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Supervised clustering 
 A supervised clustering analysis was performed to replicate specific gene interactions, previously reported by other authors,  that could explain the migraine outcome.  For this, we clustered genes from a genome wide expression array into groups (Axes) reported by Preininger et al [224].   Probes in every axis were selected according to the supplementary list provided.  12665 probes were chosen for comparison purposes with the Emory-Georgia Tech Center for Health Discovery and Well-Being (CHDWB) cohort in Preininger’s work. Principal Component Analysis (PCA), logistic regression analysis and Perason’s correlations were performed using R [219].    
Unsupervised clustering 
 Unsupervised clustering analysis was performed using the Weighted correlation network analysis (WGCNA) package implemented in R [225]. WGCNA can be used for finding clusters (modules) of highly correlated genes, for summarizing such clusters using the module eigengene or an intramodular hub gene, for relating modules to one another and to external sample traits (using eigengene network methodology), and for calculating module membership measures. Correlation networks facilitate network based gene screening methods that can be used to identify candidate biomarkers or therapeutic targets.   
Menstrual Migraine population 
 
For expression analysis the ΔΔCt method was used. The  ΔΔCt  algorithm, is a convenient method to analyze the relative changes in gene expression. It requires the assignment of one or more housekeeping genes, which are assumed to be uniformly and constantly 
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expressed in all samples, as well as one or more reference samples. The expression of other samples is then compared to that in the reference sample [226]. The ΔΔCt calculations were executed using Microsoft Excel software [227].  The statistical significance of differentially expressed genes between cases and controls was determined by a standard t-test.    
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Among the most relevant epidemiological observations is the significant sexual dimorphism 
in the prevalence of migraine in men and women after puberty (3-4 times higher in women). 
European and American studies have shown that 6-8% of men and 15-18% of women 
experience migraine each year. The higher rates in women are thought to be hormonally-
driven and numerous epidemiological, clinical and molecular studies support this theory. 
Genetic association studies in sex hormone receptor pathways and metabolism have provided 
some evidence supporting a hormonal role in migraine etiology.  In the following chapter we 
aimed to investigate the hormonal influence on migraine by studying the ESR1 and PgR 
genes in the Norfolk Island population.                

                CHAPTER 4  ASSOCIATION OF ESTROGEN RECEPTOR GENE (ESR1) POLYMORPHISMS WITH MIGRAINE IN THE LARGE NORFOLK ISLAND PEDIGREE.               
This chapter has been published as a journal paper : 
 
Rodriguez-Acevedo AJ, Maher BH, Lea RA, Benton M, Griffiths LR. 2013. Association of oestrogen-receptor gene (ESR1) polymorphisms with migraine in the large Norfolk Island pedigree. Cephalalgia. 2013 Oct;33(14):1139-47.   

4.1 WORK FLOW                                                   
4: 
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4.2 ABSTRACT  
Background 
 
ESR1 (Estrogen receptor 1) is located in region 6q25.1 and encodes a ligand-activated transcription factor composed of several domains important for hormone binding and transcription activation.  PGR (Progesterone receptor) is located in 11q22-23 and mediates the role of progesterone interacting with different transcriptional co-regulators.  
ESR1 and PGR have previously been implicated in migraine susceptibility.  Here, we report the results of an association study of these genes in a migraine pedigree from the genetic isolate of Norfolk Island, a population descended from a small number of Isle of Man “Bounty Mutineer” and Tahitian founders.  
 
Methods 
 
 A number of molecular markers in the ESR1 (143) and PGR (43) genes (Appendix 1)were evaluated in a sample of 285 related individuals (135 males; 150 females). A pedigree-based association analysis using the GenABEL package in R.  Additionally, a haplotype analysis was carried out using the haploview software.  
 
Results and Conclusions 
 A total of ten markers in the ESR1 gene showed association with migraine (P<0.05)  in the Norfolk Island population. No association was detected in any of the evaluated SNPs in the PGR gene.  Three haplotypes in the ESR1 gene were found to be associated with migraine (P=0.004, 0.03, 0.005).  These results provide evidence to support the hormonal driven mechanisms in migraine aetiology.  However, future genetic studies in larger populations and expression analysis are required to clarify the role of ESR1 in migraine susceptibility.   
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4.3 INTRODUCTION  Migraine has been defined as a common disabling primary headache disorder by the International Headache Society (IHS) [43].  The second edition of the International Classification of Headache Disorders (ICHD-II) drafted by the IHS [43] classifies migraine into two major groups, migraine without aura (MO) and migraine with aura (MA).  MO is the most common form with headache attacks lasting between 4-72 hours.  MA sufferers, in addition, often experience aural symptoms preceding the headache phase of the migraine episode [228].    Migraine is more common in those aged between 35 and 45 years although generally attacks start in puberty. Among the most relevant epidemiological observations is the significant sexual dimorphism in the prevalence of migraine in men and women after puberty (3-4 times higher in women) [229]. European and American studies have shown that 6-8% of men and 15-18% of women experience migraine each year. The higher rates in women are thought to be hormonally-driven and numerous epidemiological, clinical and molecular studies support this theory [29, 164, 230, 231]. Genetic association studies in sex hormone receptor pathways and metabolism have provided some evidence supporting a hormonal role in migraine etiology.     As part of a systemic review of genetic association studies in hormonal receptors and pathways in migraine, Schurks et al. [164] found that to date 8 genes have been investigated, namely ESR1, ESR2, PGR, AR, FSHR, NRIP1, CYP19A1 and MTHFR.  However, results from these studies are contradictory and need to be replicated in different populations.     The Estrogen receptor 1 (ESR1) gene is located on chromosome 6q25.1 and its protein 
ER1 (or ERα) [232], mediates the action of 17β-estradiol or E2, an important endogenous steroid hormone [233].   In the human brain the ER1 protein is mainly expressed in frontal and prefrontal cortex, amygdale, mediobasal hypothalamus and locus coeruleus [234]. It acts as an activator and regulator of important neurotransmitter systems such as the serotonergic, noradrenergic and GABAergic systems. In addition, the Progesterone receptor (PGR) gene, is located on chromosome 11q22-23, and mediates the role of progesterone interacting with different transcriptional co-regulators.  PR protein is expressed in a variety of human tissues, including the uterus, mammary gland, pancreas, 74  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
bone, ovary, testes and various regions of the human brain, including serotonin neurons [169].    In the present study we analyse ESR1 and PGR SNP data from a Genome Wide Association Study (GWAS) to investigate hormone receptor molecular markers with migraine in the genetic isolated population from Norfolk Island, which has previously been shown to have a very high prevalence of migraine [211] and a heritability of 0.53 [211]. The modern Norfolk Island population comes from a settlement of 194 inhabitants that resettled from the Pitcairn Islands in 1856.  All of these inhabitants were the descendants of nine “Bounty” mutineers and twelve Tahitian women [16]. This population is therefore characterized by founder effect, geographical and cultural isolation, high levels of consanguineous unions during early population expansion, population bottlenecks, admixture and a homogenous environment [208]. Thus, these characteristics together make Norfolk an excellent model to investigate the genetics of migraine.   4.4 METHODS  
Population Samples 
 Phenotypic data and biological specimens (venous blood) were obtained from 600 subjects (261 males, 339 females).  DNA was isolated using a standard salting-out procedure (24).   Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, and medication use.  A in depth interview and comprehensive medical questionnaire was undertaken on all individuals and used to obtain phenotypic data including migraine information regarding family history, symptoms, triggers and medication. Migraine diagnosis was in accordance with ICHD-II guidelines. The inclusion criteria used to select cases was a diagnostic of MA or MO with other non-migraineurs included in the control population.  Genealogical data were obtained from multiple sources, including questionnaire, municipal and historical records. Because all the individuals share a common genetic background all individuals diagnosed with subtypes MA or MO were grouped together and phenotyped as being affected with migraine. The study protocol was approved by the Griffith University Human Research Ethics Committee. All subjects provided signed, informed consent prior to participation   
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 DNA samples from the Norfolk Island Population were genotyped according to the manufacturer’s instructions on the Illumina Infinium High Density (HD) Human610-Quad DNA analysis BeadChip version 1. This method was selected for having a high genomic coverage of common SNPs and CNV regions. A total of 620,901 genome wide markers were genotyped in a sub-sample of 285 related individuals (135 males; 150 females). All samples were genotyped individually but 28 randomly selected samples (5% of both cases and controls) were repeated to ensure concordance and accuracy of genotyping. Of these related individuals 76 are migraine cases (22 males, 54 females). These individuals possessed high inheritance information and were extremely informative for pedigree-based analysis, facilitating cost-effective genotyping.  Markers had a median spacing of 2.7kb (mean = 4.7kb) throughout the genome.  Each Human610-Quad DNA analysis BeadChip employed a four-sample format requiring 200ng of DNA per sample. Samples were scanned on the Illumina BeadArray 500GX Reader. Raw data was obtained using Illumina BeadScan image data acquisition software (version 2.3.0.13). For the present study 143 SNPs from ESR1 gene and 43 SNPs in PGR gene were selected.  These molecular markers are distributed along each gene and in intergenic regions.   
Statistical Analysis 
 Data analysis was performed with the GenABEL package [218], a statistical tool implemented as a library in R [219].  R is a free, open source language and environment for statistical analysis. First, a quality control of the data was performed using the default settings provided by the Software.  GenABEL quality control checks the data for SNPs and samples with extremely low genotype call rate (<95%), SNPs with MAF (Minor Allele frequency) (<0.87%); SNPs out of HWE (Hardy Weinberg Equilibrium), samples with extreme autosomal heterozygosity (FDR=0.01) and these who have Genome Wide Identity by State (IBS ≥ 0.95); The software excludes all marker and individuals that fail to pass these tests.  The quality control is repeated iteratively until no further errors are found.  A polygenic analysis was carried out to account for the pedigree relatedness followed by a family-based association test. The MM score employed is a score test for association between a trait and genetic polymorphism in samples of related individuals.  This test is similar to that implemented by Abecasis et al [220]. Subsequently, a P-value is calculated. Because the SNPs analysed in this study are in high LD, it is probably that its transmission is not independent, therefore, we did not performed a Bonferroni correction on the obtained P-values.  Haplotype analysis was carried out in Plink-1.07-dos [221]. Plink uses 76  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
a two marker Expectation–Maximization (EM) to estimate the maximum-likelihood values of the four gamete frequencies, from which the D′, LOD and r2 calculations derive. Haplotype phase and population frequency are inferred using a standard EM algorithm with a partition–ligation approach for blocks with greater than 10 markers. By default, pairwise LD is only calculated for SNPs within 200kb.  Haploview 4.2 was used as a graphical tool to depict results from PLINK [235].    4.5 RESULTS 
 
Genotyping A total of 186 markers in 285 individuals were analysed using the GenABEL package in the R platform [219]. Among these markers, four (rs11967900, rs17081771, rs9397459, rs7739506) were excluded due to a low minor allele frequency (<0.086); 1 marker was excluded because it was out of HWE (rs9479122); and 2 markers were excluded for having a low call rate (rs4870053, rs504372). A total of 17 individuals were also eliminated from the analysis because of low genotyping call rate (<95%) or high IBS (>=0.95). In total 138 markers and 268 individuals passed all quality control criteria and were included in the analysis.   Table 4.1 shows the top ten markers analysed in the PGR and ESR1 genes ranked by P 
value.  Association was detected in 10 markers (≤ 0.05) in the ESR1 gene.  Association was detected in regions upstream and downstream of the ESR1 gene.  Interestingly SNPs rs2813554, located closely to SYNE1 (a neighbour gene), and rs9322361 present in an intronic region of SYNE1, also showed association.  We also looked at a gender specific analysis but none of the SNPs included in this study showed a positive gender association with migraine (P>0.07). This may be due to lower power from the reduced gender specific number of samples.  In contrast, no association with migraine was detected for any of the markers in the PGR gene.    
Haplotype Analysis Marker–marker linkage disequilibrium (LD) measures, D′ and r2 were computed for both the ESR1 and PGR genes.  The pairwise D′ results produced by Haploview are presented graphically in Figures 4.1 and 4.2. Several regions of high LD were identified within ESR1  
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Table 4.1.  Top ten markers analyzed in the ESR1 and PGR genes.  Because there are some markers located in an intergenic region between ESR1 and SYNE1 genes, the marker function in this table  is given with respect to the position of one gene or another according to the USCS Genome Browser (26).  
    SNPs  Position  Function  Minor/Major Allele  MAF  P-value   
 ESR1  rs2813554  152484031 Intergenic/Downstream SYNE1  A/G  0.211 0.01  
    rs9383939  152047871 Upstream ESR1  A/G  0.045 0.01  
    rs10484919  152016115 intergenic/Upstream ESR1  T/C  0.186 0.01  
    rs9341066  152461219 Intronic 8 ESR1  A/G  0.045 0.02  
    rs2813544  152467275 Intronic/Dowstream ESR1  A/G  0.194 0.02  
    rs7767143  152137387 Intronic/Dowstream ESR1  A/G  0.331 0.02  
    rs851971  152019166 Upstream ESR1  A/G  0.302 0.02  
    rs851967  152022849 Upstream ESR1  A/G  0.303 0.02  
    rs851998  152025031 Upstream ESR1  C/T  0.302 0.02  
    rs9383938  152029050 Upstream ESR1  G/T  0.166 0.04  
 PR  rs11571133  101002666 Upstream  A/G  0.015 0.11  
    rs537681  100988034 Intronic  C/T  0.436 0.12  
    rs7116336  100962873 Intronic  T/A  0.301 0.22  
    rs600677  100887598 Upstream  A/G  0.209 0.23  
    rs635984  100923166 Intronic  C/G  0.481 0.31  
    rs558959  100911508 Intronic  C/T  0.292 0.33  
    rs606789  100913165 Intronic  A/G  0.283 0.33  
    rs511484  100918433 Intronic  C/G  0.282 0.33  
    rs547378  100922939 Intronic  A/G  0.278 0.33  
    rs11224575  100924033 Intronic  A/G  0.325 0.33  
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Figure 4.1.  ESR1 structure and associated haplotypes in gene region.  Horizontal bold blue lines indicate ESR1 and SYNE1 genes.  Vertical bold blue lines indicate the position of the exons in ESR1.  Red arrows indicate transcription direction for every of the genes in the graphic.  The red box in the 5’ end of ESR1 indicates the position of a promoter associate sequence present in a migraine associated region in a strong LD. The diagram in the lower part is an intermarker linkage disequilibrium plot for the markers with the top fifteen p-values in the polygenic analysis  (Figure 4.1).  A total of 23 haplotype blocks were identified and a haplotype association analysis was performed.  Association was detected in 4 haplotype blocks in ESR1 gene.  The first block includes 9 markers and it spans 25 kb through the 5’ end of the gene.  The first SNP in this block, rs10484919, is 2.8 kb upstream the transcription start site, however it does not belong to the promoter region (10 kb upstream transcription start site).  The last marker in block 1 is rs7745737, located at the 5’ end of intron 1.  The 6th and 7th block are 2.7 kb and 0.362 kb long respectively and are separated by 2.5 kb. The last associated block is number 21 and it spans 24.88 kb through the 3’ end of the gene.  This block starts 1774 bp downstream ESR1 and finishes in the last exon of the SYNE1 gene.       
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Figure 4.2. PGR Intermarker linkage disequilibrium (LD) plot.   In the upper part of the graphic the PGR gene structure is shown. Vertical bold blue lines indicate the position of the exons in PGR. The diagram in the lower part is an intermarker linkage disequilibrium plot for the markers with the top fifteen p-values in the polygenic analysis.   Areas delimited with a solid black line show haplotypes detected after the analysis performed with Haploview.
Exon 1 2 3 4 5 6 7 PGR 
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Association analysis in the ESR1 gene was also performed using haplotypes formed by the markers with the top fifteen single-marker p-values (<0.065). We selected just 15 markers out of 143 to carry out the haplotype analysis in order to avoid large haplotypes including too many markers that can result in many haplotype configurations and therefore cause the dilution of association signals. Figure 4.1 shows the 3 haplotype blocks that were detected.  The first block spans 31.75 kb in a region upstream of the gene.  The second block is in intron 1 and the last block includes a region of 16.7 kb downstream ESR1 gene (Figure 4.1). Table 4.2 presents the association study results obtained for these haplotype blocks and Table 4.3 shows D’ values  of the ESR1 SNPs in the associated haplotype blocks.  Haplotype TGGCTA in block 1 (p-value=0.018, OR=1.6, CI=0.96-2,70) is significantly overrepresented in migraine cases.  In contrast, haplotype CAATGG (p-value=0,007, OR=0.6, CI=0,39-0,97) is more frequent in controls suggesting a protective role in the disease.  A third haplotype, the most common for the first block, seems to have a neutral effect (see Table 4.4).A second block detected in intron 2, including 2 SNPs, also suggests association with migraine (p-value=0.03, OR=0.7, CI=0,47-0,96).  A similar result is seen in block 3 with the frequency of haplotype GAA almost doubled in cases compared to controls (p-value=0.0014, OR=1.7, CI=1.05-2.69), suggesting that this haplotype may be a risk factor for the disease.     Haplotypic association analysis in the PGR gene identified 4 haplotype blocks (Figure 4.2), however none of these showed association with migraine.  Table 4.5 shows the most common haplotype for every block detected in PGR gene and its frequency. As in the individual SNPs analysis, we did a specific gender analysis for haplotypes and found no positive association results in either men or women (p>0.1).  4.6 DISCUSSION  Previous case-control association studies have demonstrated association between migraine and the polymorphism G594A in the ESR1 gene (rs2228480) in two different Australian cohorts (P-value=0.003 and P-value ≤ 0.001) [157]. In contrast, other association studies in Spanish and Finnish population did not report any association with migraine and rs2228480. However, this polymorphism has been associated with breast cancer (P-value=0.05) (16), supporting a role for the gene in diseases with complex hormonal influences on pathogenic process.  In addition, six studies have also reported association results for the polymorphism C325G in the ESR1 gene (rs1801132).  Two of these studies suggested an increased risk for migraine under a recessive 81  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
Table 4.2.  Association test for Haplotype blocks in ESR1. 
 Blocks SNPs P-value   Block 1 rs10484919 rs851971 rs851967 rs851998 rs9383938 rs9383939 0.004   Block 2 rs3020343 rs3020348     0.028   Block 3 rs2813544 rs2813550 rs2813554       0.005    
Table 4.3.  D’ values  of the ESR1 SNPs in associated haplotype blocks 
 Block 1   rs10484919 rs851971 rs851967 rs851998 rs9383938 rs9383939  
   rs10484919              
   rs851971 1.00        
   rs851967 1.00 1.00       
   rs851998 1.00 1.00 1.00      
   rs9383938 1.00 1.00 1.00 1.00     
   rs9383939 0.98 1.00 1.00 1.00 0.985    
 Block 2   rs3020343 rs3020348          
   rs3020343   1.00       
   rs3020348 1.00            
 Block 3   rs2813544 rs2813550 rs2813554        
   rs2813544           
   rs2813550 1.00        
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Table 4.4. ESR1 Haplotypes with estimated frequencies.    Frequencies     Haplotypes Cases  Controls P-value   rs10484919 rs851971 rs851967 rs851998 rs9383938 rs9383939      T  G G C T A 0.2 0.11 0.018   C A A T G G 0.22 0.36 0.007   C G G C G G 0.57 0.52 0.516   rs3020343 rs3020348          T A     0.39 0.5 0.03   C C         0.61 0.49 0.03   rs2813544 rs2813550 rs2813554         G A A    0.25 0.14 0.001   A C G    0.13 0.21 0.026   A A G       0.62 0.65 0.488   
Table 4.5. PGR Frequency haplotype blocks 
 Number of Haplotype block Haplotype Frequency   Block 1 GTGAATTGCCGCAACCTTA 0.312   Block 2 TACGGAGA 0.281   Block 3 ATGAGCT 0.344   Block 4 GACCGG 0.281      83  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
model which appeared to be strongest among women (P-value=0.02 and P-value=0.01) [160, 162].  Joshi et al [236] also considered the ESR1 Pvu II C>T polymorphism (rs2234693) and detected significant association of the TT genotype (OR 3.45, CI 1.75, 6.81; P=0.0003) and the T allele (OR 1.729, CI 1.309, 2.284; P=0.0001) with migraine. In addition, Colson et al did not find significant results after analysing this polymorphism (P-value=0.31). Finally, SNPs rs6557170, rs2347867, rs6557171, rs4870062 and rs2077647 have been studied on ESR1 without any positive outcome in Finnish population.  The aim of our study was to investigate ESR1 and PGR genetic variations and migraine in a large Norfolk Island pedigree consisting of 285 related individuals.  Our results show strong evidence of ESR1 association with migraine in this population.  In this gene, ten out of 143 SNPs were found to be significantly associated with migraine.  Among these markers, 7 are located upstream of ESR1 (Table 4.1), suggesting a regulatory role on the expression of ESR1 transcript. Some of these SNPs have been previously associated with other oestrogen related disorders.   The rs9383939 marker which is located in haplotype block and it has been previously associated with low Bone Mineral Density (BMD) in a cohort of premenopausal American women [237].  Similarly, markers rs10484919 and rs9383938 have been significantly associated with breast cancer risk in Chinese population [238] and in Norwegian postmenopausal women [239], respectively.  Interestingly, 3 SNPs (rs2813554, rs2813544 and rs7767143) are downstream, in an intergenic region between ESR1 and SYNE1.  SNP rs2228430 previously reported to be associated in an Australian population, showed no association in our study.  Other previously associated variants such as rs1801132 and rs2234693 were not included in our analysis.    The haplotype analysis performed in the ESR1 gene supports the use of the Norfolk Island Population as a genetic isolated population with a well conserved homogeneous genetic structure. A previous study, reported an increased risk (OR 1.81) in marker rs6557170 in a case control population from Finland [159] .  The authors reported this marker to be in a haplotype with an initial significant P-value =0.01, but it was not remain significant after taking multiple testing into account. This haplotype includes two markers studied in the present investigation, rs6557170 and rs6557171.  Our results show no individual or haplotype association but they demonstrate the presence of several risk haplotypes that should be considered for future studies in terms of SNP selection.   In the haplotype analysis performed in the ESR1 gene considering the 15 most significant associated markers, one block of 6 SNPs was identified  5.4 kb upstream ESR1 transcription 84  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
start site.  This region includes a promoter associated site with DNAse I enriched sites. This promoter fragment is 176 bps long and marker rs9383939 (P-value=0.04) is located at position 68 (Figure 4.1).  The presence of a promoter associated region within the associated haplotype block suggests a possible causal mechanism for of the association found in this area upstream of the gene.  SNPs mapping to this region have recently being associated with other phenotypes in which estradiol metabolism is implicated.  A study comparing 6q25 breast cancer hits from Asian and European Genome wide Association studies in the Breast Cancer Consortium (BCAC), found two SNPs, located approximately 170 kb upstream of ESR1, to be associated with breast cancer risk [240]. Other SNPs mapping to this region have also been implicated in a GWAS for bone mineral density [241].  In addition, a recent paper showed that a number of genes, including ESR1 and C6orf97 (ESR1 neighbour), are co-regulated at this locus although the function of most of these genes are unidentified [242].      A second block, incorporating 2 markers is located in intron 2 of the same gene.  This implies possible LD of these markers with real causal variants present in splicing sites or coding regions in the gene.  The third associated block starts 1174 bp downstream ESR1, it extends 33.5 kb and finishes with marker rs9322361, located in intron 141 in SYNE1 gene (see Figure 4.1).  This gene encodes a spectrin repeat containing protein expressed in skeletal and smooth muscle, and peripheral blood lymphocytes that localizes to the nuclear membrane. Mutations in this gene have been associated with autosomal recessive spinocerebellar ataxia 8, also referred to as autosomal recessive cerebellar ataxia type 1 or recessive ataxia of Beauce [243].  Alternatively spliced transcript variants encoding different isoforms have been described [244]. Interestingly, 
SYNE1 has been recently   reported to be associated with bipolar disorder, recurrent major depression [245] and ovarian cancer [246].  Due to the high prevalence of depression in migraine patient reported in the literature [61], common genetic variants in SYNE1 associated with both diseases may suggest common molecular and physiological mechanisms contributing to the comorbidity. Therefore, results presented in this study implicate SYNE1, for the first time, as a new target in migraine.  
SYNE1 is expressed in different regions in the brain involved with pain processing as well as vascular tissues, possibly affecting vasodilatation or vasoconstriction processes.    The most well studied polymorphism in PGR gene is the PROGINS polymorphic 306 bp Alu insertion that occurs within intron 7 [168].  Colson et al showed that individuals who carried the PROGINS insert in an Australian case-control population, were 1.8 times more likely to suffer migraine (6).  Significant differences in genotypic (P-value ≤ 0.001) and allelic frequency 85  Chapter 4: Association of Estrogen Receptor Gene (ESR1) polymorphisms with Migraine in the Large Norfolk Island Pedigree. 
(P-value ≤ 0.001) were also seen when comparing cases and controls in an Indian population [236]. 
 The present PGR analysis showed no association at the evaluated markers.  However, four haplotype blocks were identified showing a very homogenous population and identifying a region with a very low rate of recombination.  Overall, these results suggest that PGR is not implicated in the pathogenesis of migraine in the Norfolk Island Population.    4.7 CONCLUSIONS  The results of this study show that there is evidence of ESR1/SYNE1 gene association with migraine.  Association analysis in the ESR1 gene provided strong evidence to support the hormone mediated pathogenesis model of migraine.  However, the presence of a haplotype associated with the disease that includes the SYNE1 gene, in combination with the recent evidence showing association of SYNE1 with other diseases related to migraine such as depression and bipolar disorder, suggest a new target that should be considered in migraine. Future studies are now required in larger populations potentially including expression analysis to clarify whether the real causal variant contributing to migraine susceptibility is in 
ESR1/SYNE1 or both. 
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Our previous study demonstrated the association of SNPs in the intergenic region of 
ESR1/SYNE1. The ESR1 gene has been reported to be associated with migraine from a 
number of studies coming from diverse populations.  On the other hand, the SYNE1 gene has 
been shown to provide susceptibility to some migraine comorbid disorders such as ataxia and 
depression. SYNE1 association with migraine was reported for the first time in a paper 
published as a result of the work developed in the previous chapter of this thesis.  
 
The following chapter focuses on further investigation of SYNE1, and ESR1 SNPs to see if 
association is replicated with migraine in a menstrual migraine (MM) population.  MM is a 
subtype of MO thought to be largely influenced by hormonal factors. Thus, SNPs in the ESR1, 
SYNE1 and in other hormone-related genes were selected by a candidate gene approach and 
tested for association with migraine in this MM cohort.  It is possible that migraine 
susceptibility markers located in hormonal related genes may possible have a bigger effect 
on individuals diagnosed with MM and therefore the association signals could be more easily 
detected.  We have also tested the levels of expression of these hormonally related genes with 
migraine associated SNPs, to detect and integrate genotypic and expression information in 
our study.   
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                  CHAPTER 5  GENETIC ASSOCIATION AND GENE EXPRESSION STUDIES SUGGEST THAT GENETIC VARIANTS IN THE SYNE1 AND TNF GENES ARE RELATED TO MENSTRUAL MIGRAINE.      
 
 
 
 
 
 
 
This chapter has been published as a journal paper and it won the 2014 Enrico 
Greppi Award for best migraine paper of the year: 
 
Rodriguez-Acevedo AJ, Smith RA, Roy B, Sutherland H, Lea RA, Frith A, MacGregor 
EA, Griffiths LR. 2014. Genetic association and gene expression studies suggest that genetic variants in the SYNE1 and TNF genes are related to menstrual migraine. J Headache Pain. 2014 Oct 14. Highly accessed.   
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5.2 ABSTRACT 
 
Background 
 Menstrual migraine (MM) encompasses pure menstrual migraine (PMM) and menstrually-related migraine (MRM). This study was aimed at investigating genetic variants that are potentially  related to MM, specifically undertaking genotyping and mRNA expression analysis of the  ESR1, PGR, SYNE1 and TNF genes in MM cases and non-migraine controls. 
 
Methods 
  A total of 37 variants distributed across14 genes were genotyped in 437 DNA samples (282 cases and 155 controls).  In addition levels of gene expression were determined in  74 individuals (41 cases and 33 controls).  Association and correlation analysis were performed using Plink and RStudio.   
 
Results 
  SNPs rs3093664 and rs9371601 in SYNE1 and TNF genes respectively, were significantly associated with migraine in the MM population (P-value= 0.008; P-value=0.009 respectively).  Analysis of qPCR results found no significant difference in levels of gene expression between cases and controls.  However, we found a significant correlation between the expression of ESR1 and SYNE1, ESR1 and PGR and TNF and SYNE1 in samples taken during the follicular phase of the menstrual cycle. Suggesting an interaction of these proteins during events related to the menstrual cycle. 
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Conclusions 
 Our results show that SNPs rs9371601 and rs3093664 in the SYNE1 and TNF genes respectively, are associated with MM.  The present study also provides strong evidence to support the correlation of ESR1, PGR, SYNE1 and TNF gene expression in MM.  
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5.3 INTRODUCTION  Menstrual migraine (MM) encompasses pure menstrual migraine (PMM) and menstrually-related migraine (MRM), which have been recognized as subtypes of migraine without aura (MO) in the International Classification of Headache Disorders (ICHD-III)  [1].  The diagnostic criteria are placed in the appendix section of the classification  because of uncertainty over whether they should be considered as separate entities. Pure MM is 
diagnosed when the patient fulfills criteria for MO and has confirmed that attacks occur on day 1 ± 2 of menstruation in at least two out of three menstrual cycles; MRM has the same characteristics as pure MM but attacks occur additionally at other times of the cycle  .  Hormonal fluctuations throughout a woman's life may contribute to the pathophysiology of MM.  The main neuroendocrinologic events across the menstrual cycles during the reproductive years involves hypothalamic, pituitary, and ovarian axes. Gonadotropin releasing hormone (GnRH) is synthesized in the hypothalamus and then released into the portal circulation. GnRH binds to receptors in the anterior pituitary gland and activates release of follicle stimulating hormone (FSH) and luteinising hormone (LH). Release of FSH and LH lead to development of follicles within the ovary which produce estrogen during the early to mid-follicular phases (FP) of the menstrual cycle. Serum estrogen levels rise during the late follicular phase to release LH that, in turn, will initiate ovulation within 48 to 72 hours.  After ovulation, the remnants of the dominant follicle become the corpus luteum, which then produce moderate to high amounts of both estradiol and progesterone during the luteal phase (LP) of the menstrual cycle. If fertilization and implantation of the ovum do not occur, then the corpus luteum regresses leading to decreasing serum levels of estrogen and progesterone during the late luteal phase causing 
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menstrual bleeding [148]. This drop in estrogen is thought to be an important trigger in MM, first postulated by Somerville in 1972 as the ‘estrogen withdrawal’ theory [175]. The fall in estrogen is believed to be involved in increasing the susceptibility of prime blood vessels to other factors that influence migraineogenic effects through a process that remains unknown (4). One of these factors may be prostaglandins (PGs), which have been implicated in neurogenic inflammation [247]. PGs may play a role in MM, given that there is a threefold increase in prostaglandin levels by the luteal phase, with a further increase during menstruation [248].  Different genetic variants have been identified as causing migraine. Three genes, 
CACNA1A, ATP1A2 and SCNA1A, have come from studies performed in individuals with familial hemiplegic migraine (FHM) a monogenic form of migraine with aura [3-5]; NGF, 
PGCP, PRDM16, TRPM8, and  LRP1 are genes recently associated in Genome Wide Association Scan studies (GWAS) in common migraine populations  [249]. In addition,  
ESR1, ESR2, PGR, AR, FSHR, NRIP1, CYP19A1 and MTHFR are genes with variants that have been associated with migraine without aura and these represent special concern for MM researchers due to their role in hormonal processes [250, 251].  However, results from these studies have been contradictory and they need to be replicated in different populations. In particular, it is unclear as to the effect of these genes in different migraine subtypes, including MM.     Thusly, we have investigated genetic variants in 14 genes; Estrogen Receptor 1 (ESR1), Follicular stimulating Hormone Receptor (FSHR), A CGPR receptor (RAMP1), lymphotoxin alpha (LTA), Tumor Necrosis Factor (TNF), Synaptic Nuclei expressed (SYNE1), Potassium Channel Subfamily K Member 18 (KCNK18), Estrogen Receptor type 2 (ESR2), Cytochrome P450 Family 19, Subfamily A, Polypeptide 1 (CYP19A1) and  Nuclear Receptor Interacting Protein 1 (NRIP1) along with microRNA 890 (MIR890), microRNA 891A (MIR891A), 
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microRNA and 892A (MIR892A) in a population of MM cases and controls.  These genes come from neuronal, hormonal and immunologic pathways previously associated with migraine. Genotyping analysis was followed by qPCR for determination of mRNA levels from genes significantly associated with MM in this study.    
5.4 METHODOLOGY 
 
Population 
 The population for this research consisted of 437 females recruited by the City of London Migraine Clinic, including both PMM and MRM cases and controls. Migraine diagnosis was in accordance with ICHD-II. The inclusion criteria for cases selection was the occurrence of attacks on day 1 ± 2 of menstruation in at least two out of three menstrual cycles. Diagnosis of PMM (menstrual attacks only) and MRM (additional attacks at other times of the cycle) was confirmed by diary evidence from at least three menstrual cycles.  Controls were women with no personal or family history of migraine, age and ethnicity matched to cases, where possible. Biological specimens were collected and transported to the Genomics Research Centre for further processing. Saliva samples were obtained from the 437 females (282 cases: 68 PMM and 214 MRM; and 155 controls ;median age 45.0; range 21-60 vs. 39.5; 22-61 years). Saliva samples were collected and DNA isolated using Oragene (Australia) Saliva DNA extraction kits. To perform the gene expression analysis we used 74 patients (41 cases and 33 controls ; median age 42.0; range 21-49 vs. 35.5; 24-49 years) with paired follicular and luteal phase samples available for 30 cases and 29 controls from the same population, who had not taken any hormonal treatment (including dietary isoflavone supplements) within the previous three months, were asked to donate blood samples at both luteal and follicular menstrual cycle stages.  A total number of 134 
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samples were collected in Paxgene tubes for expression analysis purposes. mRNA extraction was carried out using Qiagen  PAXgene blood miRNA kits (Catalog # 763134).  Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, medication use and contraceptive use.  The study protocol was originally approved by the Griffith University Human Research Ethics Committee and subsequently by the Queensland University of Technology Human Ethics Committee (Australia), and the East London and the City Research Ethics Committee (UK). All subjects provided signed, informed consent prior to participation.  
Genotype analysis 
 
G594A Genotyping Genotyping  of the G594A variant in ESR1 gene was carried out by using PCR-RFLP.  DNA samples (20ng/uL) were incubated in a 20 uL reaction with dNTPs (0.2mM),  5X buffer, MgCl2 (3.75mM), reverse primer (5’GCC ATT GGT GTT GGA TGC ATG C3’) and forward primer (5’GAG GAG ACG GAC CAA AGC CAC3’) (0.25uM), 5U of Taq Polymerase and water under the following cycling conditions: an initial step at 94°C for 2 min followed by 5 cycles of 94°C for 45 s, 69°C for 1 min, and 72°C for 2 min; then 30 cycles of 94°C for 30 s, 67°C for 30 s and 72°C for 45 s and a final step of 72°C for 5 min.  The restriction enzyme BtgI (New England Biolabs, Australia) was used for the determination of the SNP genotype.   
PROGINS Genotyping 
 PROGINS insertion/deletion was tested with a standard PCR. DNA samples (20ng/uL) were incubated in a 25 uL reaction with dNTPs (0.2mM), 5X buffer, MgCl2 (1.4 mM), reverse primer -5'-AAA GTA TTT TCT TGC TAA ATG TC-3'- and forward primer -5'-GGC 
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AGA AAG CAA AAT AAA AAG A-3'-(0.24uM), 6U of Taq Polymerase (Invitrogen)  and  water under the following cycling conditions: an initial step at 94°C for 4 min followed by 30 cycles of 94°C for 30 s, 51°C for 30 s, and 72°C for 45 s and a final step of 72°C for 2 min. Samples were then observed on a 2% agarose gel to detect the presence of the PROGINS insert..  
Sequenom Genotyping A total of 34 SNPs were selected from 14 different genes on nine chromosomes as the research panel for the study. Selected SNPs were located in genes involved in neuronal, hormonal and immunologic pathways previously associated with migraine. The SNPs were tested by using the Sequenom genotyping platform (Sequenom®, San Diego, CA, USA), which uses MALDI-TOF mass spectroscopy and MassARRAY technology with an iPlex system.  Primers for polymerase chain reaction (PCR) amplification and single base extension were designed by Sequenom Assay Design 3.1 software (Sequenom, San Diego, CA, USA) according to the manufacturer’s instructions.  
C325G Genotyping Variant C325G (rs1801132) was genotyped using TaqMan® SNP Genotyping Assay (life technologies, Cat. #4351379).  The reaction was prepared by adding 5 µl of Universal PCR master mix, 0.25 µl of Probe Primer, 3.75 H 2 0 and 1 µl (20ng) of DNA to a final volume of 10 µl. The thermal cycling conditions were like this:  An initial cycle at 95°C for 10 min and 40 subsequent cycles of 92°C /15 sec and 90°C /90 sec. Results were visualized using the TaqMan® Genotyper™ Software. 
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Gene expression analysis 
 A two-step quantitative reverse transcription PCR (qPCR) was performed. An amount of 100ng of RNA was converted into cDNA by adding  9.2ng/uL Invitrogen Random Hexamers, dNTPs (500uM), and free-RNAse H2O to a final volume of 32.5ul. The reaction was incubated at 65°C for 10 minutes in a thermocycler to disrupt secondary structures, followed by a second incubation on ice for at least 5 minutes.  In the second step of the reaction, 1st Strand Buffer (1X), DTT (2mM), SuperScript® III Reverse transcriptase (100U) and RNase-free H2O were added to the previous reaction product for a final volume of 50 ul. The cDNA synthesis reaction was carried out with an initial incubation of 25°C for 5 minutes, followed by a 50°C for 60 minutes and a final step of reaction inactivation at 70°C for 15 min. Stock cDNA was stored at -80°C and 1:2 diluted cDNA working samples were stored at -20°C.     To scan levels of expression of PGR, ESR1, SYNE1 and TNF genes we used SYBR Green PCR Master Mix 1X (Life Technologies, Australia), 200 nM reverse and forward primers (Appendix 2), Rox (reference probe) 2X, 100 ng of cDNA and free RNase-H2O to a final volume of 10 ul.  Fifty cycles of 50°C-2min, 95°C-3min, 95°C – 3 s, and 60°C–30 s were carried out in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Australia).  In order to allow for relative quantitation of gene expression, we used the reference genes 18S and GADPH. Efficiency tests for all primers sets to be used were performed and amplification efficiencies were found to be comparable.   
Statistics 
 As part of the quality control process, we first performed a Hardy Weinberg test followed by a standard case-control association test using Chi-square analysis with Plink V1.07 
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[221]. In order to minimize the effect of having a dissimilar number of cases and controls in our study, we implemented a logistic regression analysis in RStudio (version 0.97.312) [252] for those SNPs with P-values < 0.01 in the previous Chi-square test.  A Wald test was applied to fit the logistic regression model.    
For expression analysis the ΔΔCt method was used. The ΔΔCt calculations were executed using Microsoft Excel software. The statistical significance of differentially expressed genes between cases and controls was determined by a standard t-test.  Logistic regression was also performed using genotype and gene expression levels as predicting variables for migraine. The Pearson´s correlation was used to test correlations between expression levels of PGR, ESR1, TNF and SYNE1. The statistical significance was assessed by comparing the observed p values to an alpha threshold of 0.01. All these analyses were performed by using RStudio.    
5.5 RESULTS  
Genotyping Study 
 The initial quality control process allowed us to identify and subsequently to delete 6 SNPs for violating the Hardy/Weinberg equilibrium (rs1805087, rs1584243, rs1800683, rs1800629, rs1519480 and rs7127507),  2 SNPs (rs1800630, rs363314) for having a low genotyping calling rate (<80%), 1 SNP with 3 alleles (rs12273363) and 3 SNPs for showing a unique allele (rs146806052, rs113352055 and 5965992).  Table 5.1 shows Chi-square and p-values for the studied SNPs that passed all the quality control checks.  The analysis was completed for all cases grouped together (PMM and MRM), and individually for each subgroup. SNPs rs3093664 (TNF) and rs9371601 (SYNE1) were both significantly 
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associated with migraine in the combined PMM-MRM sample and the MRM sample.  Association after exclusion of PMM individuals from the analysis lead to an increase of the 
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  Table 5.1 Standard association analysis for all the individuals in the population and for subgroups.  PMM (Pure Menstrual Migraine) and MRM (Menstrually-Related Migraine).  * and bold font  indicate significant p-values. 
       All Population MM MRM  
 Chrom SNP Ge Alleles HWE CHISQ p-value CHISQ p-value CHISQ p-value   2 rs6166 FSHR G A 0.61 1.94 0.16 2.32 0.13 1.07 0.30   2 rs895572 RAMP1 C T 0.83 0.88 0.35 0.38 0.54 0.18 0.67   2 rs1080519 RAMP1 T C 0.66 0.90 0.34 0.06 0.81 0.01 0.92   2 rs10185142 RAMP1 T C 0.20 0.00 0.96 1.39 0.24 0.23 0.63   2 rs6729271 RAMP1 T C 0.62 1.99 0.16 0.82 0.37 0.00 0.97   2 rs6707038 RAMP1 G A 0.84 0.004 0.95 0.01 0.93 0.10 0.75   6 rs2009658 LTA G C 0.72 1.75 0.19 2.10 0.15 1.95 0.16   6 rs2071590 LTA T C 0.10 0.97 0.32 0.27 0.61 0.98 0.32   6 rs2239704 LTA T G 0.26 0.50 0.48 0.01 0.92 0.42 0.52   6 rs909253 LTA C T 0.15 1.51 0.22 2.62 0.11 0.95 0.33   6 rs2229094 LTA C T 0.10 0.72 0.40 1.45 0.23 0.30 0.58   6 rs3093664 TNF G A 1.00 7.00 0.008* 3.26 0.07 7.55 0.006*   6 rs9371601 SYNE1 T G 0.74 6.65 0.009* 0.12 0.73 9.20 0.002*   6 G594A ESR1 A G 0.85 0.62 0.43 0.60 0.44 0.70 0.40   6 C325G ESR1 G C 0.89 1.48 0.22 0.07 0.79 1.50 0.22   10 rs140325655 KCNK18 C T 1.00 0.06 0.81 1.21 0.27 0.67 0.41   10 rs963975 KCNK18 G C 0.69 3.40 0.07 1.20 0.27 3.15 0.08   11 PROGINS PgR D I 0.25 0.03 0.85 0.48 0.49 0.05 0.82   14 rs4986938 ESR2 G A 0.41 1.96 0.16 4.82 0.028* 0.83 0.36   15 rs4646 CYP19A1 A C 0.89 0.55 0.46 0.02 0.89 1.10 0.29   15 rs10046 CYP19A1 C T 0.31 0.07 0.80 0.06 0.80 0.01 0.92  
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       All Population MM MRM  
 Chrom SNP Ge Alleles HWE CHISQ p-value CHISQ p-value CHISQ p-value   21 rs2229741 NRIP1 A G 0.44 2.01 0.16 4.35 0.036* 0.60 0.44   X rs5965660 MIR890 G T 0.85 2.83 0.09 0.83 0.36 3.19 0.07   X rs4827678 MIR890 G A 0.09 0.34 0.56 0.15 0.70 0.20 0.65   X rs2202091 MIR890 C A 0.81 0.44 0.51 1.01 0.31 0.20 0.66              
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level of significance, suggesting a stronger effect of TNF and SYNE1 variants in MRM patients. Significance was detected in two SNPs (rs2229741 and rs4986938), located in ESR2 and NRIP1in PMM individuals. Table 5.2 shows allelic and genotypic frequencies and counts for associated SNPs.      Table 5.3 presents logistic regression analysis results.  Both allelic and genotypic odds ratios are shown Genotype GA in SNP rs3093664 showed a protective  effect on migraine risk in the total population (OR=0.46, 95%CI= 0.24-0.86) and in the MRM sub-population  (OR=0.46, 95%CI 0.24-0.89). This effect is likely based on the presence of the G allele, which showed a significant p-value of 0.009 for the odds ratio test in the total population (OR=0.48, 95%CI=0.28-0.84) and 0.007 in the MRM sub-population (OR=0.45, 95%CI=0.25-0.81), which suggests an important protective effect of this variant on the MRM phenotype. While the model for the GG genotype was not significant and the 95%CI straddled 1, this was likely caused by the extreme rarity of the GG genotype in both case and control populations.   Additionally, allele T in SNP rs9371601 showed a significant OR in MRM (OR=0.60, 95%CI= 0.43-0.84) and not the PMM sub-population (OR=0.93, 95%CI=0.60-1.43) (see Table 5.2), indicating that the effects of this SNP may be largely confined to the MRM sub-population. Interestingly, the genotypic odds ratio indicated that this protective effect was limited to TT genotypes and that heterozygotes did not show confident protection compared to GG homozygotes (OR=0.83, 95%CI=0.50-1.36).  Allele G in SNP rs4986938 (OR=1.90, 95%CI=1.05-3.47) and allele A in SNP rs2229741 (OR=1.61, 95%CI=1.01-2.56) seemed to be a risk factor for migraine in the PMM sub-population.  However, the effect is probably not strong due to the small size of the population.    
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Table 5.2  Alleles and genotypes frequencies for associated SNPs.  
 
  rs3093664 rs9371601   Alleles Genotypes Alleles Genotypes   G A AA AG GG G T GG GT TT Total Population 0.11 (51) 0.89 (493) 0.78 (173) 0.20 (45) 0.01 (3) 0.65 (323) 0.35 (175) 0.41 (102) 0.48 (119) 0.11 (27) MRM 0.10 (32) 0.90 (268) 0.78 (133) 0.21(35) 0.01(2) 0.66 (233) 0.33 (113) 0.44 (84) 0.47 (91) 0.09 (17) PMM 0.13(19) 0.87(125) 0.78 (40) 0.20 (10) 0.02 (1) 0.60 (90) 0.40 (62) 0.32 (18) 0.50 (28) 0.18 (10) Controls 0.20 (25) 0.80 (95) 0.62 (37) 0.35 (21) 0.03 (2) 0.56 (139) 0.44 (113) 0.33 (42) 0.44 (55) 0.23 (29)   rs4986938 rs2229741   Alleles Genotypes Alleles Genotypes   A  G AA GA GG A G AA AG GG Total Population 0.50 (148) 0.50(148) 0.29 (42) 0.44 (64) 0.28 (41) 0.43 (197) 0.57 (255) 0.20 (44) 0.48 (108) 0.32 (73) MRM 0.53 (103) 0.47(93) 0.30 (34) 0.46 (51) 0.24 (27) 0.41 (127) 0.59 (181) 0.19 (32) 0.46 (79) 0.35 (61) PMM 0.46 (46) 0.54 (54) 0.23 (8) 0.37 (13) 0.40 (14) 0.48 (70) 0.52 (74) 0.23 (12) 0.55 (29) 0.23 (12) Controls 0.58 (75) 0.42 (55) 0.31 (20) 0.54 (35) 0.15 (10) 0.38 (88) 0.62 (144) 0.16 (19) 0.43 (50) 0.41 (47) 
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Table 5.3  Odds Ratio calculation for all associated SNPs. 
 
    General MRM MM     OR 95% CI p-value OR 95% CI p-value OR 95% CI P-value 
rs3093664 Allele G 0.48 0.28-0.84 0.009 0.45 0.25-0.81 0.007  0.50 0.23-1.07 0.074 
  AG vs AA 0.46 0.24-0.86 0.008 0.46 0.24-0.89 0.01 0.44 0.18-1.06 0.03 
  GG vs AG 0.7 0.11-4.51 0.99 0.6 0.08-4.58 0.25 1.05 0.08-13 0 
  GG vs AA 0.32 0.05-1.99 0.14 0.28 0.04-2.04 0.12 0.46 0.04-5.32 0.51 
rs9371601 Allele T 0.48 0.28-0.84 0.009 0.602 0.43-0.84  0.003 0.93 0.60-1.43 0.73 
  GT vs GG 0.89 0.55-1.44 0.76 0.83 0.5-1.36 0.4 1.19 0.58-2.43 0.76 
  TT vs GT 0.43 0.23-0.8 0.003 0.35 0.18-0.7 0.001 0.68 0.29-1.59 0.29 
  TT vs GG 0.38 0.2-0.72 0.001 0.29 0.14-0.59 p < 0.001 0.8 0.33-1.99  0.76 
rs4986938 Allele G 1.32 0.88-1.99 0.17 1.22 0.78-1.90 0.37 1.90 1.05-3.47 0.03 
  GA vs AA 0.87 0.44-1.71 0.92 0.86 0.43-1.73 0.83 0.93 0.33-2.62 2.79 
  GG vs GA 2.24 1-5.01 0.02 1.85 0.8-4.31 0.09 3.77 1.34-10.57 0.005 
  GG vs AA 1.95 0.82-4.67 0.08 1.59 0.64-3.95 0.24 3.5 1.1-11.09 0.017 
rs2229741 Allele A 1.25 0.911-1.72 0.16 1.13 0.811-1.59 0.45 1,616 1.01-2.56 0.04 
  AG vs GG 1.39 0.85-2.29 0.13 1.22 0.72-2.05 0.4 2.27 1.04-4.96 0.02 
  AA vs AG 1.07 0.57-2.02 1.76 1.07 0.55-2.08 1.95 1.09 0.46-2.56 0.04 
  AA vs GG 1.49 0.78-2.86 0.16 1.3 0.66-2.57 0.4 2.47 0.95-6.47 0.03 
 
 
 
107  Chapter 5: Genetic Association And Gene expression Studies Suggest That Genetic Variants In The SYNE1 and TNF Genes are Related to Menstrual Migraine 
Expression Study 
 Our analysis of gene expression in our migraine populations indicated no significant difference in levels of expression in the studied genes between cases and controls and across the sub-populations (Table 5.4).  However, we have detected significant positive correlations in the follicular phase between the expression of TNF and SYNE1 (Rho=0.371, P-value=0.005), ESR1 and PGR (Rho=0.435, p=0.006) and ESR1 and SYNE1 (Rho=0.412, P-value=0.002), which would indicate some interaction between them. In contrast, in luteal phase, we found a correlation between SYNE1 and PGR (Rho=0. 444, P-value= 0.006) and 
TNF and SYNE1 (Rho= 0.345, P-value=0.015). Results are presented in Figure 5.1.  More interestingly, we found differences in the correlations between gene expression in cases and controls. For ESR1 and SYNE1, these differences were small, with both cases and controls maintaining similar levels of correlation (cases: Rho=0.48 P-value < 0,001; controls: Rho=0.4 P-value=0.001). For other gene correlations however, cases maintained significant relationships while the controls had weakened or non-significant relationships. For TNF and SYNE1, the relationship was weaker, but still significant in controls (cases: Rho= 0.449 P-value< 0,001; controls: Rho=0.27 P-value=0.03). For ESR1 and PGR controls ceased to maintain correlation of expression (cases: Rho=0.511 P-value< 0,001; controls: Rho=0.091 P-value=0.56) and a similar loss of correlation occurred between PGR and 
SYNE1 (cases: Rho=0.393 P-value=0.005; controls: Rho=0.243 P-value=0.12).     The results of our expression analysis suggest that although there are not significant changes in gene expression of genes that may influence migraine in PMM and MRM cases compared to controls, these genes interact in a different fashion both in the luteal and follicular stages of the menstrual cycle and in cases compared to controls.     
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Table 5.4 Student’s t-test analysis for means difference in levels of gene expression 
 
Group 1 vs Group 2 Transcript Mean Group 1 Mean Group 2 Difference t.stat t.pval 
 
 
Cases vs Controls TNF 16.77 17.14 -0.37 -1.12 0.27  
 
 
SYNE1 20.90 20.36 0.54 0.84 0.41  
 
 
ESR1 16.35 16.16 0.19 0.29 0.78  
 
 
PGR 9.61 9.23 0.39 0.33 0.74  
 
CasesF vs CasesL TNF 17.16 16.24 0.92 1.53 0.14  
 
 
SYNE1 21.56 20.01 1.55 1.20 0.24  
 
 
ESR1 15.98 16.59 -0.60 -0.59 0.56  
 
 
PGR 9.62 8.95 0.67 0.40 0.69  
 
CasesF vs ControlsF TNF 17.16 17.33 -0.17 -0.51 0.61  
 
 
SYNE1 21.56 20.68 0.89 1.18 0.24  
 
 
ESR1 15.98 16.73 -0.75 -0.96 0.34  
 
 
PGR 9.62 9.80 -0.18 -0.11 0.91  
 
CasesL vs ControlsL TNF 16.24 16.96 -0.72 -1.14 0.26    SYNE1 20.01 20.06 -0.05 -0.04 0.97    ESR1 16.59 15.62 0.96 0.84 0.40    PGR 8.95 8.69 0.26 0.15 0.88     
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Figure 5.1. Pearson´s correlation for gene expression in menstrual migraine. Each colour represents the strength and direction of the correlation between two genes.  Blue means positive correlation and red represents negative correlation between two transcripts. Panels A and B compare correlation between genes in follicular phase and in luteal phase respectively. Panels C and D compare correlation between genes in controls and cases respectively.     5.5 DISCUSSION  There have been very few studies carried out so far at the genomic level on MM, in part because of the uncertainty concerning its status as an entity independent from common migraine. In this research, we have identified significant differences between MM cases and controls, which both show increased risk of migraine development for the G alleles in the tested SNPs in the TNF and SYNE1 genes. TNF is a pro-inflammatory cytokine and is thus involved in a number of biological pathways, including apoptosis, chemotaxis and cell proliferation. The gene has been associated with neuronal damage  and pain  in response 110  Chapter 5: Genetic Association And Gene expression Studies Suggest That Genetic Variants In The SYNE1 and 
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to particular cellular states, such as hypothermia and hypoxia, and thus has a significant linkage to metabolic pathways that may influence menstrual migraine development and migraine initiation [253]. This is particularly so in view of the influence of estrogen and progesterone on inflammatory processes [254, 255], and this association may represent a link to a direct mechanism by which MM is triggered. In addition, TNF has been implicated in depression and irritable bowel disease [256, 257], recognized as migraine comorbidities [258, 259]. The rs3093664 SNP itself is an intronic polymorphism located between exons 3 and 4 of TNF away from intron splicing sites, so it is unlikely that the SNPitf has a direct effect on TNF function that would explain the association we have observed.  It is thus likely that this result is caused by linkage to a nearby rare SNP that does have functional effects. Interestingly, there is a candidate for this only 52 base pairs upstream of rs3093664, in the form of rs1800620, which is located in exon 3 of TNF and causes an alanine to threonine transition in amino acid 94 of the protein. Despite being annotated as a SNP, however, Hapmap populations show no variation in rs1800620 in tested African, Caucasian, Hispanic or Pacific Rim populations and nor do any publications mention it, so its status, and any linkage to rs3093664 remains uncertain.   
SYNE1 is a spectrin repeat containing protein usually found on the nuclear membrane and is involved in several kinds of protein-protein interactions where it serves as a scaffold and chaperone for various binding partners. The gene has been associated with several neural diseases, including depression and cerebellar/spinocerebellar ataxias, which have overlap with the familial forms of migraine driven by mutations, and may have direct effects in menstrual migraine development through these functions [260]. Interestingly, 
SYNE1 is also directly adjacent to the estrogen receptor, and polymorphisms within SYNE1 have been linked strongly to estrogen mediated events, such as ovarian cancer [261]. It is thus possible that the association seen with MM here may represent linkage to estrogen related effects, either through cross-regulation effects of the two genes or via linkage to 
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another marker in the distal parts of ESR1 that does not show linkage to those markers we have already interrogated in this study. This hypothesis is further supported by the fact that rs9371601 is also an intronic polymorphism, lying between exons 13 and 14 of the gene. Like our tested TNF polymorphism, rs9371601 also has potential SNPs it may be linked to which cause amino acid changes with undetermined frequencies, though these are more distant, the closest two being at least 2kb away up and downstream of it (rs267600867 and rs139324183).   Significant associations were also detected in two other SNPs (rs2229741 and rs4986938) in MM individuals, although their significance was not less than 0.01 and due to our relatively small sample sub population for MM samples, we may have impaired capability to detect true associations for this population. We do however,  believe it is worthy to further study these SNPs in  larger populations, as the genes containing these variants (NRIP1 and ESR2 respectively) are important hormonal receptors and modulators of hormonal action that might represent interesting targets in the etiology of menstrual migraine.SNPs, rs2229741 and rs4986938 are not amino acid changing variants, being intronic and part of the 3' UTR of their genes respectively, and it is possible that the weakness of the associations we have identified also indicate linkage to functional polymorphisms nearby.   The ESR1 and PGR markers tested in MM showed no significant association in the present study, despite previous association with migraine without aura [29, 157, 262]. It is possible that while the functional changes brought about by the tested markers affect hormonal signalling, they do not result in the kind of metabolic changes triggering menstrually related migraine. This is further supported by the different associations we obtained in the PMM and MRM sub-populations. The SNPs in NRIP1 and ESR2 are far from significant in the MRM sub populations and while the SYNE1 SNP is highly non-significant 
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in the MM sub-population, the TNF SNP shows near significance in the PMM cases (P-value=0.07), indicating a potential, if weaker, effect for this gene in that sub-population. Our results may thus indicate that migraine without aura and MRM may have different causative genes, despite sharing alterations to the hormone receptor pathways as part of their etiology [263].    Statistical analysis showed that there was no significant difference in ESR1, PGR, SYNE1 or 
TNF expression for cases or controls in any menstrual phase. We have, however, shown an interesting correlation of expression of the four proteins. Our analysis showed that expression of ESR1 correlates significantly with PGR and SYNE1, and also SYNE1 and NF are significantly correlated in the follicular phase of the menstrual cycle.  However, this correlation breaks down in the luteal phase where ESR1 correlates with TNF and SYNE1 correlates with PGR. This may represent normal expression control responses for each of the particular genes in response to the altering hormonal situation in the different phases. On the other hand, after comparing expression correlation in cases and controls separately, a change in the complex network of protein interaction between ESR1, TNF, 
PGR and SYNE1 seems to be occurring.  Highly significant p-values and stronger correlation for TNF/SYNE1, ESR1/PGR and PGR/SYNE1 in cases suggest an important role of pathways involving these genes in MM. Maintaining this correlation indicates that individuals suffering from MRM may have increased sensitivity to variations in hormonal signalling effects compared to controls. This is the first time these correlations and their relationship to migraine status has been identified.    Since SYNE1 polymorphisms have been previously associated with estrogen related events, an expression link between the pro-inflammatory cytokine TNF with SYNE1 in cases might explain why polymorphisms in both genes are associated with MM in our population. This adds some weight to the potential for this pathway to be playing a role in 
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MM and may represent the differential effects of the polymorphisms examined or more likely linked SNPs nearby, on pathway signal transduction. Identifying the specific interactions between ESR1, PGR, TNF and SYNE1 proteins and how polymorphisms factor into them would help to elucidate important mechanisms involved in MM that may be a useful avenue for development of a treatment for the disorder. Further work should also examine additional time points within the follicular and luteal phases to determine if a specific point of departure between case and control gene regulation can be identified.  
5.6 CONCLUSIONS  Our results show that SNPs rs9371601 and rs3093664 in the SYNE1 and TNF genes, respectively are associated with MRM in our population. Significant associations were also detected in SNPs rs2229741 and rs4986938 in PMM individuals, but due to the small number of PMM samples used to implement the analysis, we should be cautious about interpretation and consider both polymorphisms for future analysis in bigger populations. Statistical analysis showed that there was no significant difference between ESR1, PGR, 
SYNE1 or TNF expression in cases or controls in any of the menstrual phases. We have, however, shown a correlation of the four expressed genes in patients with PMM or MRM. Further studies should be focused on the validation of these results in larger populations with more collection timepoints for blood samples and on the understanding of protein interaction in different stages of the menstrual cycle and its effect on migraine etiology. Although we did not find any association of ESR1 and PGR variants with migraine,  we believe that future studies should continue exploring  the large family of co-activators and co-repressors that modulate the effects of ESR1 and PGR. It may be that variants in these genes result in the development of MRM. Our results also indicate that migraine without 
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aura and MRM may have different causative genes, despite both potentially sharing alterations in hormone receptor pathways [18]. 
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So far, we have tested the association of hormonal factors with migraine on the Norfolk 
Island population and in a menstrual migraine cohort.  We have found SNPs conferring 
susceptibility to migraine in the ESR1, SYNE1 and TNF genes.  We have also discussed the 
possible interaction of proteins coded by the PGR, ESR1, SYNE1 and TNF genes in patients 
suffering menstrual migraine.  Hormonal genes are thought to play a pivotal role in the 
pathophysiology of menstrual migraine, as clinical, biological and genetic studies have 
demonstrated. However, in general migraine the situation seems to be more complex and 
other genes, vascular and neuronal are thought to also contribute to the aetiology of the 
disease.  Thus, in accordance with the polygenic model underlying general migraine, the 
additive effect of hormonal, vascular and neuronal gene variants may be the key to a full 
understanding of migraine pathophysiology.  
 
In the next chapter, we consider the hormonal, vascular and neuronal variants that have 
been implicated in migraine GWA studies, to model a polygenic scenario, where genes with 
small effects are able to explain part of the susceptibility to migraine in individuals from the 
Norfolk Island population.  Additionally, we evaluated the modulatory effect of such variants 
on the blood tissue expression of genes potentially involved in the pathophysiology of 
migraine.   
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           CHAPTER 6  COMMON POLYGENIC VARIATION CONTRIBUTES TO RISK OF MIGRAINE IN THE NORFOLK ISLAND POPULATION                   This chapter is formatted as a paper and it is under review to be published: 
 
Rodriguez-Acevedo AJ, Ferreira MA,  Miles Benton, Lea RA, Griffiths LR. 2014. Association Score Demonstrates A Migraine Polygenic Model In The Norfolk Island Population. Cephalalgia. Manuscript under review     
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         6.2 ABSTRACT 
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Background 
 Migraine has been defined as a common disabling primary headache disorder.  Epidemiology studies have provided with the undeniable evidence of genetic components as active players in the development of the disease under a polygenic model in which multiple risk alleles exert modest individual effects.  Our objective was to test the contribution of a polygenic effect to migraine risk in the Norfolk Island population using a panel of SNPs reported to be disease associated in published migraine GWAS. We also investigated whether individual SNPs were associated with gene expression levels measured in whole-blood.  
Methods   Polygenic scores were calculated in a total of 285 related individuals (74 cases, 211 controls) from the Norfolk Island using 51 SNPs previously reported to be associated with migraine in published GWAS.    
Results 
 The association between polygenic score and migraine case-control status was tested using logistic regression. Results indicate that a migraine polygenic risk score was associated with migraine case-control status in this population (P=0.016). This supports the hypothesis that multiple SNPs with weak effects collectively contribute to migraine risk in this population.  Amongst the SNPs included in the polygenic model, 4 were associated with the expression of the USMG5 gene, including rs171251 (P = 0.012).    
Conclusions 
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 Results from this study provide evidence for the existence of a polygenic influence in migraine driven by gene variants affecting mitochondrial, immunological and hormonal gene mRNA levels in the cell.  Thus, this study open doors to the investigation of new biological targets to be considered in future functional or genetic studies.   
6.3 INTRODUCTION   Migraine is a common disabling primary headache disorder, classified into two major groups, migraine without aura (MO) and migraine with aura (MA) [34].  MO is the most common form with headache attacks lasting between 4-72 hours.  In addition, MA sufferers often experience aural symptoms preceding the headache phase of the migraine episode. According to the most recent Global Burden of Disease Study (GBD), migraine ranked as the fifth leading cause of disability worldwide in 2013 and it is calculated that approximately 12% of the worldwide population suffers from this disorder [264].  Although the pathophysiology of migraine is not very well understood, epidemiological studies have convincingly demonstrated that genetic components contribute to the development of the disease.  Genetic risk variants have been identified in studies of  Familial Hemiplegic Migraine (FMH), a monogenic form of MA; specifically, risk variants in/near CACNA1A, ATP1A2 and SCNA1A [3-5]. Additional common risk variants have been identified through Genome-Wide Association Studies (GWAS), namely rs9908234 [6] in NGFR, rs1835740 [6, 7] near PGCP, rs2651899 (PRDM16), rs10166942 (TRPM8) and rs11172113 (LRP1) [8]. However, the replication of these variants in other populations has been challenging [18], as has been the identification of new migraine risk variants.   
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Genetic studies of isolated populations, such as that of Norfolk Island, provide improved power to identify genetic risk variants [265]. Despite this, genetic studies of migraine in the Norfolk Island have failed to identify risk variants with large effects on disease risk [10, 211, 266]. This suggests that in this isolated population, the genetic contribution to migraine risk might be mostly determined by the combined effect of many risk variants with small effects. The aim of this study was to test this possibility by estimating a migraine polygenic risk score for individuals in the Norfolk Island based on SNPs identified in published GWAS and then testing its association with disease status.   6.4 METHODS  
Population assessment 
 Norfolk Island belongs to the Commonwealth of Australia and it is located off the eastern coast, approximately 1700 km northeast of Sydney, on the Norfolk Ridge. The modern Norfolk Island (NI) population comes from a settlement of 194 inhabitants resettled from Pitcairn Island in 1856 all descendants of nine male “Bounty” mutineers and twelve Tahitian women [28]. Since that time, the island has been isolated and strict immigration and quarantine legislation restricts migration to Norfolk.  Thus, of the approximately 1200 current permanent residents, up to 80% can trace their heritage back to the Island’s initial founders. The heritability of migraine in this population has been estimated to be 0.53 [211].    Phenotypic data and biological specimens (venous blood) were obtained from 600 subjects (261 males, 339 females).  DNA was isolated using a standard salting-out procedure [214].  Phenotypic data was obtained via a medical questionnaire that surveyed 
124  Chapter 6: Common Polygenic Variation Contributes to Risk of Migraine In The Norfolk Island Population. 
migraine family history, symptoms, triggers, and medication use.  An in depth interview and comprehensive medical questionnaire was undertaken on all individuals and used to obtain phenotypic data, including migraine information regarding family history, symptoms, triggers and medication. Migraine diagnosis was in accordance with ICHD-II guidelines. The inclusion criteria used to select cases was a diagnostic of MA or MO with other non-migraineurs included in the control population.  Genealogical data were obtained from multiple sources, including questionnaire, municipal and historical records. Because all the individuals share a common genetic background all individuals diagnosed with subtypes MA or MO were grouped together and phenotyped as being affected with migraine. The study protocol was initially approved by the Griffith University Human Research Ethics Committee and subsequently by the Queensland University of Technology Human Research Ethics Committee. All subjects provided signed, informed consent prior to participation. 
 
Genome-wide SNP genotyping 
 DNA samples from the Norfolk Island Population were genotyped according to the manufacturer’s instructions on the Illumina Infinium High Density (HD) Human610-Quad DNA analysis BeadChip version 1. A total of 620,901 genome wide markers were genotyped in a sub-sample of 285 related individuals (74 cases: 22 males and 52 females; and 211 controls: 114 males and 97 females). Twenty-eight selected samples (5% of both cases and controls) were repeated to ensure concordance and accuracy of genotyping. Samples were scanned on the Illumina BeadArray 500GX Reader. Raw data was obtained using Illumina BeadScan image data acquisition software (Version 2.3.0.13).  
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SNPs selection and score calculation 
 We used the Gene Central Database [267] to select genetic variants previously associated with migraine in published GWAS. Using genotype data from Europeans of the HapMap project [268], we reduced this list of SNPs to an independent set (r2<0.1) of 51 variants using PLINK [221] (Appendix 3). Of note is that each of these SNPs had previously been individually tested for association with migraine risk in the Norfolk Island population, with none having a significant (P<0.05) association [213].   These 51 SNPs were used to calculate a migraine polygenic score in PLINK [221].  The 
weight attributed to each SNP corresponded to the beta coefficient (β) reported in previous studies (Appendix 3). Initially, the covariates age, sex and kinship were individually tested for association with migraine and only the significantly (P-value < 0.05) associated covariates were included in the final logistic regression model where the multiple allele score was set as a predictable variable and the migraine phenotype was set as the independent variable. In secondary analyses, the polygenic risk score was also dichotomised to compare the risk of disease between the bottom and top 25% percentiles of the polygenic risk score distribution (Figure 6.1).    
Genome-wide expression 
 Sample collection has been previously described [121]. Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases: 54 females and 25 males;  256 controls: 126 females; 130 males).  Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1). Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the 
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across probes, and correlations between samples, all samples, with the exception of one, provided high-quality data.  The sample with low-quality data was removed.  Significantly expressed probes were then determined at a false-discovery rate of 5%.  Subsequently, the raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization.  
eQTL analysis 
 A total of 279 samples (72 cases and 207 controls) with both genotypic and levels of gene expression data were included in the analysis.  Transcripts within 1Mb of distance from each of the 51 SNPs included in the polygenic model were selected for analysis using the University of California Santa Cruz (UCSC) table browser data retrieval web tool [269].  We used linear regression to test the association between individual SNPs (coded additively) and gene transcription levels of genes located within 1Mb of each SNP. Genotypes were coded as 0, 1 or 2 according to the copies of a reference allele.  In this study, the reference allele was the allele with the minor allele frequency (MAF). Gene-dropping simulations under the null hypothesis of no association were used to correct for multiple testing. Specifically, empirical P-values were obtained for each SNP after correcting the observed asymptotic P-value for the number of genes tested for that SNP (“locus-wide” correction) and for all the SNPs and genes tested in the analysis (a total of 418 tests; “study-wide” correction). Briefly, for each simulation, we (1) used Merlin [270] to generate random genotypes for the 51 SNPs for the 279 related individuals; (2) tested each simulated SNP for association with the observed expression levels of the nearby genes, as in the real dataset; and (3) retained the most significant P-value for each SNP across all genes tested (for “locus-wide” correction) and the most significant P-value across all tests performed 
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(for “study-wide” correction). This procedure was repeated 1000 times, and the retained simulated P-values used to correct the observed asymptotic P-values for multiple-testing.  
 6.5 RESULTS  
Polygenic score 
 We identified 140 SNPs previously reported to be associated with migraine in published GWAS, including a set of 51 SNPs in low linkage disequilibrium (r2<0.1) with each other (Appendix 3). Individually, all 51 SNPs were not significantly associated with the risk of migraine in the Norfolk Island population [213]. We reasoned that if some of these were indeed true risk factors with small effects on migraine susceptibility, then a polygenic risk score that aggregated the effects of all 51 SNPs would be significantly associated with disease status. To test this possibility, we used the association beta coefficient values reported by published migraine GWAS to generate a polygenic risk score across all 51 SNPs per individual. We found that this polygenic score was significantly and positively associated with migraine case-control status (P=0.016); cases had a higher load of risk alleles when compared to controls (Figure 6.1). Individuals in the top 25% of the polygenic score distribution were 3.1-fold (CI=1.37-7.55, P=0.008) more likely to be affected by migraine than individuals in the bottom 25% of the distribution (Figures 6.2 and 6.3).  
eQTL analysis In order to evaluate the potential biological role played by these 51 SNPs, we tested the association between each SNP and the expression levels of nearby genes. A total of 1347 genes were located within 1Mb of one of the 51 SNPs. However, expression levels for only 327 of these genes were available in the Illumina array used, being represented by 337  
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Figure 6.1.  Scores vs Migraine boxplot distribution.  This figure shows the boxplot distribution of the scores in the controls and the cases in the Norfolk Island Population.  A significant P-value (0.016) was obtained after testing migraine and score correlation using a logistic regression model.  
  
Figure 6.2. Histogram of Scores. Scores were calculated for all individuals in the population.  Individuals 
with extreme scores  are indicated by grey (scores ≤ 0.003) and black (scores ≥ 0.02) bars.  A logistic regression analysis showed that higher scores are more frequently present in migraine cases than in healthy controls (P-value = 0.008 ; OR = 3.11; CI=1.37-7.55)   129  Chapter 6: Common Polygenic Variation Contributes to Risk of Migraine In The Norfolk Island Population. 
  
Figure 6.3. Bar plot for the score frequencies.  The frequency of higher scores (≥0.02) (black), lower 
scores (≤0.003) (grey) and intermediate scores (0.02≥ scores ≤ 0.003) (white) among cases and controls shows a statistically significant difference (χ2 = 6.81; P-value=0.0009; OR=2.94; CI= 1.28 to 6.73) in their distribution, which suggests that migraine sufferers tend to have a higher genetic load of risk alleles than their respective controls 
 probes. Results showed that 10 SNPs were significantly associated with the expression of a nearby gene after a locus-wide correction for the number of genes tested for each SNP (Table 6.1). Of these, the association for 4 SNPs remained significant after a study-wide correction for multiple testing (Figure 6.4): rs1712517 with USMG5 (corrected P=0.012); rs11172113 with STAT6 (P=0.033); rs11906854 with CPNE1 (P=0.044); and rs4803455 with BCKDHA (P=0.044). The predicted biological functions for these genes are listed in Table 6.2. For USMG5 and STAT6, the allele that increased migraine risk was associated with increased gene expression, whereas the reverse was observed for CPNE1 and BCKDHA (Figure 6.4). We additionally tested the correlation between the levels of transcription of these eQTL genes and migraine status and no significant p-value (p≤0.05) was detected.   
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Table 6.1. eQTL analysis.  Results from a logistic regression analysis.   Alleles were coded as 0, 1 and 2 according to the number of copies of a reference allele (A1).  Allele frequency of A1 is indicated in the minor allele frequency (MAF) column; Corrected P-values by a permutation test are indicated: the Gene P-value (G_Pvalue), locus P-value (L_P-value) and study P-value(S_P-value)  were calculated by dividing the number of times  P-value ≤ Raw P-value (R_P-value) by the total permutations (1000) in the same gene, the same locus and in the total study, respectively.  Odd Ratio (OR) and their respective  95 % Confidence Intervals (CI 95%) are calculated for the minor allele (A1).  Finally, we show the risk allele reported by every GWAS in the “GWAS risk allele” column. 
     Association with gene-expression Association with migraine risk 
SNP A1 MAF Probe Gene  Asymptotic 
P-value 
Empirical P-
value after 
locus-wide 
correction 
Empirical P-
value after 
study-wide 
correction 
OR CI 95% GWAS Risk 
Allele 
rs1712517 G 0.4462 ILMN_1773313 USMG5 0.00003 <0.001 0.012 0.83 0.76-0.90 T rs11172113 C 0.4104 ILMN_1763198 STAT6 0.00008 0.001 0.033 0.87 0.81-0.93 T rs11906854 G 0.1147 ILMN_2276000 CPNE1 0.0001 <0.001 0.044 0.82 0.71-0.89 G rs4803455 A 0.4588 IILMN_1670841 BCKDHA 0.0001 0.003 0.044 0.8 0.71-0.89 C rs11906854 G 0.1147 ILMN_1670841 CPNE1 0.0004 0.004 0.16 0.79 0.70-0.90 G rs3094117 G 0.3297 ILMN_1721113 HLA-C 0.0004 0.016 0.16 1.46 1.18-1.80 T rs7085387 G 0.233 ILMN_1715661 TFAM 0.0006 0.004 0.26 1.17 1.07-1.28 A rs2076054 C 0.276 ILMN_1715963 FBXO7 0.001 0.014 0.44 1.25 1.08-1.45 C rs3094117 G 0.3297 ILMN_1716922 DHX16 0.002 0.082 0.82 0.93 0.86-0.97 T rs3094117 G 0.3297 ILMN_2101885 TUBB 0.002 0.082 0.82 0.91 0.86-0.97 T rs10037055 T 0.2572 ILMN_2278850 RAB24 0.002 0.082 0.82 0.93 0.89-0.97 G rs10037055 T 0.2572 ILMN_1714393 RAB24 0.003 <0.001 1.23 1.08 1.02-1.14 G rs11906854 G 0.1147 ILMN_1795317 SCAND1 0.003 0.047 1.23 1.17 1.05-1.30 G rs2274316 C 0.3065 ILMN_2126239 SMG5 0.009 0.366 3.67 1.07 1.01-1.13 C rs11906854 G 0.1147 ILMN_2411963 RBM39 0.013 0.21 5.51 1.12 1.02-1.22 G rs2274316 C 0.3065 ILMN_1696749 LMNA 0.024 0.94 11.76 1.09 1.01-1.17 C rs4478147 G 0.4821 ILMN_1815780 MAPK10 0.033 0.13 15.93 0.94 0.90-0.99 G  
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Figure 6.4.  Transcription levels vs gentoypes.  Genotype vs Levels of expression Boxplot Distribution.  a. rs1712517 vs USMG5;b. rs11172113 vs STAT6;c. rs11906854 vs CPNE1; d. rs4803455 vs  BCKDHA. Significant eQTLs (S_P-value ≤ 0.05) are presented.  The linearity in the distribution suggest a genetic additive model followed by SNPs rs1712517, rs11172113, rs11906854 and rs4803455 influencing the levels of expression of the USMG5, STAT6, CPNE1 and BCKDHA genes respectively.   6.6 DISCUSSION   As with other complex diseases, published GWAS confirm that common risk variants which individually explain a large proportion of migraine heritability do not exist. Instead, multiple risk variants with small and cumulative effects on the phenotype are most likely to explain the heritability of migraine.   Consistent with this hypothesis, we found that a polygenic risk score computed based on SNPs identified in published GWAS was associated with migraine case-control status in the isolated population of Norfolk Island. Our results also support a regulatory role for these SNPs on the expression of mitochondrial, immunological and hormonal genes. As the number of bona fide migraine risk SNPs increases, a polygenic score can potentially be used to predict the risk of 132  Chapter 6: Common Polygenic Variation Contributes to Risk of Migraine In The Norfolk Island Population. 
migraine and eventually it could represent a predictor with better discrimination properties between different sub-classifications of the disorder. This methodology, fitting associated and non-associated SNPs simultaneously into the polygenic model, have been applied successfully in the past to explain a large proportion of the heritability for human height [271], schizophrenia and bipolar disorder [272].  Similarly, more simplistic models where only associated variants from independent case-controls association studies are included were able to predict coronary heart disease [273], and prostate cancer risk  [274]. This is the first time that the later methodology has been applied to support a polygenic model in migraine.  The score analysis provides evidence for the existence of a polygenic influence on susceptibility of migraine; however, it provides little guidance as to which of the SNPs included in the polygenic score represent true migraine risk factors in the Norfolk Island population. Results from our gene expression analysis identified 4 SNPs that regulate the expression of a nearby gene, which provides further independent support for these variants. The most significant association was observed between rs1712517 and USMG5 (Up-regulated during skeletal muscle growth) expression, which is consistent with results reported in a previous large GWAS of gene expression [275].  Earlier studies in lymphoblastoid cell lines [276, 277] and in circulating monocytes [278] also identified rs1712517 as an eQTL SNP for the USMG5 gene. Interestingly, the USMG5 gene is highly expressed in mitochondria where it plays a critical role in maintaining the ATP synthase population [279]. Mitochondrial dysfunction can occur as a result of the reduced capacity to produce ATP, and this impairment in energy supply can affect the function of neurons and other cells, increasing the risk for neurological disorders [280]. USMG5 also lies in a genomic region previously associated with schizophrenia [281].  In our study, the allele that increased USMG5 expression (A) was associated with decreased migraine risk.   Another notable association was observed between rs11172113 and the expression of the STAT6 gene, also consistent with previous reports [275, 277].  The protein encoded by the STAT6 (Signal Transducer and Activator of Transcription 6) gene is a member of the STAT 
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family of transcription factors which carries out a dual function: signal transduction and activation of transcription. It is also involved in IL4 (interleukin-4) and IL3 (interleukin-3) mediated signalling.  Cytokines are involved in a number of cellular processes including apoptosis, chemotaxis and cell proliferation and they have been associated with neuronal damage and pain in response to particular cellular states, such as hypothermia and hypoxia.  The role of cytokines in the neuro-inflammatory response and its influence in the development of migraine has been widely studied [282].  We discovered a previously unrecognised eQTL for the BCKDHA gene, rs4803455, which is located 65Kb upstream of the transcription start site. The allele that increased gene expression levels (A allele, Figure 6.4) was associated with increased migraine risk (Sumplemental Table 1).  BCKD is a mitochondrial multienzyme complex comprised of three catalytic components, one of them, a branched chain α-ketoacid decarboxylase subunit (E1) is encoded by  the BCKDHA gene [283].  The gene is involved in the metabolism of the essential branched-chain amino acids (BCAAs) leucine, valine, and isoleucine and other mutations have been implicated in the development of maple syrup urine disease, an autosomal recessive metabolic disorder  [284].    Finally, the biggest limitation faced by this and other neurological studies [285-287] is the use of expression profiles from peripheral blood samples.  The reasons behind this fact are the inconsistency of gene expression levels all through the brain caused by the  vast amount of cell types [288] and  the technical inconvenience in collecting brain tissue samples in post-mortem [289].  This contrasts with the accessibility of peripheral blood tissue which in turn, facilitates the acquisition of a bigger sample size. Interestingly, a recent study by McKenzie et al. [290], described the eQTLs overlapping  in brain regions and blood, supporting the use of blood samples when conditions do not allow the targeting of specific disease tissues. However, cell types specific to the pathophysiology of the investigated disorder should be used whenever possible to perform transcription analysis.  
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 In conclusion, we provide evidence for a significant polygenic component to migraine risk in the isolated population of the Norfolk Island. Our results also point to two putative migraine risk genes that affect mitochondrial function, USMG5 and BCKDHA, which might represent novel biological targets for migraine treatment.    6.7 CONCLUSIONS  Results from this study provide evidence for the existence of a polygenic influence in migraine driven by gene variants affecting mitochondrial, immunological and hormonal gene mRNA levels in the cellular environmental.  Additionally, we have replicated eQTLs from previous studies further validating our approach.  We have also reported four eQTLs (rs1712517-USMG5; rs11172113-STAT6; rs11906854-CPNE1; rs4803455- BCKDHA) interacting with genes relevant to the migraine pathophysiology that were significant at a study level.  The rs4803455-BCKDHA is a novel eQTL reported for the first time in this study. Further studies are needed to fully understand the role of these variants in the development of migraine.  Thus, this study open doors to the investigation of novel biological targets for migraine treatment to be considered in future studies.   
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In chapter 6 we provided evidence to show that common migraine variants detected in GWAS 
confer a small impact on the phenotype that, unless added with the effects of other genes, 
would remain undetectable.  Fifty five SNPs, showing no evidence of susceptibility when 
analysed individually, reached statistical significance (P-value=0.018) when the association 
analysis is performed after adding them all into the model. Additionally, twenty eight genetic 
markers showed to be controlling the expression of different genes in cis, some of which are 
of migraine pathophysiology interest. The implementation of this polygenic scoring method 
for in migraine prognosis will be feasible once more variants are added to the model to 
increase its power to differentiate migraine patients from healthy controls.  
 
Thus, in the next chapter we aim at the discovery of novel genes and genetic variants with 
small effects on the migraine phenotype through the use of a pathway analysis in an 
expression data set using the Norfolk Island population.  Once the 
downregulated/upregulated pathways were identified, we performed a leading edge analysis 
to select the genes providing the highest enrichment score to the pathway.  Subsequently, 
SNPs potentially controlling the expression of these genes were studied in order to determine 
if they corresponded to eQTLs. The integration of data from the SNP array and the genome 
wide expression array, both described in previous chapters, allowed us to detect novel genes 
and genetic variant related with migraine.   
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              CHAPTER 7    PATHWAY ANALYSIS IMPLICATES MITOCHONDRIAL AND NA+/K+ PUMPS SUBUNITS GENES IN THE SUSCEPTIBILITY OF MIGRAINE IN THE NORFOLK ISLAND POPULATION              This chapter is formatted as a paper and it is under review to be published: 
 
Rodriguez-Acevedo AJ, Miles Benton, Lea RA,,Griffiths LR. 2014. Pathway analysis implicates mitochondrial and Na+/K+ pumps  subunits genes in the susceptibility of migraine in the Norfolk Island Population. Bioinformatics. Manuscript under 
revision.   141  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 

7.1 WORK FLOW  
  
7: 
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7.2 ABSTRACT  
Background  Migraine has been defined as a common disabling primary headache disorder which is influenced by both genetic and environmental risk factors.  So far, few genes having a major effect on the disease have been identified. It is thought that the wide phenotypic variation of migraine may be influenced by a complex network of interacting genes..   
Methods  In an attempt to discover genetic pathways involved in the pathophysiology of migraine we compared the gene expression profiles of individuals suffering migraine (n=79) with healthy controls (n=254) from the Norfolk Island genetic isolate.  Gene expression analysis was performed using data generated from Illumina HumanHT-12 v4 arrays. Statistical significance of differentially expressed genes between cases and controls was determined by standard t-tests. Subsequently, a gene set enrichment analysis was performed with GSEA software to identify differentially expressed set of genes between cases and controls (grouped by their common biological function, chromosomal location, or regulation).  Additionally, a leading edge analysis was performed to identify the genes with the highest enrichment scores. This subset of genes was selected to perform follow-up SNP based association testing using the GenAbel program.  
Results 
 Our initial results suggest that cardiac muscle contraction, tryptophan metabolism, proximal tubule bicarbonate reclamation, oxidative phosphorylation, Parkinson’s and Huntington’s disease pathways are down-regulated in individuals suffering migraine.  The leading edge analysis implicated 49 genes with the highest enrichment scores.  Among these genes those involved in oxidative phosphorylation seemed to enrich the majority of the down-regulated pathways. In particular, SNPs located in NDUFS4, NUDFB8, NUDFA8, 
NUDFA10 and COX7A2L were significantly associated with migraine (p≤0.001) and may represent variants responsible for the down-regulation of the identified pathways.   
Conclusions 
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In this study we have used a gene set enrichment analysis of blood transcript data to provide evidence that genetic variants involved in oxidative phosphorylation are associated with migraine in the Norfolk Island population.  These findings suggest that pathways involved in energy metabolism may represent suitable targets for future studies of migraine risk and pathogenesis.. 
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7.3 INTRODUCTION  Migraine is the third most prevalent disorder worldwide for the Global Burden of Disease Survey [11]. According to the third edition (version Beta) of the International Classification of Headache Disorders (ICHD-III) [34], migraine has been defined as a common disabling primary headache disorder, classified into two major groups, migraine without aura (MO) and migraine with aura (MA).  MO is the most common form with headache attacks lasting between 4-72 hours.  MA sufferers, in addition, often experience aural symptoms preceding the headache phase of the migraine episode.   Migraine is believed to begin with the activation and sensitization of trigeminal sensory afferents that innervate cranial tissues, in particular the meninges and their large blood vessels; this, follows the sequential activation and sensitization of second and third order trigeminovascular neurons, which in turn stimulate diverse areas of the brainstem and forebrain [2, 291, 292].  However the general mechanism is not well known and there are still an important number of questions to be answered.   In efforts to establish a better understanding of migraine pathophysiology, different genetic variants have been identified. In particular, three genes, CACNA1A, ATP1A2 and 
SCNA1A, have been identified from studies performed in familial hemiplegic migraine (FHM), a severe monogenic form of MA [3-5]. Recent Genome Wide scans have also provided insight into genetic variants related to the most common subtypes of migraine such as: rs9908234 [6] in the intronic region of Nerve Growth Factor Receptor Gene (NGFR); rs1835740 [6, 7] located downstream of the carboxypeptidase Q (CPQ) gene; rs2651899 in the PR Domain Containing 16 (PRDM16) gene; rs10166942 in the upstream region of the Transient Receptor Potential Cation Channel, subfamily M, Member 8 (TRPM8) gene ,and rs11172113 [8] in the low density lipoprotein receptor-related protein 1 (LRP1) gene. In addition, other important studies using different approaches have shown that KCNK18 [9] and genomic regions Xq27 and Xq28 [10] may also play an important role in migraine pathophysiology.      To study the underlying mechanisms and document new biological markers in different types of disorders, microarray gene expression studies have proved to be a valuable tool. For example, a group of 11 genes from 8 functional categories were identified by Urbach et 
al. [293] while studying cortical spreading depression, defined as a wave of electrophysiological hyperactivity followed by a wave of inhibition, usually in the visual 147  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
cortex. Using an hemiplegic migraine animal model, Vries et al [294] showed that RNA 
expression profiles from cerebellar tissue from S218L (a mutation in the CaV2.1 α1 subunit of P/Q-type Ca2+ channels)[101] mutants and wild-type mice changes significantly, particularly tyrosine hydroxylase, a marker of delayed cerebellar maturation 
[15]. The α-fodrin gene (SPTAN1) has also been shown to be differentially expressed in lymphoblasts originating from patients diagnosed as having migraine with aura (MA) [295]. Another study by Hershey et al. [296] found that platelets genes were upregulated in migraine and chromic migraine samples.  In a later study, the same author defined groups of differentially expressed genes (immunomodulation/inflammation, mitochondrial function, and DNA homeostasis) when comparing genomic expression patterns of menstrual-related migraine (MRM) to migraine occurring outside the menstrual period and headache-free controls [139].   To identify new biological markers and establish a better understanding of the processes underlying migraine pathophysiology, a traditional GWAS in the Norfolk Island population was performed in the past [211].  In this study, the SNP rs4807347 in ZNF555, showed evidence of association with migraine but no other major hits were identified.  Thus, to develop alternate approaches that may yield insight into this complex disorder, we performed a microarray analysis to study differential gene expression patterns in migraine cases and controls from the genetic isolate of Norfolk Island. Norfolk Island it is located off the Australian eastern coast. The modern Norfolk Island population comes from a settlement of 194 inhabitants descendants of nine male “Bounty” mutineers and twelve Tahitian women [28]. Thus, up to 80% of current permanent residents can trace their heritage back to the Island’s initial founders.  All these characteristics alongside recent evidence suggesting a high heritability of migraine in the Norfolk Island population (h2=0.53) [211], makes Norfolk Island an excellent model for the identification of migraine biomarkers.   7.4 METHODS  
Population 
 Phenotypic data and biological specimens (whole blood) were obtained from 600 subjects (261 males, 339 females). Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, and medication use.  DNA was isolated using a standard salting-out procedure [214].Migraine diagnosis was in 148  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
accordance with ICHD-II guidelines. The inclusion criteria used to select cases was a diagnosis of MA or MO. Genealogical data were obtained from multiple sources, including questionnaire, municipal and historical records, mitochondrial DNA (mtDNA) variants and genome wide SNP data. Because all the individuals share a common genetic background and under the hypothesis of common variants influencing the two main subtypes of migraine, all individuals diagnosed with subtypes MA or MO were grouped together and phenotyped as being affected with migraine. The study protocol was approved by the Griffith University Human Research Ethics Committee and subsequently by the QUT Human Research Ethics Committee. All subjects provided signed, informed consent prior to participation.  
Genome-wide expression 
 RNA extraction and expression profiling procedures have been previously described in detail [121]. Blood samples were collected in PAXgene tubes (QIAGEN) and total RNA was extracted using PAXgene Blood miRNA Kits (QIAGEN) according to the manufacturer’s instructions. RNA quality was assessed with the Bioanalyzer 2100 (Agilent Technologies) and a total of 250 ng of RNA was amplified and labelled with the Illumina TotalPrep-96 RNA Amplification Kit (Life Technologies) according to the manufacturer’s instructions.   Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases and 256 controls).  Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1). Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the number of expressed probes (at detection P-values ≤ 0.05), mean raw expression values across probes, and correlations between samples, all samples, except one which was subsequently removed, provided high-quality data. The raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization.  
Genome-wide SNP genotyping  EDTA anticoagulated venous blood samples were collected from all participants. Genomic DNA was extracted from blood buffy coats via standard phenol-chloroform procedures. 149  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
DNA samples were genotyped according to the manufacturer’s instructions on the Illumina Infinium High Density (HD) Human610-Quad DNA analysis BeadChip version 1. A total of 620,901 genome wide markers were genotyped in a sub-sample of 285 related individuals (135 males; 150 females) selected from a core 377-member pedigree. Of these related individuals 76 are migraine cases (22 males, 54 females). These individuals possessed high inheritance information and were extremely informative for pedigree-based analysis, facilitating cost-effective genotyping [211]. Markers had a median spacing of 2.7kb (mean = 4.7kb) throughout the genome.  Each Human610-Quad DNA analysis BeadChip employed a four-sample format requiring 200ng of DNA per sample. Samples were scanned on the Illumina BeadArray 500GX Reader. Raw data was obtained using Illumina BeadScan image data acquisition software (version 2.3.0.13).  
 
Statistical Analysis 
 
Gene Expression and Pathway Analysis 
 Because of its simplicity and interpretability, we used a standard T-test to evaluate the statistical significance of differentially expressed genes between cases and controls. Additionally, to achieve more accurate results we also applied a logistic regression analysis corrected by sex, age and kinship using R (version 2.15.2) software [252]. Thus, two gene lists were initially generated. A third final gene list containing only common transcripts between the two previous gene lists was then derived to perform following analysis.   Subsequently, a pathway analysis was performed using GSEA [223]. GSEA assess gene set enrichment of KEGG (c2.kegg.v4.0.symbols.gmt, 161 gene sets) pathways that show an overrepresentation of up- or down-regulated genes between cases and controls.  Each gene is ranked by its expression difference using weighted Kolmogorov-Smirnov global statistic.  GSEA reports two main scores: the enrichment score (ES), which reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes and the normalized enrichment score (NES) which normalizes the enrichment score in order to be comparable between gene sets.  
 
Gene Association Analysis 
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In order to identify possible migraine associated variants in genes encoding differentially expressed transcripts, we selected a subset of SNPs distributed in a range of 200kb either side of the genes with the most significant enrichment scores from the pathway analysis.  This range was selected aiming to identify potential associated variants located in intronic, exonic and other upstream/downstream regulatory elements of these genes.  However, caution is needed in this respect as multiple neighbour genes may be tagged by a SNP or set of SNPs. Initially a subset of 8042 SNPs spanning 49 genes was established; then a quality control was performed and 45 SNPs were excluded for having low (<0.11) minor allele frequency and/or low (<95%) genotypic call rate.  A total of 7997 SNPs spanning 49 genes passed the quality control.  An association analysis was carried out to account for the pedigree relatedness followed by a family-based association test.  An “mmscore” was employed as a score test for an association between migraine and genetic polymorphism in samples of related individuals. This score is implemented by GenABEL and it is similar to the score calculated by Abecasis et at. [220] using family trios. By default, GenABEL initially checks the data for: SNPs and samples with low call rate (<95%), SNPs with Minor Allele Frequency (MAF) (<0.87%); SNPs out of HWE, samples with extreme autosomal heterozygosity (FDR at 0.01), and those which have genome wide Identity by State (IBS) ≥ 0.95. Subsequently, GeneABEL estimates residuals of the trait and the inverse of the variance-covariance matrix for further use in analysis with the common “mmscore” command to calculate the above mentioned mm score.    To detect possible eQTLs involved in the modulation of under-regulated pathways in the cases population, we selected individuals with both genotypic and gene expression data.  A final subset of 279 individuals (207 controls and 72 cases) was used for the purposes of this analysis.  Initially, the covariates age, sex and kinship were individually tested for association with levels of gene expression and no significance was detected (P-value < 0.05). Thus, these variables were not included in later analyses.  We then modelled the potential association between a candidate SNP and a target gene by a standard linear 
regression: γ = β0 + β1A + ϵ, where γ represents observed expression level of a specific target gene and A the genotype of a given individual at the SNP.  Genotypes were coded as 1, 2, 3 (aa, Aa, AA) to evaluate the genotypic association while a code of 0, 1 or 2 copies of a reference allele was assigned to test for allele association.    7.5 RESULTS  
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 After the differential expression analysis, we detected no significant (FDR ≤ 0.1) changes between the gene expression of cases and controls (Appendix 4).  Detected log 2 fold changes ranged from -0.99 to 1.061, suggesting subtle changes in gene expression playing a possible role in the migraine phenotype.  To test this hypothesis we carried out a pathway analysis in our data set.  This type of analysis considers multiple contributing factors in the same metabolic route to detect changes that could remain undiscovered when studying single gene effects [44].    
GSEA analysis  Pathway analysis was performed using GSEA. Probes were collapsed into a final number of 18513 genes. After the analysis, 75 gene sets were shown to be down-regulated in cases, however, only 9 of them reached statistical significance at different levels (1 at FDR < 25%, 1 at P-value <- 0.01 and 7 at P-value <- 0.05).  Pathway enrichments were evaluated by their normalized enrichment score (NES), nominal P value, and false discovery rates (FDR). Table 7.1 shows the top 10 enriched pathways, ranked by NES for the control subset.  Because not all of the members of a gene set will typically participate in a biological process it could be useful to extract the core members of high scoring gene sets that contribute to the ES. Those core genes are known as leading edge genes, and they can be interpreted as a core set of genes that account for the enrichment signal [223].  Table 7.2 shows the leading edge subset in our dataset. A number of 121 unique leading edge genes, redundantly distributed in the 10 most significant selected pathways were identified.   Leading edge genes that are also redundant across different under/up-regulated pathways represent the most interesting findings as they can be key functional biological targets that account for most of the down/up-regulation signal detected in the pathway analysis. Figure 7.1 shows in different colour intensities the degree of gene overlapping between the top 10 down-regulated pathways from this analysis.  Huntington’s disease pathway showed to have thirty-eight genes in common with the oxidative phosphorylation pathway; it also shares forty-two genes with the Parkinson’s disease pathway.  Similarly, the oxidative phosphorylation and Parkinson diseases pathways share thirty-nine genes; ten genes are shared between cardiac muscle contraction, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease pathway and three genes belong to the interception between the PTBR and cardiac muscle contraction pathways.  Figure 7.2 152  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
shows a histogram with all genes participating in at least two pathways.  To show the functional interaction of this group of genes, we performed a network analysis using the web-based tool STRING [297] (Figure 7.3). Interestingly, a dense number of interactions.
Table 7.1.  Significantly enriched pathways. Size: number of genes; NES: normalized ES, FDR:False discovery rate. 
        Pathway name Size NES Pval FDR   Proximal tubule bicarbonate reclamation 16 1.75 0.016 0.34   Cardiac muscle contraction 47 1.74 0.004 0.17   Tryptophan metabolism 24 1.66 0.016 0.26   Parkinsons disease 94 1.61 0.031 0.31   Oxidative phosphorylation 97 1.55 0.048 0.40   Tyrosine metabolism 19 1.54 0.037 0.37   Arginine and proline metabolism 32 1.47 0.051 0.52   Glycosylphosphatidylinositol GPI anchor biosynthesis 23 1.44 0.087 0.54   P53 signaling pathway 49 1.43 0.036 0.53   Huntingtons Disease 138 1.42 0.077 0.48          
Table 7.2.  Leading edge analysis.   Leading edge genes can be interpreted as the core of a gene set that accounts for the enrichment signal ES.  A number of 121 unique leading edge genes redundantly distributed in the 10 most significant selected pathways were identified.   
 Pathway Leading edge subset   Proximal Tubule Bicarbonate Reclamation FXYD2    AQP1    ATP1B3    SLC25A10    ATP1B1    GLUD1   MDH1   Cardiac Muscle Contraction CACNA2D4   CACNA1D   UQCRQ    COX7C    COX5A   COX7A2L   FXYD2   CYC1   ATP1B3   CACNA2D2   UQCRFS1   ATP1B1   SLC9A6   COX6A1   COX7A2   COX4I1   CACNB3   COX6C   Tryptophan Metabolism IDO1    KYNU    ALDH2     ACAT1    WARS   
 Parkinsons Disease 
NDUFA4 NDUFS4 UQCRQ COX7C SLC25A4 NDUFS7 COX5A NDUFS3 NDUFB5 COX7A2L SNCA ATP5G1 CYC1 NDUFA9 NDUFB2 CASP3 CYCS UQCRFS1 NDUFAB1 NDUFA8 COX6A1 NDUFA10 COX7A2 COX4I1 ATP5H NDUFV2 SDHB ATP5J NDUFA7 UBE2L6 UQCRC1 SEPT5 PARK2 SLC25A6  NDUFA2 ATP5O NDUFB9 NDUFB7 COX6C NDUFS1 COX5B NDUFS8  NDUFB8 NDUFC1 NDUFB1 ATP5F1 UQCRB 
 
 Oxidative Phosphorylation 
ATP5F1   ATP5G1   ATP5H   ATP5J   ATP5J2   ATP5L   ATP5O   ATP6V0B      ATP6V1D   ATP6V1G1   COX10   COX15   COX17   COX4I1   COX5A   COX5B   COX6A1    COX6C   COX7A2   COX7A2L   COX7C   CYC1  NDUFA10   NDUFA2   NDUFA4   NDUFA7   NDUFA8   NDUFA9   NDUFAB1   NDUFB1   NDUFB2   NDUFB5   NDUFB7   NDUFB8   NDUFB9   NDUFC1   NDUFS1   NDUFS3   NDUFS4   NDUFS7   NDUFS8   NDUFV2   PPA1   SDHB   UQCRC1    UQCRFS1   UQCRQ UQCRB 
 
 Tyrosine Metabolism    NAT6    HGD    ALDH3B1    ADH1C    COMT    TRMT11   FAH   Arginine and proline metabolism ALDH2 GLUD1 PYCR1 GLUL ARG1 AMD1 ODC1 SAT2 P4HA1 LAP3 OAT GAMT   GPI anchor biosynthesis PIGK PIGY PIGQ PIGP DPM2   P53 signaling pathway CASP3 CYCS PMAIP1 CCNG2 PPPM1D THBS1 SESN3 CDKN1A TP5313  
 Huntingtons Disease 
AP2A1   AP2B1   AP2M1   AP2S1   ATP5G1   ATP5F1 ATP5H   ATP5J   ATP5O   BAX   CASP3   CLTB   COX4I1   COX5A   COX5B   COX6A1   COX6C   COX7A2   COX7A2L   COX7C   CYC1     DNAL1   GPX1   NDUFA10   NDUFA2   NDUFA4   NDUFA7   NDUFA8   NDUFA9   NDUFAB1   NDUFB2   NDUFB5   NDUFB7   NDUFB8 NDUFB9  NDUFC1 NDUFS1   NDUFS3   NDUFS4   NDUFS7   NDUFS8   NDUFV2   POLR2D   POLR2F   POLR2H POLR2G   POLR2J   POLR2L   SDHB   SLC25A4   SLC25A6   SOD1   TFAM   TGM2   UQCRC1   UQCRFS1   
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UQCRQ UQCRB   
 
Figure 7.1.  Pathways Correlation.  Pathways Correlation.  Color intensity shows the overlap between subsets. The intensity of the cell for two different sets,  A and B,  corresponds to an X/Y ratio where X is the number of leading edge genes from set A and Y is the union of leading edge genes in sets A and B. A dark blue cell indicates that sets A and B have the same leading edge genes (e.g Huntington’s disease and Parkinson disease pathways) and a white cell indicates that sets A and B have no leading edge genes in common (e.g Huntingtons disease and p53 pathways).   
  
Figure 7.2.  Genes that appeared in at least two gene sets.  Genes that appeared in at least two gene sets.  A total of 121 leading edge genes were identified; 49 of them participate in at least two enriched pathways in our analysis. This genes were selected for further analysis.   154  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
  
Figure 7.3.  Functional interactions between leading edge genes.   Binding type interactions are shown in blue lines.  Black lines represent any kind of reaction between the two molecules.  Purple lines indicate catalysis processes involved in the interaction of the two proteins. Grey lines indicate another type of interaction that is not functional.   The first cluster (left corner) is a dense cloud of interactions between NADH:oxidoreductase proteins, all of them located in  mitochondrial membranes.  A second cluster, in the middle, is mainly composed of mitochondrial ATP synthases and Cytochrome C oxidase (COX)  subunits.  The final and smallest cluster (right corner) includes ATP1B1, ATP1B3 and FXYD2 genes.  These three genes are sodium/potassium transporting subunits and their localization is the cellular membrane of different tissues.    between NADH:oxidoreductase proteins, mitochondrial ATP synthases and Cytochrome C oxidase (COX) subunits, all of them located in the mitochondria, were detected.    
Gene Association Analysis   In order to identify possible genetic polymorphisms that could help explain the observed pathway down-regulation in cases, we selected 7997 SNPs distributed in a range of 200 kb either side of the forty-nine leading edge genes presented in Figure 7.2 , to perform an association analysis for cis-acting eQTL. SNP rs6872379 in NDUFS4 (P-value=0.0002), and SNPs rs17028994, (P-value=0.0002), rs17029060 (P-value=0.0003), rs17773172 (P-value=0.0003) and rs13419919 (P-value=0.0003) in COX7A2L, are significant at a P-value 
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≤ 0.001. Table 7.3 shows the associated SNPs, their chromosome, gene name, alleles and their P-values.  
Table 7.3. Associated SNPs (P-value<0.001) flanking regions around genes detected after the leading edge analysis.  This variants represent possible genetic factors involved in the control of  expression of the genes indicated in column 3.   
        
 SNP Chr Gene A1 A2 P-value   rs6872379 5 NDUFS4 G A 0.00018   rs17028994 2 COX7A2L C T 0.00023   rs17029060 2 COX7A2L G A 0.00030   rs17773172 2 COX7A2L T C 0.00034   rs13419919 2 COX7A2L T C 0.00035   rs12218075 10 NDUFB8 T C 0.00070   rs6735806 2 NDUFA10 C A 0.00071   rs2900195 9 NDUFA8 A C 0.00100   rs7875955 9 NDUFA8 A C 0.00124   rs1897139 3 ATP1B3 C T 0.00125   rs9810380 3 ATP1B3 A G 0.00125          
 
 
Gene Expression-Genotype Correlation  A logistic regression analysis was performed to identify whether markers positively associated with migraine correlated with levels of expression of their respective transcripts. Results for the genotypic and allelic association are shown in Table 7.4.  Genotypes in SNPs rs1897139 and rs9810380 are equally significantly correlated (as a result of a high LD between them) with levels of expression of ATP1B3 (P-val=0.002). A boxplot depicting this correlation is presented in Figure 7.4.  Risk alleles were also tested and results suggest that allele T in SNP rs1897139 (OR = 0.77; IC = 0.65-0.94) and allele G in SNP rs9810380 (OR = 0.77; IC = 0.65-0.94) significantly associate with decreased levels of expression of ATP1B3 (probe ILMN_1759628 and probe ILMN_1783304).   7.6 DISCUSSION  We have investigated the differential patterns of gene expression in migraine patients and healthy controls from the Norfolk Island genetic isolate. Although a standard T-test and a 
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logistic regression analysis showed no evidence of differential gene expression in both groups, when using pathway analysis approach the cardiac muscle contraction, 
157  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
Table 7.4.  eQTL analysis.  P-value, Odd Ratio (OR)  and 95%  Interval Coefficients (IC95%) are presented for the association between a SNP and the closest  transcript to it.  For the genotypic P-value all genotypes were considered in the analysis.  For the allelic P-value, genotypes were coded as 0,1 and 2 following an additive model where the number refers to the dose of a reference allele, which in this case is A1 (Allele1). Markers   rs1897139 and rs9810380 seem to be playing a role in the expression of the ATP1B3 gene.                 
   Alleles P-val    
Gene SNP Transcript A1 A2  Genotypic Allelic OR IC 95% ALDH2 rs2239194 ILMN_1793859 A G 0.31 0.3 0.9 0.75-1.09 ATP1B3 rs1897139 ILMN_1759628 T C 0.004 0.008 0.77 0.65-0.94 
 rs1897139 ILMN_1783304 T C 0.002 0.005 0.77 0.64-0.92  rs1897139 ILMN_1654322 T C 0.62 0.34 1.04 0.95-1.14  rs9810380 ILMN_1759628 G A 0.004 0.008 0.77 0.65-0.94  rs9810380 ILMN_1783304 G A 0.002 0.005 0.77 0.64-0.92  rs9810380 ILMN_1654322 G A 0.62 0.34 1.04 0.95-1.14 COX7A2L rs17028994 ILMN_3237665 T C 0.81 0.61 0.93 0.71-1.22 
 rs17029060 ILMN_3237665 A G 0.96 0.78 1.01 0.90-1.14  rs17773172 ILMN_3237665 C T 0.78 0.79 1.01 0.90-1.14  rs13419919 ILMN_3237665 C T 0.95 0.75 1.02 0.91-1.14 NDUFA10 rs6735806 ILMN_2225698 A C 0.52 0.29 0.97 0.93-1.02 
 rs6735806 ILMN_1791119 A C 0.28 0.11 0.96 0.92-1 NDUFA8 rs2900195 ILMN_1759729 C A 0.50 0.8 1 0.96-1 
 rs7875955 ILMN_1759729 C A 0.92 0.92 1 0.96-1.04 NDUFB8 rs12218075 ILMN_1661170 C T 0.80 0.53 0.98 0.92-1.04 NDUFS4 rs6872379 ILMN_1812312 A G 0.89 0.65 0.97 0.87-1.09 
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Figure 7.4. Logistic Regression Analysis. Gene expression levels of ATP1B3 versus rs1897139 and rs9810380 SNPs genotypes.  tryptophan metabolism, proximal tubule bicarbonate reclamation, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease pathways showed to be down regulated in migraine cases.  On the other hand, an association analysis performed with SNPs on genes from the significantly enriched pathways showed that SNPs in genes 
NDUFS4, COX7A2L, NDUFB8, NDUFA8 and ATP1B3 might be associated with migraine and they may play a role in the down regulation of these transcripts. Also an eQTL analysis suggested that SNPs rs1897139 and rs9810380 are associated with the expression of 
ATP1B3, a gene showing enrichment in both the proximal tubule bicarbonate reclamation and cardiac muscle contraction pathways, which is thought to influence pain variability and nociception [29].   The most significantly enriched gene sets after the GSEA analysis were the cardiac muscle contraction, tryptophan metabolism and proximal tubule bicarbonate reclamation pathways.  All of these shared the important mechanism of ion transportation into and out of the cell that could lead to processes such as muscle contraction, regulation of blood pH and action potentials in neurons.  Genes in the cardiac muscle contraction pathways are of special interest as the role of ion channels and pumps in migraine have been widely reported in the literature [103, 114, 291, 298].  Additionally, pathways such as Parkinson’s disease, oxidative phosphorylation and Huntington’s disease, represent interesting biological targets in our attempt to explain genetic differences between migraine sufferers and healthy individuals, as these are all enriched by mitochondrial genes involved in the respiratory chain. Biochemical evidence suggest that abnormal mitochondrial function can lead to high intracellular Ca2+, over 159  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
production of free radicals and poor oxidative phosphorylation activity, which consequently causes energy failure in neurons and astrocytes, and may thus trigger migraine mechanisms, including spreading depression [56]. Genetic [299], morphological [300] and therapeutic evidence [113] supporting the relationship of mitochondrial processes with migraine has also been reporte. Interactions between genes are presented in the core of the graphic and show the vast number of interactions between the analysed genes.  Figure 7.3 shows a gene network with only the genes that enriched more than one pathway.  The first cluster (left corner) is a dense cloud of interactions between NADH:oxidoreductase proteins, all of them located in the mitochondrial membrane.  A second cluster, in the middle is mainly composed of mitochondrial ATP synthases and Cytochrome C oxidase (COX) subunits.  The last and smallest cluster (right corner) includes ATP1B1, ATP1B3 and FXYD2 genes.  These three genes are sodium/potassium transporting subunits that localize to the cellular membrane of different tissues.  The high number of interactions in this network, allows us to predict that small changes in levels of transcription or activity in any of the leading edge genes detected in our analysis, may significantly affect the general network functionality, resulting in pathological consequences, such as migraine.   A strong association with migraine was detected in SNP rs6872379 (P-value=0.0002), located 36.3 kb upstream of NDUFS4. This gene encodes an accessory subunit of NADH:ubiquinone oxidoreductase complex (Complex I) in the mitochondria and it plays a vital role in cellular ATP production [301]. Although this SNP has not been previously associated with a specific disorder, other markers in this gene has been associated with different neuronal disorders such as Leigh’s syndrome [132] and diverse encephalopathies [133]. Even though no significant correlation between rs6872379 and 
NDUFS4 gene expression was detected in our analysis (P-value = 0.89), it is possible that this SNP may influence subtle changes in the expression levels of this gene and thus final protein abundance, predisposing carriers to disorders like migraine.  Four more SNPs positively associated with migraine (rs12218075, P-value= 0.0007; rs6735806, P-value=0.0007; rs2900195, P-value=0.001; rs7875955, P-value=0.001) are located in genes 
NUDFB8, NUDFA8 and NUDFA10.  They are all accessory proteins of complex I in the mitochondrial membrane [302] further supporting the potential role of mitochondrial metabolic pathways in migraine.   Additionally, four variants (rs17028994, rs13419919, rs17773172 and rs17029060) in 
tight LD (D’ ≥ 0.96) were identified as associated with migraine and are located 160  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
approximately 200kb upstream from COX7A2L.  This gene represents a regulatory subunit of Cytochrome c oxidase (COX) in the mitochondria, and mediates the higher level of energy production in target cells by estrogen [303]. It is well known the importance of estrogen in the pathophysiology of migraine [134] and the evidence provided in this paper could provide insight into new mechanisms, where the interaction of hormones and oxidative phosphorylation genes could explain the onset of migraine episodes under specific physiological conditions.    Associated SNPs rs1897139 and rs9810380 showed to be in strong LD and seem to be playing a role in regulation of the ATP1B3 gene expression (P-value=0.002).  Both SNPs are located in intron 1 and 293 bp lie between them.  The protein encoded by this gene belongs to the family of Na+/K+ and H+/K+ ATPases beta chain proteins, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na+ and K+ ions across the plasma membrane.  ATP1B3 protein is also a determinant of pain variability and it modulates nociception [135].The role of ion channels and pumps has shown to be a crucial factor in the episodic activation and sensitization of the trigeminovascular pain pathway, both biological mechanism involved in the pathophysiology of migraine [2, 114].  Migraine is a complex disease and multiple factors are expected to play key roles in the pathology of this disorder.  We hypothesise in this paper that transcript levels and genetic variants may interact in a different fashion in individuals suffering from migraine.  More evidence is required to elucidate the network of genes and expression control mechanisms that are involved in a complex disease like migraine.    7.7 CONCLUSIONS  Pathway analysis in the Norfolk island population suggest that cardiac muscle contraction, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease pathways are down-regulated in individuals suffering from migraine.  Genes involved in the respiratory chain and Na+ and K+ pumps subunit genes, were enriched in the majority of the pathways implicated in the disorder. Thus it is possible that the migraine phenotype is being driven by the influence of genes participating in the oxidative phosphorylation process. Additionally, ATP1B3, participating in the cardiac muscle contraction pathway, might also be involved in the pathophysiology of migraine in the NI population as shown 161  Chapter 7: Pathway Analysis Implicates Mitochondrial and Na+/K+ Pumps Subunits Genes In The Susceptibility of Migraine In The Norfolk Island Population. 
by the association analysis. More interesting is the fact that an eQTL possibly related to the down-regulation of this gene was also detected in this study. The product of ATP1B3 is thought to modulate nociception through establishing and maintaining the electrochemical gradients of Na+ and K+ ions across the plasma membrane what in time, has great impact on the activation and sensitization of the trigeminovascular pain pathway, widely known as one of the most important biological mechanism behind the initialisation of migraine episodes This study has additionally identified eleven SNPs in 6 genes as being potentially implicated in migraine.  These findings together represent an insight into the role of oxidative phosphorylation related genes in the causation of migraine and they also expose new biological targets that should be considered in future functional studies.     
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In chapter 7 we detected down-regulated pathways in migraine sufferers.  From these 
pathways, 49 genes, mainly involved in mitochondria functioning and ATPases activities, 
provided the strongest signals to the pathway enrichment score.  We have also identified two 
eQTLs, rs1897139 and rs9810380, which seem to be controlling the expression of the ATP1B3 
gene, a gene involved in nociception.  Thus, we have shown probed that the use of newer 
statistical approaches could lead to the identification of new variants, through the mining of 
large data sets resulted from high through-put techniques.   
 
It is also evident that analysis by grouped genes instead of by individual variants, gives more 
power to the study as the combined effect of all of these is taken into account.  This also 
provides a more realistic approach to the study of biological systems, where the activity of 
one gene impacts on other elements in the system as they are bound together by a vast 
amount of direct and indirect interactions modelled as gene networks. 
 
Early in this work, we explored the replication of previous associations in hormonal related 
genes.  We then added the effects of hormonal genes to other known vascular and neuronal 
genes into a polygenic model.  We then performed a pathway analysis to discover new 
variants based on the interaction with other genes in the same pathway.  In chapter 7 we will 
continue exploring the association of new variants with migraine, focusing on groups of 
correlated genes.  Using a supervised clustering strategy we evaluated if groups of highly 
correlated genes, previously reported by other studies, could also stratify the Norfolk Island 
population according to the individual’s migraine status.  
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       CHAPTER 8 
 INVESTIGATION OF COMMON AXES OF PERIPHERAL BLOOD GENE EXPRESSION AND ITS RELATIONSHIP WITH MIGRAINE IN A NORFOLK ISLAND POPULATION             This chapter has been formatted as a paper and it is under review to be published:  
 Astrid J Rodriguez-Acevedo,  Anita Goldiner, Miles Benton, Melanie A. Carless, 
Harald H. Goring, Joanne E. Curran, John Blangero, Rodney Lea, Lyn Griffiths. Investigation of Common Axes of Peripheral Blood Gene Expression in the Norfolk Island Population. Bioinformatics.  Manuscript under revision.  

8.1 WORK FLOW  
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8.2 ABSTRACT  
Background 
 Norfolk Island belongs to the Commonwealth of Australia and it is located off the eastern coast, approximately 1700 km northeast of Sydney, on the Norfolk Ridge.  The modern Norfolk Island (NI) population comes from a settlement of 194 inhabitants resettled from the Pitcairn Islands in 1856, all of them descendants of nine male “Bounty” mutineers and twelve Tahitian women. Nine common axes of peripheral blood variation previously described are explained by 10 of the genes most closely associated with each Axis, called Blood Informative Transcripts (BIT).  BITs can be used to differentiate immunological and metabolic status between healthy individuals and patients suffering different types of diseases.  We aimed to define the axes of variation in a Norfolk Island population to see how they compare with other populations, and to explore the possible association of the BITs with migraine in NI.    
Methods 
  Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases and 256 controls).  Only  12665 probes were selected from NI data set in order to make it comparable with other populations. Principal Component  (PC), logistic regression and correlation analysis were performed in  R.   
 
Results and Discussion 
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 A weak correlation was found between transcripts in Axis 1 and Axis 9 in NI although this can be explained by the fact that they are greatly influenced by environmental factors.  In contrast, when compared with other populations, NI was the only population showing a high correlated core of Axes 2, 4, 6, 5 and 8.  We have also tested the association between BITs and migraine in affected individuals, although no positive results were found.   
Conclusions:   Here we have shown that in the Norfolk Island population, transcripts in most of the Axes are co-regulated.  Additionally, there are unique correlations between different axes, for example, a uniquely correlated core of transcripts for genes in Axes 2, 4, 6, 5 and 8.  Future studies should consider the inclusion of more phenotypic information.  These studies, in turn, will help in the understanding of the Axes interactions reported in this chapter. They should also focus on exploring the inter-individual variation that will help in unravelling the complex structure of this extended Norfolk Island pedigree.     
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8.3 INTRODUCTION  Gene expression studies have become a fundamental technique to explore further phenotypes in complex diseases.  This approach has lead to the discovery of new genes, pathways and networks underlying relevant pathophysiological process that would remain undetected by only the use of Genome Wide Association Studies (GWAS)[304]. A better understanding of disease aetiology will ultimately take us to a new era of personalized therapy. This era has already started and it has been called “predictive”, “preventive”, “personalized” and “participatory” (P4) medicine [305].  Thus, high-through put techniques couple with traditional clinical assessment to generate a vast amount of data on an individual patient basis for more efficient and accurate treatment strategies.   Preinenger et al. [224] provided us with a good example of the use of gene expression studies in the new P4 medicine era. They redefined 28 co-regulated gene expressed modules originally implemented by Chaussable et al. [306] into 9 common axes of peripheral blood variation.  The authors showed that approximately one half of the transcriptome is highly correlated with one of these 9 Axes.  More importantly, 10 of the genes most closely associated with each Axis, called Blood Informative Transcripts (BIT), can be used to differentiate metabolic status between healthy individuals and patients suffering different types of diseases. Chausabell’s modules and the 9 variation axes were conceived using different sets of gene expression profiles from whole blood, and, consequently, they target blood-related diseases such as systemic lupus erythematosus among others [306].    Many studies on non-blood related disorders make use of peripheral blood samples to perform gene expression analysis. This is the case for neuronal disorders [285-287].   The 
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inconsistency of gene expression levels all through the brain caused by the vast amount of cell types [288] and the technical inconvenience in collecting brain tissue samples in post-mortem [289], contrast with the accessibility of peripheral blood tissue.  In turn, blood accessibility, facilitates the acquisition of a bigger sample size and, in a recent study by McKenzie et al. [290], the eQTLs overlapping in brain regions and blood are described.  This, supports the use of blood samples when conditions do not allow the targeting of specific disease tissues, which is the case in gene expression migraine studies.    Migraine is a complex disorder [34] and it is believed to begin with the activation and sensitization of trigeminal sensory afferents that innervate cranial tissues, in particular the meninges and their large blood vessels. This, follows the sequential activation and sensitization of second and third order trigeminovascular neurons, which in turn stimulate diverse areas of the brainstem and forebrain [2, 291, 292].    However the general mechanism is not well understood and there are still a number of questions to be answered.  We have performed an Illumina bead chip microarray analysis for the study of gene differential expression patterns of migraine cases and controls from the genetic isolate of the Norfolk Island population.  The heritability of migraine in this population is estimated to be 0.53 [211].  Norfolk Island belongs to the Commonwealth of Australia and it is located off the eastern coast, approximately 1700 km northeast of Sydney, on the Norfolk Ridge. The modern Norfolk Island (NI) population comes from a settlement of 194 inhabitants resettled from the Pitcairn Islands in 1856.  All of them were the descendants of nine male “Bounty” mutineers and twelve Tahitian women [28]. Since that time, the island has been isolated, and strict immigration and quarantine legislation restricts migration to Norfolk.  Thus, of the approximately 1200 current permanent residents, up to 80% can trace their heritage back to the Island’s initial founders. We aimed to defined the 9 axes of variation in the NI cohort and see how they compare with 
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populations where axes have already been replicated [224].  We also aim to explore the possible association of the axes BITs with migraine.     
 
8.4.  METHODOLOGY  
Population 
 Phenotypic data and biological specimens (venous blood) were obtained from 600 subjects (261 males, 339 females).  DNA was isolated using a standard salting-out procedure [214].  Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, and medication use.  An in depth interview and comprehensive medical questionnaire was undertaken on all individuals and used to obtain phenotypic data, including migraine information regarding family history, symptoms, triggers and medication. Migraine diagnosis was in accordance with ICHD-II guidelines. The inclusion criteria used to select cases was a diagnostic of MA or MO with other non-migraineurs included in the control population.  Genealogical data were obtained from multiple sources, including questionnaire, municipal and historical records. Because all the individuals share a common genetic background all individuals diagnosed with subtypes MA or MO were grouped together and phenotyped as being affected with migraine. The study protocol was approved initially by the Griffith University Human Research Ethics Committee and subsequently by the QUT University Human Research Ethics Committee. All subjects provided signed, informed consent prior to participation. 
 
 
 
Genome-wide expression 
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 Sample collection has been previously described [121]. Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases and 256 controls).  Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1). Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the number of expressed probes (at “detection p values” ≤ 0.05), mean raw expression values across probes, and correlations (across probes) between samples, all samples provided high-quality data, except for one sample that was of questionable quality (this was removed). Significantly expressed probes were then determined at a false-discovery rate of 5% on the basis of p values generated in a binomial test on the counts of samples in which a probe generated 
“detection p values” ≤ 0.05 (success) and > 0.05 (failure). Subsequently, the raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization. 
 
Axes analysis 
 Probes in every axis were selected according to the supplementary Axes list provided by [224].  Only 12665 probes were chosen for comparison purposes with data set from CHWB and Morocco . Principal Component Analysis (PCA), logistic regression analysis and correlations were performed using R [252].  Details about packages and specific parameters are described in the respective graphics footnotes.   
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8.5. RESULTS  A total number of 4391 unique transcript probes and 3779 genes are associated with at least one Axis. Thus, 34% of our total data set (12883 probes) clustered into 9 correlation axes. Table 8.1 shows the characteristic of the 9 axes in the Norfolk Island population previously defined by Preininger et al [224].  Some of the transcript probes reported in the original axes were not available in our dataset. Therefore, the numbers of genes and probes in NI axes are slightly smaller. Axis 1 has 97.5% of the original number of genes while Axes 4, 5, 6, 7 and 9 have more than 95% of the total genes (99.6%, 99.3%, 98.9%, 97.63%, 95.04%, respectively).  Axis 2 (93.24%), Axis 3 (90.1%) and Axis 8 (78.45%) have the biggest difference in numbers with respect to the original axes.  We consider that there is a good representation of the most significant transcripts in every axis and consequently the 9 axes will be included in the analysis, unless is indicated. The biological function of the Axes, assessed using the ToppGene suite [307], are describe in detail in [224] and they are presented in Table 8.1.  Loadings and variance plots are presented for Axis 1 to Axis 9 from left to right and top to bottom in Figure 8.1.  Ten different sets of 586 random probes (average number of probes among all axes) were selected from the total data set and an average percent variance of 17.33% in PC1 was obtained.  Axis 8 and 2 are the best correlated of the Axes in our analysis showing a 55.44% and 44.78%, respectively, of explained variance by their first PCs. The direction and length of the arrows in the loading plots from these Axes give an indication of the strong covariance between probes. Thus, Axes 3 (30,1% v), 4 (32,36% v ),  5 (30,54% v) , 6 (36,13% v ) and 7 (32,9% v )  showed a moderate co-variation between probes while Axis 1 and 9 seem to lack significant correlation as percent variances ( Axis 1   
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Table 8.1. Characteristics of blood expression axes in Norfolk Island population.  
       Axis Probes Genes Gene Ontology   Axis 1 913 844 Translation; Ribosome constituents   Axis 2 244 221 Oxygen transporter activity   Axis 3 107 90 B-cell activation   Axis 4 1078 979 mRNA metabolism, RNA splicing, intracellular transport   Axis 5 1211 1021 Cytokine receptor activity   Axis 6 562 544    Axis 7 215 165 Viral response   Axis 8 468 448 RNA processing   Axis 9 252 230 Signal transduction by phosphorylation Programmed cell death         =24,45%; Axis 9 = 17,03%) resemble those obtained for randomly selected probes (17,33%).    Data published by Preininger et al [224], includes variances for a subset of the top 175 most strongly correlated probes across Axis 1 to 7. Thus, they can be compared with variances from the modules proposed by Chaussabel et al [306]. To compare our results with previously published data, we subset from the NI data set the top 175 most correlated probes in [224] when possible for Axis 1 to 7.  Table 8.2 compares the number of probes and genes, and percent variance in CHWB/MOR population with Norfolk Island.  In general, the average percent variance explained by PC1 in Axes is less in Norfolk Island (46,28%) than in the other populations ( 57,2% and 50,2%). As expected, transcript correlation in these Axes subsets increased importantly. However, Axis 1, 3 and 7 remain as the weakest set of correlated transcripts while, in agreement with Preininger et al.  [224], Axis 6 shows the strongest correlation. This might suggest that probes with less correlation to the original Axes are more susceptible to population or assays specific effects, while probes at the top of the list 
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Figure 8.1.  Covariance of gene expression in Axes.  Loadings are plotted, to the left, in PC1 (Dim1) and PC2 (Dim2) for each axis. The percentage of  variance are indicated in parenthesis.  To the right of every loading plot, a bar plot is showing the variances corresponding to the first 8 principal component in every axes.     
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Table 8.2.  Percent variance given by PC1 in Axes from Norfolk Island compared to CHWB 
and MOR.  Comparison of percent variance explained by PC1 in  seven axes from CHWB /MOR populations and Norfolk Island.  Number of top 175 associated probes, are indicated in column 2 for CHWB/MOR population and in column 4 for Norfolk Island.  Similarly, number of genes are presented in columns 3 and 5 for CHWB/MOR and NI, respectively.  Average (Avg) numbers of genes, probes and variances are presented in the last row.  In general, PC1 in different Axes explain less variance in NI than in the contrasting populations.   
 remain co-regulated across the analysis performed in different populations and platforms.  Figure 8.2 shows the loadings and variance plots for these subsets.   We then selected the ten transcripts with the highest correlation within each axis.  These transcripts, previously denominated as Blood-Informative Transcripts (BIT) by Preininger et al. [224], were highly co-regulated and showed a strong correlation with genetic, environmental and other phenotypic variables.  It was demonstrated that BITs can be used as predictive biomarkers to evaluate disease susceptibility as they can track immunological and metabolic changes.   In each case, correlation of transcripts in BIT with one another is much stronger than it is when randomly selected transcripts are clustered and tested.  Transcripts in Axis 1, 4 and 9 showed the weakest correlation. In general, even though the extent of variance is much less in NI, our findings seem to be consistent with the rest of population (Table 8.3).  
        CHWB and MOR NI Variance   Axes Probes Genes Probes Genes % CHWB % MOR % NI   Axis 1 175 165 171 162 63.1 46.5 33.3   Axis 2 175 157 166 149 63.3 34.6 55.4   Axis 3 118 99 107 90 41.6 32.4 36.2   Axis 4 175 158 175 158 40.7 60.2 41.7   Axis 5 175 150 175 150 63.9 61.5 46.8   Axis 6 175 171 175 171 80.4 74.4 73.8   Axis 7 175 134 172 132 47.5 42.1 36.8  
 Avg 175 148 163 144 57.2 50.2 46.28  
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Figure 8.2.  PC1 vs PC2 loadings.  Covariance of gene expression in a subset of 175 transcripts from each Axis (Total number of transcripts for Axis 3).    Loadings are plotted in PC1 and PC2 for each Axis. The percent variance is indicated in parenthesis  for PC1(Axis X) and PC2(Axis Y).  To the right of every loading plot a scree plot is shown. Only the first 8 principal components are depicted.  At the right bottom, One of the 10 randomly selected sets of 175 transcripts is shown in order to compare it with results from the Axes of variation.    
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Table 8.3.  BIT PC1 variance comparison across different populations.   Values represent the percentage of variance of the BIT abundance explained by each Axis PC1 in the Atlanta CHDWB, Morocco [308], Red Cross donors in Brisbane Australia [309], an independent Twin Study in Brisbane [310], a Celiac disease study [311], a Tuberculosis study in London and South Africa [312],  the DILGOM Finnish study [313] and Norfolk Island.   
             CHDWB Morocco BNE 
RC 
BNE Twin Celiac TB DILGOM NI   Axis 1 71.4 66.0 52.9 63.8 81.9 68.6 62.7 38.6   Axis 2 84.4 73.6 59.4 69.3 73.8 76.2 80.1 86.4   Axis 3 76.6 72.0 68.5 63.5 72.6 76.1 70.2 55.8   Axis 4 53.4 69.4 54.7 84.3 92.3 35.3 46.0 52.3   Axis 5 75.6 76.5 71.4 82.8 73.1 72.8 70.5 61.6   Axis 6 92.9 93.4 84.7 90.0 98.3 93.1 91.5 93.6   Axis 7 82.5 77.2 82.5 68.7 80.7 82.8 80.4 71.8   Axis 8 58.9 69.3 51.7 85.7 85.2 64.9 44.4 54.4   Axis 9 53.3 78.6 48.3 60.8 75.0 82.8 52.9 39.8              Table 8.3 shows the the percent variance of the 10 BIT explained by each Axis PC1 in the Atlanta CHDWB, Morocco [308], Red Cross donors in Brisbane Australia [309], an independent Twin Study in Brisbane [310], a Celiac disease study [311], a Tuberculosis study in London and South Africa [312], the DILGOM Finnish study [313] and Norfolk Island.  BITs in Axis 1 were among the least correlated transcripts in Morocco, BNE RC, BNE Twin, and TB populations. Also, percent variance in BITs from Axis 6 accords with percent variances in all the previously studied populations, where it shows the strongest correlation among all axes.  Lower percent variances in NI with respect to the rest of population can be explained in part by the differences in platforms, normalization and standardization processes in the data set. Additionally, the unique characteristics of NI, as a genetic isolate, might be playing an important role in the way genes are interacting.  Figure 8.3 shows PC1 and PC2 loadings (right) and scores (left) plots for all the Axes in NI.  A list of the Axis BITs have been provided in Appendix 5  180  Chapter 8: Investigation of Common Axes of Peripheral Blood Gene Expression and Its Relationship With Migraine In a Norfolk Island Population 
 
  
 
Figure 8.3.  PC1 loadings and scores.  Every panel shows the PC1 loadings of the 10 BIT transcripts in the CHDWB study on the left, and the individual PC1 and PC2 scores on the right.  The same result for a typical random set of 10 probes is included as well.        
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Figure 8.4. BIT and PC1 scores Correlation.  Correlation between BIT scores and PC1 scores based on the 250 most strongly associated probes in every Axis.     
 
Figure 8.5. BIT Axis Correlation . Panels show the correlation between the BIT Axis scores for all individuals in CHDWB, Brisbane Red Cross, Morocco, TB, and Norfolk Island.  Las panel at the right bottom corner, includes scores for all the axes in NI.   BIT and PC1 scores from the 250 most strongly associated probes in every Axis were generated and its correlation coefficient is shown in colours in Figure 8.4 and Figure 8.5.  Positive and strong correlations (all greater than 0.93; P-value<- 2.2-16)  were found for 
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Axis 2, 3, 4, 5, 6 and 8.  In contrast, no correlation (r=0,04)  was found between the BIT and 250 probes scores in Axis 1. Also, a negative correlation was found after testing scores in Axis 7 (r=-0.9; P-value<- 2.2-16) and Axis 9 (r=-0.7; P-value<- 2.2-16).    Figure 8.5 shows the covariance between the BIT across different populations including NI.  As previously stated by [224], the covariance between the Axes is somewhat study-specific.  There are some consistencies between NI and the other populations like the negative interaction between Axis 5 and Axis 1, similarly positive correlation between Axis 5 and Axis 7 was also replicated in NI.  However, some inconsistencies in NI with respect to the other studies also highlight.  For instance, a relatively strong negative correlation between Axis 3 and Axis 1; the positive correlation between Axis 2 and Axis 4 and the high correlation between Axis 2, 6, 4 and 5.  Once Axis 8 and 9 are included in the analysis, this correlation core seems to also contain Axis 8.  These results might reflect the genetic homogeneity in NI contrasting with the genetic diversity in general populations from different ancestries.    
Phenotypic Association 
 A logistics regression analysis was performed to check for association between BITs and migraine status in individuals from NI. No significant association was detected with any of the Axes as outlined in Table 8.4.  We also analysed the correlation of Axis with the first 5 principal components when using the complete dataset of expression.  Table 8.5 shows the correlation coefficients for PC1 Axes scores (full sets) with PC1 to PC5 scores.  High correlations were detected between Axis 4, 5, 6 and 8 with PC1. There is also a strong negative correlation of Axis 9 with the 
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same PC.  These findings confirm previous observations about the high correlation between these axes.  Figure 8.6 shows the PC1 and PC2 loadings distribution in 
Table 8.4. BIT scores vs Migraine Status.  Association between the BIT scores and the status of affection in migraine was evaluated.  We used a logistic regression analysis corrected by age, sex and kinship. 
      
 BIT Axes Coefficient OR CI95%   Axis 1 -0.0269 0.97 [0.85-1.10]   Axis 2 -0.048 0.95 [0.87-1.04]   Axis 3 -0.036 0.96 [0.86-1.07]   Axis 4 -0.019 0.98 [0.88-1.09]   Axis 5 0.06 1.07 [1.18-0.96]   Axis 6 -0.04 0.95 [0.88-1.04]   Axis 7 -0.019 0.98 [0.88-1.08]   Axis 8 0.01 1.01 [0.89-1.14]   Axis 9 0.10 1.10 [0.97-1.26]          
Table 8.5. Axis and PC correlation.  Correlation between PC1 Axes scores and first 5 PC scores using the entire data set.   
          PC1 PC2 PC3 PC4 PC5  
 Axis 1 0.11 -0.04 0.01 0.01 0.01  
 Axis 2 0.22 0.58 -0.05 0.38 0.03  
 Axis 3 -0.09 0.61 -0.08 0.03 0.29  
 Axis 4 0.89 0.40 0.04 0.05 -0.14  
 Axis 5 0.81 0.28 0.28 0.06 0.36  
 Axis 6 0.80 -0.24 -0.43 0.13 0.12  
 Axis 7 -0.47 0.07 -0.14 -0.1 -0.33  
 Axis 8 0.94 -0.08 -0.26 0.01 0.02  
 Axis 9 -0.83 0.06 -0.03 0.11 -0.28  
          NI population.  Loadings are represented in different colours according to the axes where they belong.  This supports previous evidence about the weak or strong correlation of transcripts probes in NI.   Panel A shows the distribution of loadings from Axis 1.  As it can be seen, transcripts are not localize in a specific region in the diagram, instead, they are 
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spread reflecting a lack of correlation with other transcripts in both PC1 or PC2.  This result was expected as transcripts in this axis poorly correlate with each other and BIT.  
 
Figure 8.6.  PC1 and PC2 loadings distribution for  the all Axes.  Probes are coloured differently in every Axis. From left to right and top to bottom Axes are presented individually as follows: Axis 1(A): Red; Axis 2(B): Blue; Axis 3(C):Green; Axis 4(D): Magenta; Axis 5€: Orange; Axis 6(F): Yellow; Axis 7(G): Maroon; Axis 8(H): Pink; Axis 9(I): Grey.  The last panel (J) shows all the Axes together with the same individual colour code.  Probes that are concentrated in one area in the graphic tend to have a higher correlation than probes that are spread over all the graphic area.   
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 failed to explain the variability from the axes as a whole.  Axes 2 and 3 have moderate correlations with PC2 and a clear distribution in the upper half of the diagram (Panel B) can be seen for transcripts in Axis 2. That is a reflection of the strong correlation repeatedly found across the different subsets in this Axis.  On the other hand, transcripts in Axis 3, look sparser and the co-variation between transcripts is more modest than it is for Axis 2.  Axis 4, 5, 6, 7 and 8 have strong correlations with PC1 and clusters of co-regulated transcripts can be seen in the graphic.  Axis 7 does not correlate to any of the first 5 principal components and although it showed strong internal correlation, the BITs from this Axis correlate in a negative fashion with the other transcripts scores in PC1.    8.6 DISCUSSION  Axes of gene expression variation were conceived as risk evaluators for different diseases and they have proven to be highly reproducible across studies. We have shown that in the Norfolk Island population, transcripts in most of the axes remain co-regulated.  Although the strength of such interactions is, for most of the Axes, much lower in this specific data set when compared with others (Table 8.2, Table 8.3). These results can be attributable to technical and methodological factors such as the platform used and the normalization and standardization process applied to the NI data set.  This theory is supported by the fact that the most (Axis 1, 4 and 9) and least (Axis 6) correlated axes in NI are the same in other data sets. Thus, across the 7 datasets presented in Table 8.3, Axes 1, 4, 8 and 9 possess the lowest percentage variance explained by PC1 while Axis 6 has by far the strongest correlation in all data sets.  Transcripts probes in Axes 2 and 6 showed the highest correlation in NI (Axis2: 86.4%; Axis 6: 93,6%).    
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Interestingly, interactions between different NI Axes changed substantially with respect to other populations. Thus, the NI population was the only data set showing a high correlated core of transcripts for genes in Axes 2, 4, 6, 5 and 8.  Those Axes in turn are highly correlated with the PC1 and PC2 derived from the entire data set (Table 8.5).  These findings highlight the importance of the Axes in explaining a considerable extent of variability in the Norfolk Island population, as PC1 and PC2 together cover 29.76% of the total variability in the full NI set. It is also surprising that there is a strong positive correlation between Axis 4 and Axis 6 in the NI population. These Axes showed a negative correlation in the Morocco and Brisbane Red Cross populations, and they seem not to correlate in the Tuberculosis and Atlanta data sets.  Future studies should focus on studying this unique correlation.  The inclusion of phenotypic association and gene network design could help in the understanding of the exclusive gene interactions found in this study.   On the other hand, the lack of general correlation between transcripts in Axis 1 and Axis 9 across different subsets (total transcripts, top 250, top 170 and BIT) and the limited intra-Axis correlation of Axis 1, Axis 7 and Axis 9 BITs, suggest that gene interactions in Norfolk Island follow a different pattern compared to other populations. Of note is that Axes 1 and 9 are greatly influenced by environmental factors, as was demonstrated by Preininger et al. [224] on the Moroccan population [308].  Axis 1 could distinguish between Boutroch residents, a small village in Morroco, from urban citizens in Agadir. Axis 9 showed a strong association to variable “lifestyle”.  It is believed that part of the geographical genomic effect comes from exposure to environmental agents influencing axes that seem to relate to anti-microbial responsiveness.  Further studies exploring inter-individual variation are needed in the Norfolk Island population to determine if environmental factors are structuring the population into genomic subgroups recognizable through the 9 Axes of genetic variation.   
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In spite of the different Axes interactions in NI, most of the Axis (with the exception of Axis 1, 7 and 9) showed a well-defined structure and high correlation between transcripts.  Thus, we consider that they have the potential to predict and explain the risk of disease in individuals from Norfolk Island.  We have tested the association between BITs and migraine in affected individuals and no positive results were found.  The main reason could be that Axes are enriched by biological functions that have little or no effect on migraine pathophysiology.  Enriched pathways in the Axes include inflammation, viral response and signalling within B and T lymphocytes as well as neutrophils.  It is also possible, that in view of the sensitivity of some of the Axes to environmental factors, the inclusion criteria of migraine sufferers and healthy controls need to be adjusted to eliminate possible noise interfering with association signals.  Other blood diseases and traits have been previously associated with BITs in the past and we believe that they can explain other blood-related phenotypes in Norfolk Island. However, these traits are out of the scope of this manuscript which mainly focused on the genetic factors of migraine.  In summary, we have evaluated blood variation Axes in the Norfolk Island population and we have provided enough evidence to support the reliability of Axes 2, 3, 4, 5, 6 and 8 to group highly correlated genes in our population.    
8.7. CONCLUSIONS  We showed that in the Norfolk Island population, transcripts in most of the Axes remain co-regulated.  Transcripts in Axis 1 and Axis 9 showed a weak correlation while a highly correlated core comprised by Axes 2, 4, 6, 5 and 8 was found only in the NI population.  Those axes in turn, are highly correlated to PC1 and PC2 from the entire data set.  Additionally, we have tested the association between BITs and migraine in affected individuals but no positive results were found.  We believe that biological functions 
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associated with these axes might have little or no effect on migraine pathophysiology. Future studies on the Norfolk Island population should consider more phenotypic information.  The inclusion of new traits will help in the understanding of the axes interactions. Similarly,  future studies should focus on exploring the inter-individual variation that could contribute in unravelling the complex structure of this extended Norfolk Island pedigree.    
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Chapter 8 covered the study of highly correlated gene groups in relation to migraine.  Such 
groups of genes were defined in a previous study where the authors also identified 
transcripts able to discriminate patients suffering from a different range of disorders and 
their respective controls.  We performed a migraine association test with these transcripts 
but no significant results were obtained.  This can be caused by the unique correlation 
patterns that genes in the Norfolk Island seem to be following, as demonstrated by the 
comparison of the inter-Axis analysis across different populations.  These results motivated 
us to elucidate how genes in the Norfolk Island Population are distributed.  In this way, 
instead of evaluating groups of genes pre-established in other studies, we defined groups of 
correlated transcripts or clusters specific for individuals in our study.  After defining the 
specific clusters, we carried out an association analysis on the migraine status.  Chapter 8 
explains in detail how this process was performed using an hierarchical unsupervised 
clustering methodology.  
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                     CHAPTER 9   UNSUPERVISED CLUSTERING ANALYSIS IN THE NORFOLK ISLAND POPULATION                
This chapter has been formatted as a paper and it is under review to be published:  
Astrid J Rodriguez-Acevedo,  Anita Goldiner, Melanie A. Carless, Harald H. Goring, 
Joanne E. Curran, John Blangero, Rodney Lea, Lyn Griffiths. Unsupervised clustering analysis and migraine module association  in the Norfolk Island population.  
Bioinformatics. Manuscript under revision. 
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9.1 WORK FLOW  
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9.2 ABSTRACT  
Background 
 Migraine is a complex disorder [26] and it is believed to begin with the activation and sensitization of trigeminal sensory afferents that innervate cranial tissues, in particular the meninges and their large blood vessels. However the general mechanism is not well understood and there are still a number of questions to be answered. To see if any difference could be detected between the expressions patterns of migraine cases and controls in the Norfolk Island population we have utilised 9 groups of genes found to be highly correlated in other populations. [224].  These groups of genes (Axes of variation) claim to be able to track metabolic changes in patients suffering different blood disorder when compared to healthy controls.  However, we found that the Norfolk Island population seems to have different gene interactions to other populations and this was reflected in the lack of gene correlation inside every Axis. Consequently, these groups of genes were not able to differentiate metabolic state between patients suffering migraine and healthy controls. Thus, we decided to perform an unsupervised clustering analysis to detect groups of genes highly correlated in this dataset and further define gene clusters (modules) specific to the Norfolk Island population.  We then aim to evaluate if there is a difference in levels of expression of these new clusters between cases and controls.  For this objective we used a network construction approach.  
Methods 
 Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases and 256 controls). The 
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eigengene network was constructed using the WGCNA package implemented in R. Modules were compared after calculating their eigengenes and applying a Pearson’s correlation.  Principal component analysis was carried out to visualize the distribution followed by the loadings and the scores.  All analysis were carried out using R.  
 
Results 
 We have identified 8 meta modules consisting of 14164 (11692 genes) transcripts which account for approximately 61,25%  of the total probe set in our microarray.  No association between migraine and any tested modules.  Approximately 85% of the transcripts included in the Axes were detected also by WGCNA in 19 modules.   The ME14 module shared 727 genes (37%) with axes 4, 6, 8 and 9, while the ME9 module shared   410 genes (23.3%) with axes 4, 7, 8 and 9.  Also, genes in Axes which did not have a strong correlation in NI (Axes 1, 4, 5 and 9) are dispersed over different modules supporting the idea that the Norfolk Island population has a particular genetic structure.  
Conclusions 
 In spite of the lack of module association with migraine, we have identified a robust group of correlated genes that could be used to track expression changes in disorders related to blood such as cardiovascular diseases.  Modules may also be useful in explaining the impact of different environmental factors on individual investigated expression patterns.  We showed that highly conserved genes from Axes were also part of the modules, but the interaction between these axes with other genes is different in the Norfolk Population compared to 5 different populations presented in the previous analysis.  This evidence highlights the unique genetic organization of the Norfolk cohort. 
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9.3 INTRODUCTION  Migraine is a complex disorder [34] and it is believed to begin with the activation and sensitization of trigeminal sensory afferents that innervate cranial tissues, in particular the meninges and their large blood vessels. This, follows the sequential activation and sensitization of second and third order trigeminovascular neurons, which in turn stimulate diverse areas of the brainstem and forebrain [2, 291, 292].  However, the general mechanism to explain the pathophysiology of migraine is not well understood and there are still questions to be answered.    Norfolk Island belongs to the Commonwealth of Australia and is located off the eastern coast, approximately 1700 km northeast of Sydney, on the Norfolk Ridge. The modern Norfolk Island (NI) population comes from a settlement of 194 inhabitants resettled from Pitcairn Island in 1856.  All are descendants of nine male “Bounty” mutineers and twelve Tahitian women [28]. Since that time, the island has been isolated, and strict immigration and quarantine legislation restricts migration to Norfolk.  Thus, of the approximately 1200 current permanent residents, up to 80% can trace their heritage back to the Island’s initial founders. The heritability of migraine in this population is estimated to be 0.53 [211].   
 We have previously replicated the implementation of 9 blood axes of variation and their respective Blood-Informative Transcripts (BITs) [224] to test if they could track changes in gene expression in migraine patients from the Norfolk Island population.  Although our results were mostly consistent with the original study [308-313], the Norfolk Island population showed also different patterns in gene correlation compared to other populations. These results motivated us to define gene clusters specific to the Norfolk Island population based on a network construction approach.   
199  Chapter 9: Unsupervised clustering Analysis in the Norfolk Island Population 
 
Network methods are frequently used in genomic and systems biologic studies to describe the pairwise relationship of a large number of variables [314, 315]. This methodology has been successfully applied to the analysis of other traits in different populations including percent body fat and tuberculosis infection [316, 317].  This type of analysis has not yet been considered in regards to migraine studies.  Thus, we aim to define clusters of correlated genes in the Norfolk Island population and identify the gene interactions that are potentially influencing the migraine aetiology.    
9.4 METHODS  
Population 
 Phenotypic data and biological specimens (venous blood) were obtained from 600 subjects (261 males, 339 females).  DNA was isolated using a standard salting-out procedure [214].   Phenotypic data was obtained via a medical questionnaire that surveyed migraine family history, symptoms, triggers, and medication use.  An in-depth interview and comprehensive medical questionnaire was undertaken on all individuals and used to obtain phenotypic data, including migraine information regarding family history, symptoms, triggers and medication. Migraine diagnosis was in accordance with ICHD-II guidelines. The inclusion criteria used to select cases was a diagnostic of MA or MO with other non-migraineurs included in the control population.  Genealogical data were obtained from multiple sources, including a questionnaire, municipal and historical records. Because all the individuals share a common genetic background all individuals diagnosed with subtypes MA or MO were grouped together and phenotyped as being affected with migraine. The study protocol was approved by the Griffith University Human 
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Research Ethics Committee. All subjects provided signed informed consent prior to participation.  
Genome-wide expression 
 Sample collection has been previously described [121]. Expression profiling was performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 individuals (79 cases and 256 controls).  Array images were scanned on the Illumina iScan and analyzed initially with the Gene Expression Module from GenomeStudio (v.2011.1). Background subtraction was applied, and missing bead types were imputed with GenomeStudio. On the basis of the number of expressed probes (at “detection p values” ≤ 0.05), mean raw expression values across probes, and correlations (across probes) between samples, all samples provided high-quality data, except for one sample that was of questionable quality (this was removed). Significantly expressed probes were then determined at a false-discovery rate of 5% on the basis of p values generated in a binomial test on the counts of samples in which a probe generated 
“detection p values” ≤ 0.05 (success) and > 0.05 (failure). Subsequently, the raw expression levels of probes detecting significant expression were shifted by a constant amount so that the minimum observed value of any probe in any sample was 1.0; this was followed by log2 transformation and quantile normalization. 
Network construction 
 
Calculation of adjacency matrix We have constructed a weighted gene network specified by an n x n symmetric adjancency matrix A= (aij), where 0 ≤ aij ≤ 1 reports the connection strength between nodes i and j.  Nodes are referred as genes in a gene co-expression network.  For the i-th gene, the scaled connectivity (also referred to as scaled degree) is  
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𝐶𝐶𝑖𝑖(A) ≡ ∑ 𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖 ≠𝑖𝑖 𝑛𝑛 − 1   Genes with high connectivity are sometimes referred to as “hub” genes.  The adjacency matrix was transformed to a Power(A, β ) that raises each adjacency to a fixed power β, i,e., 
 
𝑃𝑃𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆𝑖𝑖𝑖𝑖(𝐴𝐴,𝛽𝛽) ≡ 𝑟𝑟𝑖𝑖𝑖𝑖𝛽𝛽   
By choosing a  power β > 1 the power transformation can be used to emphasize large adjacencies at the expense of low ones, i.e, the power transformation can be used for “sof-thresholding” [318].  The resulting network after this procedure is called a weighted gene co-expression network [319].  Subsequently, a topological overlap transformation TOM(A) replaces each adjacency aij  by a normalized count neighbors that are shared by the nodes i, 
j. for weighted networks A , the topological overlap measure (TOM) is defined as  
𝑇𝑇𝑇𝑇𝑇𝑇𝐼𝐼𝐼𝐼(A) ≡ ∑ 𝑟𝑟𝑖𝑖𝑖𝑖 𝑟𝑟𝑖𝑖𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖 ≠𝑖𝑖,𝑖𝑖min�∑ 𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖 ≠𝑖𝑖 ,∑ 𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖≠𝑖𝑖 � + 1 −  𝑟𝑟𝑖𝑖𝑖𝑖   The topological overlap of two genes reflects their similarity in terms of the commonality of the genes they connect.  The TOM transformation can lead to a more robust network and largest modules [320]. For cluster detection, a dissimilarity transformation needs to be done.  Tej dissimilarity transformation Dissim(A) turns an adjacency matrix (which is a measure of similarity) into a measure of dissimilarity by subtracting it from 1, i.e.,   
𝐷𝐷𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑚𝑚𝑖𝑖𝑖𝑖(𝐴𝐴) ≡ 1 −  𝑟𝑟𝑖𝑖𝑖𝑖  The dissimilarity is used as input to average linkage hierarchical clustering. 
(Equation 9.2) 
(Equation 9.3) 
(Equation 9.4) 
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Module detection 
 Modules are defined as clusters that result from using a pairwise node dissimilarity as the input of average linkage hierarchical clustering.  Branches in the resulting cluster tree (dendrogram) are referred to as modules.  We used the dynamic tree cut method [321] to obtain the cluster in the Norfolk Island population.  This module detection approach has been successfully used in several studies [316, 317].  The algorithm implements an adaptive, iterative process of clusters decomposition and combination and stops when the number of clusters becomes stable.  It starts by obtaining a few large clusters by the static tree cut.  The joining heights of each cluster are analysed for a characteristic pattern of fluctuations indicating a sub-cluster structure; clusters exhibiting this pattern are recursively split.  To avoid over-splitting, very small clusters are joined to their neighbouring major clusters.  The group of genes (modules) whose expression profiles are highly correlated were summarized into one representative gene called the module eigengene [319] to form an eigengene network. The module eigengene is defined as the first right singular vector of the standardized module expression data.    Sample quality control (excessive missing values and identification of outlier microarray samples) was performed using the nearest-neighbour chain algorithm described by Murtagh [322].  This algorithm exploits the fact that pairs of mutually closest points can be merged in any order if the distance update formula fulfils certain criteria.   The WGCNA [225] package was used to performed the clustering analysis.   
Gene ontology and network visualization 
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For the gene ontology analysis, we used the Database for Annotation, Visualization and Integrated Discovery (DAVID ) v6.7 [323].  Only genes with Module Membership (MM) values > |-0.6| within every module were used as input gene lists.     9.5 RESULTS  As part of the quality control, clustering of samples was performed, and the resulting dendrogram is shown in Figure 9.1.  One sample (366680) was eliminated from the analysis as its position in the dendrogram is considerably further away from the rest of the samples.  Then, it is considered an outlier.  A total number of 334 samples were included in the analysis.  Once the population was clean, population traits were drawn in the dendrogram to detect any obvious clustering of samples with respect to gender, age, migraine status or kinship (Figure 9.2).  Evident clustering was not identified using this approach.    For the construction of the weighted gene network, a threshold power of 5 was chosen based on the criterion of approximate scale-free topology [318].  The scale independence and the mean connectivity graphics are presented in Figure 9.3.   
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Figure 9.1.  Sample Clustering dendrogram. Clustering dendogram of samples based on their Euclidean distance.  The red line indicate the threshold line at 90 or 0,9 dissimilarity.  Using the cutreeStatic command in WGCNA all samples above the selected height cut are eliminated from the analysis.
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Figure 9.2.  Sample dendogram with traits.  The leaves of the tree correspond to the samples. The first color band underneath the tree indicate gender (red:males, white:females), the 3rd band represents migraine status (red:cases ,white:controls) and the 2nd and 4th band are age and kinship with red colour  indicating  higher values. 
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Figure 9.3.  Analysis of network topology for various soft-thresholding powers. The left panel shows the scale-free fit index (y-axis) as a function of the soft-thresholding power (x-axis). The right panel displays the mean connectivity (degree, y-axis) as a function of the soft-thresholding power (x-axis). We choose the power 5, which is the lowest power for which the scale-free topology fit index reaches 0.90.    
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A Hierarchical cluster tree (average linkage, dissTOM) of the 23131 genes is presented in Figure 9.4. The colour bands provide a simple visual comparison of module assignments (branch cuttings) based on the dynamic hybrid branch cutting method [324]. A number of 31 clusters (first band under the dendrogram) were initially identified.  Subsequently, we identified modules whose expression profiles were similar to merge them into single modules. We choose a height cut of 0.1, corresponding to 0.9 of correlation (Figure 9.5) to merge the modules. The new 19 merged module colours are shown underneath the original modules in Figure 9.4 at the bottom of the graphic. To avoid confusion, merged modules will be assigned the prefix ME (MErge) plus a number corresponding to their respective position from left to right in the dendrogram presented in Figure 9.5. This identification is located below every merged module in Figure 9.4. Figure 9.5 shows a dendrogram with the Euclidian distances for the eigengenes, showing the relationship between modules.  Table 9.1 presents the number of genes and the Gene Ontology (GO) annotation for every module. A full gene ontology analysis carried out in DAVID is provided in Appendix 6.  Eight meta-modules, or group of correlated modules, are also indicated in the bottom dendrogram shown in Figure 9.5.  The first meta-module consists of the ME1, ME2 and ME3 eigengenes.  The biological function of this meta-module is determined by the ME2 module, enriched by genes participating in mRNA processing.  Modules ME1 and ME3 seem to contain genes with biological roles still to be defined.  The second (ME4 and ME5), third (ME6) and fourth (ME7, ME8 and ME9) meta-modules modules suggest the orchestrated expression of genes involved in mRNA splicing and proteins with acetylation activity.  Eigengenes ME11, ME12 and ME13 form a fifth meta-module. Genes in this meta-module are not significantly enriched by any specific biological function with the only exception of 9 genes from the ME12 module, involved in haemoglobin metabolism and gas transport.   
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Figure 9.4.  Gene Clusters. A clustering dendrogram of genes, with dissimilarity based on topological overlap, together with assigned merged module colors and the original module colors.  A dendogram is shown in the superior panel of the graphic, where probes are distributed along the x-axis and the dissimilarity between nodes or height are shown in the y-axis. Underneath, the first band (Dynamic Tree) show the original colour modules and the second band (Merged modules) corresponds to the merged modules according their eigengenes values correlation. 
Dynamic Tree Cut 
Merged Tree  
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Figure 9.5. Hierarquical clustering of eigengenes modules.  The top panel shows the relationship of the 31 modules detected by the first clustering procedure.  A red line indicates the height cut of 0,1 dissimilarity choosen to merge the most highly correlated modules.  The bottom panel shows a number of 19 new modules after merging the most similar modules.  The new modules are denominated by a consecutive number preceded by the prefix ME (Merged Modules) .  transport.  The sixth meta-module is represented by the ME14 and the ME15. They both are involved in RNA metabolism.  The seventh meta-module corresponds to the ME16, ME18 and ME19 modules mainly enriched by genes involved in translational processes. Finally, the eight meta-module is defined by the ME10 eigengene itself. This last module 
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has no significant association to any gene ontology reported in the different systems used for the analysis.  
Table 9.1.  Module characteristics in the Norfolk Island Population.  Module names, assigned numerical code, number of probes, number of genes and Gene ontologies are presented.  NA: no significant gene ontologies were found for these clusters.           Module color Code Probes Genes Gene Ontology   Brown  ME4  1017 990 NA   Blue ME17 1103 1056 Gene expression, nucleobase-containing and cellular macromolecule metabolic process.    Cyan ME7 1198 1118 Immune response   Dark Green ME12 793 741 haemoglobin metabolism and gas transport   Dark Orange ME6 211 208 Phosphoproteins   Dark Red ME18 663 609 Translation control   Dark Turqouise ME14 2066 1949 RNA metabolism, phosphoproteins   Light Cyan ME9 361 356 Mitochondrial Genes   Light Green ME1 314 308 NA   Mid Night Blue ME13 365 357 NA   Pink ME11 617 614 Mitochondrial Genes   Red ME2 1942 1863 RNA metabolic process   Royal Blue ME5 280 277 Acetylation, phosphoproteins, nuclear location   Salmon ME9 1824 1759 Alternative splicing , RNA binding   Sky Blue ME15 128 127 NA   Steel Blue ME3 119 118 Acetylation proteins   Tan ME16  453 446 Phosphoproteins   White ME19 164 156 Translational termination genes   Dark Grey ME8 546 493 Acetylation, mRNA splicing          
 
Module membership and intramodular connectivity  Module membership (MM) and intramodular connectivity were calculated for every module.  Their correlation and p-values are shown as headings at the top of every panel in Figure 9.6.  Modules with high correlation coefficients indicate the most robust modules in the analysis, as it shows that all genes inside every module connect well with each other.  
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Figure 9.6.  Module membership vs intramodular connectivity correlation. Module membership (MM) and intramodular connectivity were calculated for every module.  Their correlation and p-values are shown as headings at the top of every panel.  From left to right and top to bottom, the modules are presented in the following order : ME17, ME4, ME8, ME18, ME7, ME12, ME6, ME9, ME00, ME10, ME11, ME2, ME1, ME13, ME5, ME9, ME15, ME3, ME16 and ME19. 
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On the other hand, low correlation coefficients (ME4, ME6 and ME13) give an indication of modules whose genes are well connected with each other but they did not correlate as expected with the modular eigengenes. Information regarding the identification of hub genes can be also interpreted from this analysis.  Hub genes are nodes with the highest number of connections in a network and they might represent they represent interesting biological targets to follow up as they can possibly play a regulatory role in a specific group of genes.  Thus, we can select genes falling in the right upper section of the graphic as hub genes in their corresponding networks.  Most of the modules in our study seem to be highly correlated.    We performed a principal component analysis to visualize the probe distribution in every module and to calculate how much variance was explained by their first PC.  Figure 9.7 shows 20 panels with two loadings plots per module. To the right of each panel, the total number of probes in every module are shown; to the left, transcripts were ranked according to the absolute MM value and only those with MM > |-0.6| (high module membership) were plotted.  The plots show that variances in PC1 increase only when genes with high MM are included in the analysis.  It also shows how genes are both negative and positively correlated with every module (direction of the arrows) reflecting, as it is expected in a biological model, positive and negative feedbacks inside the network.  PC1 explains an average of 50% variance in every module.  Modules ME4, ME11 and ME13, have the lowest PC1 percent variances (32, 38 and 13% respectively) suggesting a weaker correlation between genes.  
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ME1 All Probes ME1 Probes MM > |-0.6| ME2 All Probes ME2 Probes MM > |-0.6| 
ME3 All Probes ME3 Probes MM > |-0.6| ME4 All Probes ME4 Probes MM > |-0.6| 
ME5 All Probes ME5 Probes MM > |-0.6| ME6  All Probes ME6 Probes MM > |-0.6| 
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ME7 All Probes ME7 Probes MM > |-0.6| ME8 All Probes ME8 Probes MM > |-0.6| 
ME9 All Probes ME9 Probes MM > |-0.6| ME10 All Probes ME10 Probes MM > |-0.6| 
ME11 All Probes ME11 Probes MM > |-0.6| ME12 All Probes ME12 Probes MM > |-0.6| 
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Figure 9.7.  PC1 vs PC2 loadings modules.  Every panel represents two different diagrams for every module.  From left to right and top to bottom: ME1, ME2, ME3, ME4, ME5, ME6, ME7, ME8, ME9, ME10, ME11, ME12, ME14, ME16, ME17, ME18, ME19.  As ME13 and ME15 are small modules, only one diagram is provided for each of them at the end of the graph.. To the right of each panel, the total number of probes in every module were included; to the left, transcripts were ranked according to the absolute MM value and only those with MM > |-0.6| (high module membership) were plotted. 
ME14 All Probes ME14 Probes MM > |-0.6| ME16 All Probes ME16 Probes MM > |-0.6| 
ME17 All Probes ME17 Probes MM > |-0.6| ME18 All Probes ME18 Probes MM > |-0.6| 
ME19 All Probes ME13 All Probes ME19 Probes MM > |-0.6| ME15 All Probes 
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Module trait association  Figure 9.8 shows the association of every module with gender, age, migraine status and kinship.  Each cell reports the correlation (and P-value) resulting from correlating module eigengenes (rows) to traits (columns). The colours in the panel indicate the strength of positive/negative correlation.  We have also quantified the association of individual genes with the trait of interest (migraine) by defining the Gene Significance (GS).  GS is the absolute value of the correlation between the gene and the trait. Using the GS and MM measures we can identify genes that have a high correlation with migraine. Scatterplots showing the distribution of genes according to their GS and MMs are presented in Figure 9.9.  Results indicate that no association with migraine was detected between any of modules.   
Axes and modules Comparison 
 We compared PC1 scores from the nine axes of blood variation, studied in the previous chapter, with the PC1 scores from the 19 modules detected using WGCNA.  Figure 9.10 shows a coloured correlation matrix for the nine axes and the 19 modules. Axes 4, 5, 6 and 8 seem to have a positive correlation with ME1, ME4, ME7, ME9, ME14, ME15 and ME16 while a negative correlation was detected with ME5, ME6, ME8 and ME9.  Axes 1, 2 and 3 showed a general weak correlation with the modules, and only Axis 2 showed a high correlation with ME12 and ME13. To determine if positive correlations are a consequence of whether a highly co-expressed group of genes in the Axes and modules or shared genes between the groups, we have calculated the number of genes intersecting module and axes regions in a Venn diagram showed in Figure 9.9.  Modules were divided into five different  
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Figure 9.8.  Module-trait associations. Each row corresponds to a module eigengene, column to a trait. Each cell contains the corresponding correlation and p-value. The table is color-coded by correlation according to the colour legend.  
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 Figure 9.9. Scatterplot of Gene Significance (GS) for migraine vs Module Membership . GS can be defined by the minus log of the p-value.  The higher the absolute value the more biological significance the gene has.  In this study, no genes were found to be associated with migraine in any of the modules analysed.  
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Figure 9.10.  Axis and Modules Correlation.  Coloured Correlation coefficients to measure the relationship between Axes, modules and meta-modules.   groups (Group 1: ME7, ME12, ME6 and ME18; Group 2: ME14, ME9, ME1 and ME13; Group 3: ME5, ME9, ME15 and ME3; Group 4: ME9, ME16, ME19 and ME8; Group 5: ME2, ME17 and ME4) and intersects were evaluated with one axis at a time. Only Axes 2, 4, 5, 6 and 8 were compared.  Figure 9.9 shows Venn diagrams for the highest correlations detected in Figure 9.8.  There is an important number of genes in the modules that were also detected in the axes.  Among the most important module-axis overlapping are the ME12 -Axis 2 (139 genes), ME18-Axis 4 (136 genes) and ME7-Axis 5 (377 genes). A more discrete overlapping was found between ME7-Axis 4 (56 genes), ME15-Axis 6, ME16-Axis4 (64 genes) and ME8-Axis 5 (53 genes).  Interactions between modules and axes are complex as same genes can be found in different axes and modules. Table 9.2 summarizes the percentage of common genes shared between axes and modules.  This table is quite revealing in several ways. Firstly, to note is the importance of ME9 and M14 in this analysis as they gather an important number of genes from 
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Table 9.2.  Percentage of genes shared between Axes and Modules. Axes are presented horizontally, while Modules are vertically in the table.  Numbers represent the percentage of shared genes between specific Axes and Modules.  As genes were repeated within the Axes and the modules, the sums across and along the table do not equal 100%.  Coloured numbers represent highly positive (red) and highly negative (blue) correlations previously presented in Figure 9.1.                 Axis 1 Axis 2 Axis 3 Axis 4 Axis 5 Axis 6 Axis 7 Axis 8 Axis 9   ME1 3 1 0 1 1 2 2 2 3   ME2 8 4 23 9 5 10 9 5 13   ME3 3 0 2 0 0 1 0 0 1   ME4 5 0 0 4 4 2 0 2 2   ME5 3 1 1 2 4 2 3 3 5   ME6 1 0 0 1 1 2 1 1 1   ME7 4 2 2 7 38 9 12 5 17   ME8 5 0 0 3 5 5 4 1 7   ME9 14 5 11 16 12 15 18 17 20   ME10 4 1 2 1 2 2 2 1 3   ME11 0 1 8 1 1 1 1 2 2   ME12 0 64 2 2 2 2 1 2 5   ME13 1 13 2 3 3 3 2 3 5   M14 22 3 8 32 16 35 10 76 29   M15 0 0 0 0 0 14 0 1 0   ME16 2 1 3 7 2 3 1 4 8   ME17 9 3 12 18 6 8 7 7 10   ME18 18 1 2 15 5 3 2 8 7   ME19 4 0 0 2 1 1 1 2 4               different axes.  Thus, the M14 module shared 727 genes (37%) with Axes 4, 6, 8 and 9 (Figure 9.11), while the ME9 module shared 410 genes (23.3%) with Axes 4, 7, 8 and 9 (Figure 9.11).  Secondly, this table also shows how genes in axes that did not have a strong correlation in NI (Axes 1, 4, 5 and 9) are dispersed over different modules. This fact supports the idea of genes interacting in a different way in NI [224].    To compare the percent variance gather by modules and axes in Norfolk Island we selected the top 175 positively correlated transcripts from every module (following the 
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methods in the previous chapter) and performed principal component analysis.  Results are shown in Figure 9.12.    
 
 
Figure 9.11.  Shared Genes between M14 and ME9 with Axes4, 6, 7, 8 and 9. The Turquoise and ME9 modules gather an important percentage of genes from different Axes.   The PC1 correlation and variances within every module suggest robust clusters with larger number of genes than those reported for the blood axes variation in the Norfolk Island population.    
9.6. DISCUSSION  We have performed a hierarchical clustering analysis in the Norfolk Island population to detect specific module associated with migraine status.  Although no association was detected, interesting results with respect to the general genetic structure of the Norfolk Island population were revealed.  We have identified eight meta modules consisting of 14164 (11692 genes) transcripts that account for approximately 61,25% of the total probe set in our microarray.  Modules with a significant gene ontology enrichment p-value represent the most interesting networks as one can attribute a possible biological role when population traits are tested for association.  Gene networks for every module are presented at the end of this document as Appendix 6-22.   
M14 M9 
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Figure 9.12. PC1 vs PC2 loadings and variances in modules. In order to compare the percent variance gather by modules and axes in Norfolk Island we selected the top 175   positively correlated transcripts from every module and performed principal component analysis.  The strong PC1 loadings correlation and variances for each of the modules suggest  robust clusters with larger number of genes than those reported for the blood axes variation in the Norfolk Island population.         
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 In the Norfolk Island gene network, the ME2 module represents a cluster of mostly phosphoproteins, involved in RNA metabolic processing and ATP binding.  The gene network for this module shows only one connection that has been reported for the CCDC22 gene and it appears to be a hub gene.   The APEX1 gene is a multifunctional DNA repair enzyme, and it is one of the genes with more connectivity in the ME3 module which is highly correlated with the ME2 and the ME1 modules.  ME6 is a small cluster of genes which contains phosphoproteins from the nucleoplasm.  One of its hub genes is the EWSR1 gene or Ewing sarcoma breakpoint region 1 gene.  This gene is thought to be participating in the tumorigenic process.  This module is negatively correlated with the modules located to the left in the distance dendrogram.  Additionally, it is not included in any of the meta-modules detected suggesting a unique expression pattern in this specific network.  The ME7 is one of the most interesting among the detected modules. It is a very well connected module whose biological activities are related with immunological response and phosphoproteins associated to the cell membrane.  The CXCR1 gene, a chemokine receptor 1 and the TNFRSF1A gene, a tumour necrosis factor receptor superfamily member, are hub genes in this network. This module has a strong positive correlation with ME9, enriched by RNA binding proteins, and a negative correlation with ME8, enriched by genes participating in mRNA splicing. The ME9 and the ME8 represent highly connected networks with genes like SF3B2 (an splicing factor) and EFTUD2 (an elongation factor) as ME8 hub genes and RPS3A (ribosomal protein S3A ) and RPS18 (ribosomal protein S18) at the top of the MM ranked list genes in the ME9 module. The ME7, ME9 and ME00 modules belong to the same meta-module and the strong interactions detected suggest a very robust and specific group of genes working together in a coordinated fashion. Interactions between genes in this meta-module have been previously reported.  Thus we hypothesized that this set of genes must be the most 
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conserved among the human genome.  This idea is also supported by the fact that these modules gather together a large number of genes from the previously detected blood axes of variation.    The ME9 is quite far from the rest of modules, and this is probably a consequence of the fact that it groups mitochondrial genes.  Similarly, the ME9 module (close to the ME9) is also enriched by genes in mitochondrial more specifically in the membrane.  This module did not show high MM values and according to Figure 9.1 its genes do not seem to correlate very well.  This fact was expected as the ME00, which groups genes that did not correlate with any of the modules is in its proximity. That observation also suggests that the eigengene obtained by a group of uncorrelated genes is very similar to the eigengene obtain for the ME11.  The same assumption could be drawn for the other modules surrounding the ME00 modules, particularly the ME12 and the ME13.  Surprisingly, the ME12 module appears to contain well-correlated genes, mainly phosphoproteins related to haemoglobin biology.  On the other hand, the ME13 module have only 18 genes with an MM value > |0,6| and the correlation between MMs and connectivity are also low (cor=0.73 in Figure 9.5).  When performing the PC analysis using the top 250 transcripts with the highest MMs values, ME13 reached a PC1 percent variance of 63% while when using only transcripts originally assigned to this module, the percent variance was only 13.2%.  This observation could suggest that spurious correlations affected the analysis and that this module could be a false group of co-expressed genes. On the other hand, ME14 is one of the largest modules (1949 genes).  It is also enriched by a different variety of gene ontologies such as RNA processing and protein biosynthesis as well as different proteins locations such as nucleus, mitochondria and cytoplasm.    Even though no significant biological role was attributable to some modules, the identification of hub genes inside these networks could give insight into the very general 
229  Chapter 9: Unsupervised clustering Analysis in the Norfolk Island Population 
 
biological activities leading to the correlation of specific groups of genes.  Such is the case of ME1, where the ATP5D gene, a mitochondrial membrane ATP synthase which produces ATP from ADP, is one of the genes with the highest connectivity and membership.  Thus, it is possible that ME1 is driven by mitochondrial genes that lead to the activation of multiple genes with diverse biological activities like gene expression and ATP metabolism.  Similarly, the ME15 was not enriched by any gene ontology. However, the presence of some interleukins genes (IL18 and IL10) and AIRE, an autoimmune regulator, might suggest a role on the immune response.   The ME15 is also very well correlated, and its PC1 gather 84% of variance as shown in Figure 9.12.  The network for this module shows only the interactions reported until today.     Other modules like the ME4, have only four genes with MM > |0,6| and did not have a significant ontology. However, the APEX1 gene, previously mentioned as being one of the hub genes in the ME3 module, is also present in this network.  This closeness would explain the slightly positive correlation of these two modules.  Further, ME4 is part of the second meta-module that also contains the ME5 module.  The ME5 module is significantly (Bp-value:0,00016) enriched by genes with an acetylation and phosphorylation activities.    The ME16, ME17, ME18 and ME19 correlate positively to form the last meta-module detected in Norfolk Island population and it is also positively correlated with the fourth and sixth meta-modules.  Biological functions include mainly phosphoproteins participating in respiratory cell processes.    No association was found between the modules and migraine status.  Similarly, when genes were individually tested using the GS corrected p-values, none of them reached the significant level. Different limitations could explain these results. Firstly, although published studies support the use of blood gene expression profiles to study neuronal 
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disorders, it is always recommended to use tissues directly related to the trait under study, in this case, brain samples. Additionally, migraine has a higher incidence in women, in consequence, the limitation of cases to only females could narrow the inherent gender variability in the present study.  Finally, previous selection of the most variable genes will eliminate highly conserved genes that have little or no variability at all, and instead, are noise sources masking genes with low impact in complex disorders like migraine.     We also compared the 19 modules with the previously defined 9 Axes of blood variation.  Approximately 85% of the transcripts included in the Axes were also detected  by WGCNA. The ME9 and ME14 gathered an important number of genes from different axes.  Thus, M14 shared 727 genes (37%) with axes 4, 6, 8 and 9 (Figure 9.11), while ME9 shared 410 genes (23.3%) with axes 4, 7, 8 and 9 (Figure 9.11).  Also, genes in axes which did not have a strong correlation in NI (Axes 1, 4, 5 and 9) are dispersed over different modules supporting the idea that genes are interacting in a different way in the Norfolk Island population.    
9.7 CONCLUSIONS  In spite of the lack of module association with migraine, we have identified a robust group of correlated genes that could be used to track expression changes in disorders related to blood.  Modules can also be useful in explaining the impact of different environmental factors on an individual’s gene expression patterns.  We showed that highly conserved genes from Axes were also included in the modules, but the interaction between these and other genes is different in our population.  This observation highlights the genetic isolated nature of Norfolk Island. It also opens up doors to perform further studies of modules integrating GWAS information and environmental factors. These studies will  contribute to 
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gain knowledge of the complex gene network accross different ethnicities and population cohorts.   
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OVERVIEW  Multiple genetic studies on migraine have been carried out until today and although they add valuable knowledge to the complex panorama on the pathophysiology of this disorder, they also seem to suggest that there is still a long way before we completely understand the molecular mechanisms behind a migraine attack.  So far, genes encoding ion transporters have high effects but they have been only reported for Familial Hemiplegic Migraine (FHM), a familiar form of migraine.  However, efforts on replication these findings in common forms of migraine have essentially failed [19, 325].  Additionally, modern evidence from GWAS had shown that common migraine susceptibility loci possess modest effects (Odd Ratios between 1-1.2) [326].  This evidence suggests that disease risk in common forms of migraine is conferred by other –perhaps regulatory genes that control neurotransmitter and ion pathways in a more subtle manner than the ion transporters themselves. Thus, this research investigated hormonally related genes variants in the Norfolk Island population and in a menstrual migraine population.  The study also used a variety of approaches to investigate gene pathways, gene clusters and gene networks that play a role in migraine.  The following section outlines the main findings, conclusions and future directions based on the results obtained in this thesis, under relevant chapter headings.  
ESR1 POLYMORPHISMS AND MIGRAINE -CHAPTER 4:  We investigated the hormonal receptor genes, ESR1 and PGR, in a large pedigree from Norfolk Island.  143 SNPs in the ESR1 gene and 43 SNPs in the PGR gene were tested for migraine association in a sub-sample of 285 related individuals (76 cases and 209 controls) from the Norfolk Island pedigree .  Results showed that ten markers in the ESR1 gene had a significant association with migraine (P-value<0.01).  Among these markers, 
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seven were located upstream of the gene close to a promoter associate sequence.  This suggests a regulatory role on the expression of the ESR1 gene.  Interestingly, three associated SNPs (rs2813554, rs2813544 and rs7767143) are located in an intergenic region between ESR1 and SYNE1 genes, suggesting the possible implication of SYNE1 in migraine pathophysiology.  However, the implication of this gene and other genes found in the Norfolk Island population should be a sign of caution as the genetic background in isolated populations like this, does not always reflect what is actually happening in terms of genetics in general populations.  Thus, the genetic variants detected here may have a smaller or null impact on the phenotype in other outbred populations.  Additionally, high LD regions commonly present in inbreeding populations make it difficult to use traditional statistical methods for controlling multiple comparisons as the independence between SNPs may not exists [202].  Thus, neither Bonferroni nor FDR corrections were applied in this part of the study. However, we used a gene-dropping methodology to correct p-values in the Norfolk Island population through a permutations procedure, considered to be the gold standard in correction by multiple comparisons [131, 327].  Because the Norfolk Island population is a genetic isolate, the modelling of an appropriate algorithm is challenging in terms of programming and computing.    
RELATION OF SYNE1 AND TNF  GENES TO MENSTRUAL MIGRAINE-CHAPTER 5  Association with the SYNE1 gene was replicated in our MM cohort where 34 SNPs , distributed amongst the ESR1, FSHR, CGPR, RAMP1, LTA, TNF,  SYNE1, KCNK18, ESR2, 
CYP19A1, NRIP1, MIR890, MIR891A and MIR892A genes were investigated. The further association analysis showed that SNPs rs3093664 (TNF) and rs9371601 (SYNE1) are associated with migraine in the total population (P-values: 0.007 and 0.009, respectively).  Analysis performed in the sub sample populations showed that the level of the association 
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test significance increased in the MRM sample with respect to the total sample when the same SNPs, rs3093664 (P-value=0.007) and rs9371601 (P-value=0.003) were tested.  These findings implicated ESR1, TNF and, for the first time, SYNE1 gene in susceptibility to of general migraine and Menstrual Related Migraine.  Another central aim of this research was to investigate the levels of expression of hormonal related genes in the Norfolk Island population and in the MM population.  Results indicated that there was no significant differential expression patterns in patients with migraine compared to controls (FDR>0.91).  Additionally, fold changes in the top hundred probes (P-value < 0.005) ranged from -1.028 to -0.92. These findings might indicate subtle changes in levels of gene expression that could not be detected with the use of traditional methods like t-test and logistic regression analysis in our data set.   Gene expression analysis was also completed for the previous migraine associated PGR, ESR1, SYNE1 and TNF genes.  Results after comparing levels of expression demonstrated that there was no significant difference in transcription levels between cases and controls and across the sub-populations.  However, after completing a Pearson’s correlation analysis between the same transcripts, significant positive correlations in the follicular phase between the expression of TNF/SYNE1, ESR1/PGR, and ESR1/SYNE1 were found.  In contrast, in luteal phase, we found a correlation between SYNE1/PGR, and TNF /SYNE1.  More interestingly, there were significantly detected differences in the correlations between 
gene expression for these genes in cases and controls. For ESR1 and SYNE1, these differences were small, with both cases and controls maintaining similar levels of correlation. This suggests that although there are no significant changes in gene expression of genes that may influence migraine in PMM and MRM cases compared to controls, these genes interact in a different fashion both in the luteal and follicular stages of the menstrual cycle and in cases compared to controls. These interactions have not 
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previously been studied and they serve as a reference in the relationship that hormones and cytokines might have in the events that lead to migraine attacks, particularly in the case of the transition from the luteal to the follicular phase and vice versa.    Further studies should be directed towards fine-mapping of the region comprised of the 
ESR1 and SYNE1 genes.  In this way, causal variants may be detected and functional studies could be carried out based on more solid evidence.  The use of next generation sequencing techniques could also identify rare variants with a larger impact on an individual’s phenotype [19].  It is also worth considering the gene candidate strategy in migraine genetic studies as a humble but efficient tool to design better experiments.  In the case of ESR1, for example, 519 target genes have been identified [279] implicating a vast network of interactions, each one potentially affecting the development of migraine and other hormone-related disease.  Thus, panels specially designed to study these target genes and proteins are also a clever methodology to consider in the future.   One of the main limitations of this study is the reduced number of controls studied with respect to the number of cases.  Similarly, the lower proportion of females suffering PMM with respect to those ones suffering MRM is also a drawback in this study, as comparisons between groups can become challenging and the selection of statistical analysis narrows.  However, in general terms, the menstrual migraine population represents an ideal model for further study of hormonal genes and migraine.  POLYGENIC MODELLING OF MIGRAINE -CHAPTER 6  Multiple gene variants have been implicated in migraine aetiology from GWAS. However,  the replication of these variants in other  populations has been challenging [29] and the 
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genetic role attributable to them remains controversial [9, 10].  Two explanations arise. Firstly, causal variants are not in complete linkage disequilibrium (LD) with the SNPs that have been genotyped. The lack of complete LD might, for instance, occur if causal variants have lower minor allele frequency (MAF) than genotyped SNPs [336].  Secondly, individual causal variants explain just a small amount of variation wherein their effects do not reach significance in studies using different samples.  This explanation seems to be suitable for the specific migraine scenario, whose polygenic nature has been highlighted by multiple studies [35, 131, 337].  Thus, it is accepted that multiple risk alleles may exert modest individual effects rather than few genes exerting large effects in migraine susceptibility.      We have tested a migraine polygenic model where ranked groups of associated markers selected from previous GWASs were analysed by constructing, for each subject in the Norfolk Island population, a polygenic score consisting of the weighted sum of migraine-associated alleles.  Subsequently, we tested for association between the score and migraine status to determine whether associated markers reside within those contributing to the score. We also carried out an eQTL analysis in order to identify the possible functional role of these variants in the proposed polygenic model.   A significant association (P-value =0.018) identified for 55 SNPs, was found between the polygenic score and migraine.  Additionally a standard Chi-square test also supported this association (P-value=0.024). On the other hand the eQTL analysis showed that from twenty eight SNPs, five of these which were never reported before (rs7085387, rs7916968 , rs4478147 rs6756590 and rs10166942), were significantly correlated to the expression of genes in their surroundings.  Some of the eQTL transcripts include the USMG5, STAT6, CPNE1, HLA-C, TFAM, WDR37, SSR2, RAB24, DHX16, FBX07, MAPK10 and RBM39 which according to the gene ontology analysis have mitochondrial, immunological 
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and hormonal roles.  To note, these functional categories have been widely implicated in migraine pathophysiology.    Our molecular genetic data strongly support a polygenic basis to migraine that involves common SNPs, some of them, with possible regulatory roles on the expression of mitochondrial, immunological and hormonal genes. This polygenic score can be used to predict individual trait values or risks of migraine potentially giving a predictor with better discrimination properties than one based on established markers only.  We have also provided evidence to suggest that these groups of common variants fitting a polygenic model might be influencing the phenotype by controlling the expression of genes involved in diverse migraine pathophysiological pathways.  On the other hand, as has been shown by this and previous studies, mitochondrial genes might play a key role in the development of migraine with subtle changes in the levels of expression of some of these genes.    Finally, it is worth to be mentioned that as a consequence of the highly complex Norfolk island’s pedigree structure, the power of this population to detect gene association in migraine has not yet been calculated. Thus, the lack of association of common variants in this population may be a result of the insufficient sample size instead of a suggestive differential genetic structure in regards to the aetiology of migraine.  On the other hand, it is possible that a particular genetic architecture characterized by the dominant effect of low frequency alleles, that is rare variants, in this genetic isolate remained undetectable by the techniques and methods used in this thesis.    Future studies should implement the polygenic scoring in bigger sample populations and include a larger number of SNP variants to add more power to the model.  This strategy is already being used with a number of other diseases and in future it could have a potential 
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clinical use in migraine.  The implementation of a gene panel could also help in the diagnostics of subtypes of migraine and the investigation of a panel of genes involved in response to migraine treatments could increase efficacy in the management of migraine.  It will also represent a big achievement in the pharmacogenomics research field [22]. Additionally, statistical efforts aiming to the investigate the power to detect genes associated with migraine in the Norfolk Island population should be performed. Similarly,  whole genome sequence studies in this cohort would allow the identification and analysis of rare variants, undetectable by methods like GWAS and candidate genes approaches.     MIGRAINE PATHWAY ANALYSIS IN THE NORFOLK ISLAND POPULATION-CHAPTER 7  Previous studies of gene expression of migraine show lists of genes with moderate differences in expression levels.  However, these lack interpretation into biological mechanism, such as gene pathways, and hence provide little information to explain the pathophysiology of migraine.  This strategy is also not in accordance with the theory of multiple factors with small effects playing key roles in disease susceptibility.   We performed a pathway analysis using Gene Set Enrichment Analysis software of gene expression data from the Norfolk Island cohort, that suggests that cardiac muscle contraction, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease pathways are down-regulated in individuals suffering from migraine. Subsequently, we built a panel of forty nine significantly (P-value<0.05) enriched genes or leading edge genes from these pathways. We found that genes in this panel are mostly represented by mitochondrial genes involved in the respiratory chain and Na+ and K+ pumps subunits genes.  Afterwards, SNPs distributed in a range of 200kb either side of each gene in this panel were tested for association with migraine using the GenABEL package in R. 
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Significant association was detected in the SNPs rs687237, rs12218075, rs6735806, rs2900195 and rs7875955.  To finalise our analysis, both genetic and expression data were integrated and a logistic regression analysis was performed to detect possible eQTLs involved in the modulation of under-regulated pathways.  Results showed that the SNPs rs1897139 and rs9810380 played a role in the regulation of ATP1B3 expression.  ATP1B3 is a determinant of pain variability that modulates nociception [135].  Thus, we reported for the first time that cardiac muscle contraction, Parkinson’s disease, oxidative phosphorylation and Huntington’s disease pathways are significantly down-regulated in individuals suffering from migraine.  Interestingly, these pathways are mainly enriched by mitochondrial genes.  This study has additionally identified eleven novel gene variants located in NDUFS4, COX7A2L, NDUFB8, NDUFA10, NDUFA8 and ATP1B3 genes as being potentially implicated in migraine.     These results are important in light of the new evidence that suggests a role for mitochondria functioning in the aetiology of migraine.  Future studies should focus on functional aspects of the mitochondrial genes and proteins in the cellular environment.  A rat model to study the effects of different variables in cortical spreading depression, a proposed mechanism in the aetiology of migraine, could be a good starting point to evaluate mitochondrial malfunctioning [328].    Although the results presented here are supported by other published studies [299], it is important to note that some limitations in our study could bias the conclusions of this research.  For example, the use of blood samples as a target tissue in the study of neuronal disorders like migraine, could lead to a misrepresentation of the gene population in brain tissue, which is relevant in these kinds of disorders. Thus, if at all possible brain tissue should be used for the study of migraine in future studies [310]  
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UNSUPERVISED CLUSTERING ANALYSIS-CHAPTER 8  We have performed supervised and unsupervised clustering analysis of gene expression data to detect the possible groups of genes that could be used as biomarkers to follow up the metabolic and immunological changes that occur as a consequence of suffering migraine. We first performed a supervised clustering consisting in the construction of nine common axes of peripheral blood variation.  Phenotypic association were tested with ten of the genes most closely associated with each Axis, called Blood Informative Transcripts (BIT).  BITs can differentiate immunological and metabolic status between healthy individuals and patients suffering different types of diseases according to previous studies.   Results indicated weak correlation found between transcripts in Axis 1 and Axis 9 in the Norfolk Island population.  This was explained by the fact that these Axes are greatly influenced by environmental factors. When compared with other populations, NI was the only population showing a high correlated core of genes in Axes 2, 4, 6, 5 and 8. This suggested that this group of Axes were not independent of each other, as they appeared to be in the other populations.  This result is not surprising if we consider that Norfolk Island represents a genetic isolate where high genomic homogeneity is expected.  We have also tested the association between BIT and migraine in affected individuals, but no positive results were found.  The main reason could be that Axes are enriched by biological functions that have little or no effect on migraine pathophysiology.  Enriched pathways in Axes include inflammation, viral response and signalling within B and T lymphocytes as well as neutrophils.  Additionally, we hypothesised that according to these results the genetic structure in the Norfolk Island population is different to the other populations and genes are interacting in a different fashion.    Future studies might consider the Axes and the BITs in relation to other traits.  Although no association was detected between the Axes and migraine, the construction of these 
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genetic modules and the standardised methodology to evaluate Axes correlation with a trait in the Norfolk Island population, should be kept as valuable information to be implemented using other traits of interests such as environmental factors or common traits such as height, weight and cardiovascular risk.  
UNSUPERVISED CLUSTERING ANALYSIS-CHAPTER 9  Unsupervised clustering analysis of gene expression data was carried out by constructing an eigengene network using the WGCNA package implemented in R. After the analysis, nineteen modules and eight meta-modules consisting of 14164 (11692 genes) transcripts which account for approximately 61,25 percent of the total probe set in our microarray were identified.  Modules were colour coded. Approximately eighty five percent of the transcripts included in the Axes of blood variation defined in the previous analysis were detected and they appeared distributed in the nineteen modules. No association between migraine and the modules was detected.  In this research we demonstrate that gene interactions in Norfolk Island are different to other populations reflecting a special genetic configuration that we have delineated with the module construction.  Although the modules presented here were more robust than the modules defined in the Axes analysis, we still did not find an association with migraine.  This might have different explanations.  Firstly, the changes in levels of expression are subtle and a larger sample size would be required to identify gene clusters specific for migraine.  Secondly, blood may not be the ideal tissue to study changes of expression in patients suffering migraine.    
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In terms of gene clusters in unsupervised analysis, other analysis can be performed in the future in order to model clusters that are able to predict effective patterns of gene expression under specific circumstances.  The robustness and the conservation of the modules, are properties which could be evaluated.  They will allow not only correlation with different traits in the Norfolk Island population, but also comparison with other populations and the eventual extrapolation of findings in our samples to general populations. The evaluation of SNPs controlling the expression of the detected gene clusters is another study to be considered for future directions.  Proteomic and metabolic information can also be added to build a model where all the “omics” are integrated, which is the aim of the growing research field of systems biology.  In summary, this study opens doors to the further investigation of the genetic structure of the Norfolk Island population.  Clusters of genes from both the supervised and unsupervised analysis can be tested for their association with multiple traits including other diseases such as CVD traits and other environmental factors available in the questionnaires from the individuals participating in the Norfolk Island study.  Integrated analysis using GWAS data can also be pursued at a module level to identify how gene clusters are controlled and affected by specific DNA variants.    FUTURE DIRECTIONS  In the following paragraphs, the most interesting findings from this thesis are gathered together into a general model that describes a possible source of susceptibility to migraine, lying in different mitochondrial malfunctioning events in individuals from the Norfolk Island population.    
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Results from this study indicate that the mechanism of migraine in the Norfolk Island population may involve a complex network of mitochondrial, hormonal and immunological events.  The largest number of genes and pathways implicated in this study are those expressed in mitochondrial compartments.  Biochemical evidence suggests that abnormal mitochondrial function can lead to high intracellular Ca+, over production of free radicals and poor oxidative phosphorylation activity, which can consequently cause energy failure in neurons and astrocytes, and may in turn trigger migraine mechanisms, including spreading depression [56]. Genetic [299], morphological [300] and therapeutic evidence [113] supporting the relationship of mitochondrial processes with migraine have also been reported.    Estrogen also has an important role in mitochondrial maintenance and biogenesis [329] and three pathways of action have been proposed from studies in breast cancer cell lines: 1) direct interaction with the mitochondrial respiratory complexes (MRC) generates reactive oxygen species (ROS)  leading to protein kinase activation; 2) membrane estrogen receptor (mER) activation of Ca++ dependent proteases and protein kinases and  3) mER activation causes cytoskeletal changes leading to mitochondrial changes and protein kinase activation [330].  Additionally, Kingle et at, discuss a model based on the identification of ERα and ERβ, whose transctiptional coactivator is RBM39,  within mitochondria of various cells and tissues.  In this model, estrogen increases the interaction of both ERα and ERβ with a 5’ promoter region containing estrogen response elements (EREs) located in the human Nuclear Respiratory Factor-1 (NRF-1) gene.  EREs generally are located in promoters, introns, or 3’ untranslated regions of estrogen target genes [331]. Subsequently, NRF-1 promotes transcription of mitochondrial transcription factor TFAM which in turn targets mtDNA-encoded genes which carry out essential metabolic pathways for energy production and homeostasis.   
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Mitochondrial DNA (mtDNA) is a 16.5 kb circular genome encoding 13 mRNAs, 2 rRNAs, and 22 tRNAs with 103–104  copies of mtDNA/ mammalian cell [332].  Thirteen of the 80 proteins of the electron transport chain (ETC)  complexes I, II, III, IV, and V are encoded by mtDNA. An ETC is a series of compounds that transfer electrons from electron donors to electron acceptors via redox reactions, and couples this electron transfer with the transfer of protons (H+ ions) across a membrane. This creates an electrochemical proton gradient that drives ATP synthesis, or the generation of chemical energy in the form of adenosine triphosphate (ATP). The remaining subunits of the ETC as well as other proteins involved in mtDNA metabolism and function are nuclear-encoded.  Interesting, pathway analysis in this thesis showed that NDUF proteins, COX7A2L and USMG5, part of ETC complex I, IV and V respectively, are down regulated in individuals suffering from migraine.  The malfunctioning of these subunits might cause reduced mitochondrial ATP synthesis activity as has previously been demonstrated for USMG5 [333], and an increase in ROS with subsequent neuronal effects.    Another mitochondrial gene implicated in this thesis from the tested polygenic model and whose transcription is controlled by the molecular marker rs2076054 is the FBXO7 gene.  This protein targets PARK2, an E3-ubiquitin ligase which cooperates to mediate the autophagic clearance of damaged mitochondria (mitophagy).  It has been shown that upon treatment of cells with a mitochondrial uncoupler, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), PARK2 is recruited to depolarised mitochondria which enables their selective autophagic clearance (mitophagy)[334]. Thus, when FBXO7 fails to target PARK2,  mitochondrial turnover does not occur and malfunctioning mitochondria remain in the cellular environment.  Additionaly, the Mitochondrial Ribosomal Protein L24 (MRPL24), also implicated in this theses research, which is a transcriptional target of STAT6 and NRF-1 adds more evidence to support the possibility that functional changes 
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taking place in the mitochondria may play a role in the susceptibility to migraine in individuals from the Norfolk Island population.     On the other hand, ATP1B3, another gene implicated in this thesis, seems to be playing a mitochondrial independent role by modulating nociception as previously established in 2009 [135]. Previous studies showed that, in mutated ATP1B3 neurons, diminished Na+, K+ pump current and capacity, is a result of decreased ATP1B3 protein pool.  This affects the ability of such neurons to maintain Na+ gradient and action potential (AP) amplitude. . These events may control the activity of nociceptive afferents, decreasing pain thresholds during migraine attacks. Figure 10.1 shows the genes participating in the polygenic model that seems to be driving susceptibility of migraine.  CONCLUSIONS  This study has provided support for a role of ESR1 and SYNE1 genes in migraine and menstrual migraine.  In addition, the study has identified a number of new genes as potentially playing a role in migraine susceptibility most likely in a polygenic additive model of susceptibility.  Other novel variants detected in this thesis point to a role for ATP1B3 and also a new role of mitochondrial related genes in this disorder. Further studies focusing on these newly implicated genes may help to define their role in other outbred migraine affected populations.    
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Figure 10.1. Polygenic Model in Migraine.  The diagram shows how the genes detected in this study may be participating in a polygenic model which provides susceptibility for migraine in the Norfolk Island population RBM39 is a transcriptional co-activator for ESR1 and ESR2 genes.  Estrogen (E2) and its receptor (ESR1) bind together  to stimulate the expression of NRF-, another transcriptional factor of TFAM gene.  Once transcribed, TFAM is sent to the mitochondria to activate mtDNA transcription.  Genes NDUFS4, COX7A2 and USMG5 are part of the energy complex and its malfunctioning produce an increase of ROS, ATP depletion and the fall in mitochondrial membrane potential what causes oxidative stress and cell death.   
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APPENDICES                           
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Appendix 1.  List of SNPs included in the evaluation of ESR1 and PGR genes in the Norfolk Island 
Population study  
ESR1 rs852003 rs10484919 rs851971 rs712219 rs851967 rs866457 rs851998 rs851997 rs9383938 rs7745737 rs980281 rs6557164 rs851995 rs851993 rs9383939 rs851991 rs3020331 rs11967900 rs851982 rs851980 rs12525163 rs1159327 rs3020343 rs12195741 
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rs3020348 rs3020306 rs1999805 rs2982575 rs1336981 rs2504070 rs2485209 rs6939257 rs2504063 rs9371554 rs4870053 rs2504065 rs2248586 rs7767143 rs2504067 rs1285057 rs543650 rs17081685 rs9479117 rs2881766 rs488133 rs532010 rs9479122 rs7753153 rs11155813 rs827423 rs17081771 
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rs6902771 rs3936674 rs9479130 rs827419 rs1514348 rs1709183 rs9340835 rs9322336 rs6557170 rs11155820 rs7761846 rs6557171 rs9322343 rs988328 rs12154178 rs2347868 rs6927072 rs6912184 rs9397459 rs3020410 rs3020314 rs3020317 rs1884051 rs985191 rs985192 rs3003925 rs7739506 
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rs985694 rs985695 rs2347869 rs3020318 rs1884054 rs2347871 rs2347872 rs2982683 rs9340931 rs9340939 rs726281 rs9397463 rs926777 rs2982684 rs9371236 rs2144025 rs7743290 rs9340941 rs722208 rs13216134 rs9340955 rs13203975 rs9340978 rs2207232 rs3020411 rs3020418 rs9478265 
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rs3020432 rs2982712 rs3020433 rs3020366 rs3020368 rs6932864 rs2207396 rs9341019 rs3778080 rs3778082 rs3778084 rs3020375 rs12199102 rs3778089 rs9341052 rs3778099 rs9341066 rs2228480 rs3798577 rs2813544 rs7450824 rs2813550 rs2813554 rs9383964 rs2459111 rs2295193 rs3818109 
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rs2813566 rs17082180 rs9322361 rs17304585 rs10484863 rs2747660 rs2813487 rs2813490 rs718527 rs2813494 rs9397084 
PGR rs600677 rs601618 rs11224546 rs17728593 rs471767 rs500760 rs563656 rs558959 rs606789 rs504372 rs511484 rs547378 rs635984 rs11224575 rs543936 
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rs1144133 rs518382 rs553272 rs1824128 rs660541 rs495997 rs11224580 rs493220 rs538915 rs503362 rs508653 rs7116336 rs516693 rs578938 rs572483 rs481855 rs555572 rs555653 rs543215 rs590688 rs11224598 rs486992 rs596223 rs537681 rs501732 rs529359 rs518162 
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rs11571133  
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Appendix 2.  Primer sequences design with Sequenom Assay Design 3.1 software (Sequenom, San Diego , CA, USA). 
 
SNP Gene Forward Primer Sequence Reverse Primer Sequence Extended Primer Sequence rs1805087 MTR ACGTTGGATGCTTTGAGGAAATCATGGAAG ACGTTGGATGTACCACTTACCTTGAGAGAC aatgACCTTGAGAGACTCATAATGG rs6166 FSHR ACGTTGGATGAAGGAATGGCCACTGCTCTT ACGTTGGATGGGGCTAAATGACTTAGAGGG CAGCTCCCAGAGTCACCA rs895572 RAMP1 ACGTTGGATGTTTCACTGTTTTTGGAGCCC ACGTTGGATGGTCAAAGAAAGTTCTTCAGTG aacAGTTCTTCAGTGATAAGAAAGA rs1584243 RAMP1 ACGTTGGATGGTCTTTTTTCCTCTGACCTC ACGTTGGATGGACACATCAAACTCCAACTG ggggTCAAACTCCAACTGCTGAGCACC rs1080519 RAMP1 ACGTTGGATGCTCTTTGTGTTCCAGTTTG ACGTTGGATGCCATCAGCAGACACGAAAAC gggcAACTGAGGAAAGAGAGAAATT rs10185142 RAMP1 ACGTTGGATGGGAGCTTCTCACACGATTTC ACGTTGGATGGCTGCAGGTTGTCTGAGAG TTTCGACCTGCGATAC rs6729271 RAMP1 ACGTTGGATGCCATGTCATAAAATGTCAC ACGTTGGATGCCCTTGCTTTTTAAAGCTTTT ATGTCATAAAATGTCACAGAAATC rs6707038 RAMP1 ACGTTGGATGCTCGGTCTCAAAAAACAAAGC ACGTTGGATGGAATGGTTGGAATTAAGACGG AAGACGGTTTGTTTACCTG rs2009658 LTA ACGTTGGATGAGCTCCAACCCCTCTAACAC ACGTTGGATGGTCACCTCAAATATTATTAC ccCCTCAAATATTATTACTGCTACT rs2071590 LTA ACGTTGGATGAAGGGACAGTCAATTCAGAG ACGTTGGATGATGATTGCTCTTCAGGGAAC ggccGTCAATTCAGAGAGGAGG rs1800683 LTA ACGTTGGATGTCTATAAAGGGACCTGAGCG ACGTTGGATGACGGGCAGCCCAAGGAGAT gaatGAGAGCCTCACCTGCTGTG rs2239704 LTA ACGTTGGATGCAGCAGGTGCAGGAGGGAC ACGTTGGATGGTGCTTCGTGCTTTGGACTA TTTGGACTACCGCCC rs909253 LTA ACGTTGGATGAGAGACAGGAAGGGAACAGA ACGTTGGATGTCCATCTGTCAGTCTCATTG cGAAGGGAACAGAGAGGAA rs2229094 LTA ACGTTGGATGTGACACCACCTGAACGTCTC ACGTTGGATGAGAAGGAGGAGGTGTAGGGT cccttAACGTCTCTTCCTCCCAAGGGTG rs1800630 TNF ACGTTGGATGGCAATGGGTAGGAGAATGTC ACGTTGGATGCCTCTACATGGCCCTGTCTT ggggtAAGTCGAGTATGGGGACCCCC rs1800629 TNF ACGTTGGATGGGAGGCAATAGGTTTTGAGG ACGTTGGATGTTCTGGGCCACTGACTGATT gagtACCCTGGAGGCTGAACCCCGTCC rs3093664 TNF ACGTTGGATGAAGAGCTCTGAGGATGTGTC ACGTTGGATGAAGTTCTGCCTACCATCAGC tGGCTAGGATTTGGGG rs9371601 SYNE1 ACGTTGGATGACACATGGGTGCTCAGTAG ACGTTGGATGATGAAGTGCAGATACCAGCC ctttCAGATACCAGCCACTAGAA rs140325655 KCNK18 ACGTTGGATGGGTTTAACAGGACCACACAC ACGTTGGATGACTTACCCACGGTGCTGAAC TGAGCTCGCTCTTTTTC rs963975 KCNK18 ACGTTGGATGCTGTGACTATCCCATTCCAC ACGTTGGATGTTTGAGGTTTGACCTCAGCC ggaaTCCCTCACAGTGATTCC rs363314 KCNK18 ACGTTGGATGCGCATCCCTTCCTTTGCTTG ACGTTGGATGTGTCACCCTCAGGAGCATC ttgaTTGGCTGCCTGGTTGTC 
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SNP Gene Forward Primer Sequence Reverse Primer Sequence Extended Primer Sequence rs1519480 BDNF-AS ACGTTGGATGCTGAAGAGTAAGAACAGATGC ACGTTGGATGCTTAGGGAAATAAATGGAAGG TTTTTTCCTTAATGGCCC rs7127507 BDNF-AS ACGTTGGATGTTAAAACATTCAAGCTTCC ACGTTGGATGGAGAGAATAGAGAGTTGCGG TTCAAGCTTCCTTTCTACAA rs12273363 BDNF-AS ACGTTGGATGGCTATTGACTGCAGGGATGA ACGTTGGATGGCTGGGTGGTCTGAAACTTA CGATGCTGCAGAAGA rs4986938 ESR2 ACGTTGGATGAGGTGAACTGGCCCACAGAG ACGTTGGATGACAGCAGAAAGATGAAGCCC tggtAGTTCACGCTTCAGC rs4646 CYP19A1 ACGTTGGATGTCTCTTGTAGCCTGGTTCTC ACGTTGGATGTACCTCCTATGGGTTGTCAC tcgCTGGTGTGAACAGGAGCAGATGAC rs10046 CYP19A1 ACGTTGGATGTCTGGAACACTAGAGAAGGC ACGTTGGATGGGATGGATGATTTGTATGTG GAGAAATGCTCCAGAGT rs2229741 NRIP1 ACGTTGGATGACCTGTCAAAGTAATGGTCC ACGTTGGATGGTCTGGCTTTTTTGAGGTGC gaggTCTCAATACACATACATATCAGGG rs5965660 MIR890 ACGTTGGATGTCTGAGGACCACCACAAAAG ACGTTGGATGGATTACATGTGACTGACACC ggggACCACAAAAGTGTACTTGG rs4827678 MIR890 ACGTTGGATGTCTTCTGGCATTCGAGAAGG ACGTTGGATGAACTTTTGGCTGGCCTTTGG ggggaTCCTGATGCAGTGGAG rs146806052 NRIP1 ACGTTGGATGATATACATGGTGAGCCTTGC ACGTTGGATGCTACTCAGAAAGGTGCCAT tgaggGGTGAGCCTTGCTCTACCC rs2202091 NRIP1 ACGTTGGATGGGAAGAGTCACACATCCCTA ACGTTGGATGGGCCTATCTTGGGTTTTGAC CTCACTAATCTTAATCAGTTTTTAAT rs113352055 MIR891A ACGTTGGATGAGTAATACAGTCTCTACCGC ACGTTGGATGTCTCCTTCACCTCCTTGTAG AGTGACACTGGTAGTAGA rs5965992 MIR891A ACGTTGGATGTTTGTAGACTCTTTGGGAAC ACGTTGGATGGGTATTCAATGTTGCATAGTC TAATTACGTAGCTTCTTTGTTT 
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Appendix 3. GWAS associated SNPs list. GWAS Migraine associated SNPs.  Fifty-one SNPs were included in the multi-marker scoring analysis.  Here, we show the general information provided for every SNP from previous GWASs. From left to right, the columns show the SNP name, chromosomal region, chromosomal position, the associated trait (MO: Migraine without Aura; MA: Migraine with Aura), Associated Allele (Assoc Alle),  Risk Allele Frequency (RAF), P-value, Odd Ratio (OR), 95% Confidence Interval (95%CI), Study were the SNP was reported and the platform used to perform the SNP array.     
SNP Region Chr. Position Trait Assoc Alle RAF P-val OR 95% CI Study Platform rs10037055 5q35.3 177264278 Migraine MO G 0.83 5.00E-06 1.14 [1.08-1.19] [136] Affmetrix & Illumina [~2.3 million]    rs10166942 2q37.1 233916448 Migraine T 0.82 1.00E-12 1.28 [1.19-1.37] [137] Illumina [1,246,388]    rs10820447 9q22.32 96369762 Migraine MA T 0.16 6.00E-06 1.16 [1.09-1.23] [137] Affmetrix & Illumina [~2.3 million]    rs10826566 10p12.1 29075768 Migraine MA A 0.17 4.00E-06 1.16 [1.09-1.23] [137] Affmetrix & Illumina [~2.3 million]    rs10997517 10q21.3 67120045 Migraine MO C 0.23 6.00E-06 1.14 [1.08-1.21] [137] Affmetrix & Illumina [~2.3 million]    rs11172113 12q13.3 57133500 Migraine T 0.57 4.00E-19 1.11 [1.09-1.14] [137] Affmetrix & Illumina [~2.3 million]    rs11594111 10p13 14903407 Migraine G 0.14 1.00E-07 1.09 [1.06-1.12] [137] Affmetrix & Illumina [~2.3 million]    rs11636768 15q25.3 87152280 Migraine A 0.15 5.00E-07 1.25 [NR] [138] Affymetrix, Illumina & Perlegen [~2.5 m]    rs11726563 4p12 46821617 Migraine  A 0.84 8.00E-06 1.16 [1.09-1.23] [7] Affmetrix & Illumina [~2.3 million]    rs11777116 8p21.2 24186788 Migraine  T 0.08 6.00E-08 1.27 [1.17-1.39] [137] Affmetrix & Illumina [~2.3 million]    rs11906854 20q11.22 35795712 Migraine  G 0.14 7.00E-06 1.17 [1.09-1.26] [137] Affmetrix & Illumina [~2.3 million]    rs12282928 11p11.2 48310476 Migraine  A 0.77 9.00E-06 1.14 [1.08-1.2] [137] Affmetrix & Illumina [~2.3 million]    rs12365397 11p12 43214511 Migraine A 0.68 9.00E-06 1.05 [1.03-1.09] [137] Affmetrix & Illumina [~2.3 million]    rs12454023 18q21.31 58342372 Migraine MA T 0.5 8.00E-07 1.12 [1.08-1.18] [7] Affmetrix & Illumina [~2.3 million]    rs13263568 8q13.3 71535183 Migraine G 0.09 2.00E-06 1.1 [1.06-1.14] [137] Affmetrix & Illumina [~2.3 million]    rs1364402 7q33 136899616 Migraine MA T 0.91 4.00E-06 1.19 [1.11-1.28] [137] Affmetrix & Illumina [~2.3 million]    rs140174 22q11.23 23580796 Migraine G 0.26 8.00E-06 1.08 [NR] [6] Affymetrix, Illumina & Perlegen [~2.5 m]    rs1485395 12q13.13 53601293 Migraine MO C 0.16 7.00E-06 1.13 [1.07-1.19] [7] Affmetrix & Illumina [~2.3 million]    rs1712517 10q24.33 103273258 Migraine A 0.48 9.00E-06 1.13 [1.07-1.17] [138] Illumina [1,246,388]    rs17301853 1q25.1 174583673 Migraine MO C 0.88 7.00E-06 1.19 [1.1-1.28] [137] Affmetrix & Illumina [~2.3 million]    rs1835740 8q22.1 97154685 Migraine A 0.21 2.00E-11 1.18 [1.13-1.24] [7] Illumina [429,912] rs1861960 7q36.3 155492440 Migraine T 0.2 6.00E-06 1.07 [1.04-1.10] [7] Affmetrix & Illumina [~2.3 million]    rs2076054 22q12.3 32436887 Migraine MA C 0.26 8.00E-06 1.12 [1.07-1.18] [7] Affmetrix & Illumina [~2.3 million]    
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SNP Region Chr. Position Trait Assoc Alle RAF P-val OR 95% CI Study Platform rs2274316 1q22 156476450 Migraine  C 0.36 1.00E-08 1.07 [1.05-1.10] [137] Affmetrix & Illumina [~2.3 million]    rs2506155 10p11.22 33214251 Migraine A 0.15 3.00E-06 1.08 [1.04-1.11] [137] Affmetrix & Illumina [~2.3 million]    rs2651899 1p36.32 3167148 Migraine C 0.41 4.00E-14 1.09 [1.07-1.11] [137] Affmetrix & Illumina [~2.3 million]    rs2723279 12q24.23 117835066 Migraine G 0.69 5.00E-06 1.06 [1.03-1.09] [137] Affmetrix & Illumina [~2.3 million]    rs2877098 7p14.1 41703696 Migraine MO C 0.66 2.00E-06 1.11 [1.06-1.16] [137] Affmetrix & Illumina [~2.3 million]    rs2946505 8p22 12953643 Migraine A 0.78 9.00E-06 1.06 [1.03-1.09] [137] Affmetrix & Illumina [~2.3 million]    rs3094117 6p21.33 30769709 Migraine MO T 0.77 2.00E-06 1.12 [1.06-1.18] [137] Affmetrix & Illumina [~2.3 million]    rs378363 9p23 9020223 Migraine  A 0.77 8.00E-06 1.14 [1.08-1.2] [137] Affmetrix & Illumina [~2.3 million]    rs400824 8q21.13 80445467 Migraine  A 0.7 9.00E-06 1.12 [1.06-1.19] [137] Affmetrix & Illumina [~2.3 million]    rs4379368 7p14.1 40426601 Migraine MO T 0.11 1.00E-09 1.11 [1.08-1.15] [7] Affmetrix & Illumina [~2.3 million]    rs4478147 4q21.3 86552623 Migraine  G 0.47 2.00E-06 1.12 [1.07-1.18] [137] Affmetrix & Illumina [~2.3 million]    rs4493873 8q21.3 91063415 Migraine  C 0.64 5.00E-06 1.14 [1.08-1.2] [7] Affmetrix & Illumina [~2.3 million]    rs4803455 19q13.2 41345604 Migraine C 0.5 8.00E-07 1.05 [1.03-1.08] [137] Affmetrix & Illumina [~2.3 million]    rs4880487 10p15.3 1200943 Migraine T 0.25 3.00E-06 1.06 [1.04-1.09] [7] Affmetrix & Illumina [~2.3 million]    rs4909945 11p15.4 10652192 Migraine C 0.67 2.00E-07 1.06 [1.04-1.09] [137] Affmetrix & Illumina [~2.3 million]    rs516243 1p36.22 10690375 Migraine  A 0.49 9.00E-06 1.11 [1.06-1.17] [7] Affmetrix & Illumina [~2.3 million]    rs543844 6p21.1 44457063 Migraine G 0.34 3.00E-06 1.06 [1.03-1.08] [137] Affmetrix & Illumina [~2.3 million]    rs6478241 9q33.1 116490350 Migraine A 0.38 1.00E-09 1.16 [1.11-1.22] [7] Affmetrix & Illumina [~2.3 million]    rs6479874 10q11.23 51029595 Migraine T 0.14 3.00E-07 1.09 [1.05-1.12] [137] Affmetrix & Illumina [~2.3 million]    rs6583954 10q23.33 94774506 Migraine T 0.14 4.00E-06 1.08 [1.04-1.11] [7] Affmetrix & Illumina [~2.3 million]    rs6756590 2q35 216343848 Migraine T 0.56 1.00E-06 1.14 [1.08-1.2] [138] Illumina [1,246,388]    rs6790925 3p24.1 30438593 Migraine  T 0.38 2.00E-08 1.15 [1.10-1.21] [7] Affmetrix & Illumina [~2.3 million]    rs705162 10q26.13 123492159 Migraine A 0.26 3.00E-06 1.06 [1.04-1.09] [7] Affmetrix & Illumina [~2.3 million]    rs7068341 10p13 16592300 Migraine T 0.12 2.00E-06 1.09 [1.05-1.12] [7] Affmetrix & Illumina [~2.3 million]    rs7085387 10q21.1 58444842 Migraine MO A 0.8 2.00E-06 1.14 [1.08-1.19] [7] Affmetrix & Illumina [~2.3 million]    rs7718446 5q32 146369972 Migraine MO A 0.72 4.00E-06 1.11 [1.06-1.16] [7] Affmetrix & Illumina [~2.3 million]    rs9349379 6p24.1 12903725 Migraine A 0.6 5.00E-08 1.08 [1.04-1.1] [7] Affmetrix & Illumina [~2.3 million]    rs973009 19q13.2 38683692 Migraine MA A 0.87 4.00E-06 1.18 [1.1-1.27] [7] Affmetrix & Illumina [~2.3 million]    264  Chapter 10: Conclusions and Future Directions 
 
Appendix 4.  Differential expression analysis implementing a standard T-test Mean gene expression levels are shown in cases and controls.  The means difference (Difference), T statistics and P value are also presented for every probe.   
 
ID_PROBE Case.mean Control.mean Difference T.stat P-val ILMN_1724907 8.273856692 8.375915393 -0.102058701 -4.125107297 5.78002E-05 ILMN_1674609 9.389031525 9.500395698 -0.111364173 -3.983564687 9.97945E-05 ILMN_1698668 6.676740744 6.816958968 -0.140218224 -3.955038393 0.000120201 ILMN_2094313 6.527286147 6.641374558 -0.114088411 -3.91807574 0.000125092 ILMN_1689172 6.795332435 6.967329058 -0.171996623 -3.880588273 0.000156287 ILMN_1789436 8.555978232 8.683567748 -0.127589516 -3.696391602 0.000303481 ILMN_1716876 7.216812239 7.104724628 0.112087611 3.690815381 0.000310768 ILMN_1758371 6.728415472 6.542879807 0.185535665 3.696492679 0.000326363 ILMN_1661454 6.464416222 6.357327281 0.107088942 3.67712658 0.000331533 ILMN_3243831 6.2946037 6.404372891 -0.109769191 -3.622579633 0.000411458 ILMN_1702097 6.296420144 6.395360148 -0.098940004 -3.564875779 0.000494215 ILMN_1772821 7.134812069 7.000228816 0.134583254 3.552139484 0.000523299 ILMN_1728934 6.14207249 6.267246273 -0.125173783 -3.508658979 0.000593728 ILMN_1733103 7.087827639 6.990295472 0.097532167 3.476193971 0.000640467 ILMN_2327090 8.196295272 8.020899996 0.175395276 3.410842286 0.000809675 ILMN_1728677 9.212303762 8.997200427 0.215103335 3.411771894 0.000834659 ILMN_1772798 7.684227005 7.790047219 -0.105820214 -3.393309431 0.00088161 ILMN_1786326 6.135003142 6.242747078 -0.107743936 -3.396698315 0.000889669 ILMN_3234967 8.304090553 8.084565046 0.219525507 3.39728104 0.000906098 ILMN_2406043 7.544144073 7.70164067 -0.157496597 -3.3670339 0.00094139 ILMN_1679797 8.580322745 8.459399824 0.120922921 3.362371285 0.000966163 ILMN_1655126 8.296303903 8.173278128 0.123025775 3.319137055 0.001095669 ILMN_2331087 8.633447094 8.797879611 -0.164432517 -3.32519319 0.001104495 ILMN_1803323 6.196472911 6.303390716 -0.106917805 -3.334188961 0.00110834 ILMN_1722798 6.529129738 6.433748657 0.095381081 3.321788 0.001135953 ILMN_2246956 8.902707657 8.772328604 0.130379053 3.323859077 0.001148774 ILMN_1663042 6.536141567 6.422722189 0.113419378 3.287896567 0.001289377 ILMN_1704222 6.455297315 6.340517124 0.114780191 3.287727143 0.001313308 ILMN_1722738 6.666333161 6.8295652 -0.163232039 -3.282073567 0.001338075 ILMN_3240082 6.199486812 6.300315462 -0.100828649 -3.243974478 0.001469347 ILMN_3306444 6.329047944 6.424473531 -0.095425587 -3.227894298 0.001514234 ILMN_1798620 10.4675367 10.59761061 -0.130073917 -3.211749016 0.001595719 ILMN_1708105 6.66401139 6.760113522 -0.096102132 -3.21649981 0.001616516 ILMN_2383975 11.38755049 11.53559606 -0.148045575 -3.201693205 0.001669176 ILMN_2131336 7.095755704 6.995610282 0.100145422 3.202311219 0.001703668 ILMN_3245559 9.647121131 9.793179315 -0.146058184 -3.193703684 0.001727068 ILMN_1769545 8.317716997 8.198439271 0.119277726 3.170201567 0.001802615 ILMN_1748792 6.402319976 6.299947558 0.102372418 3.180857957 0.001855496 ILMN_1762972 8.871824368 9.021326732 -0.149502364 -3.169431499 0.001868686 ILMN_3251587 6.682047912 7.239529157 -0.557481246 -3.136347022 0.001951554 ILMN_1667432 6.117300579 6.261774589 -0.14447401 -3.160420273 0.001978028 ILMN_1704477 10.46524505 10.5773928 -0.112147754 -3.136883542 0.002066354 ILMN_1688178 7.550346323 7.733581528 -0.183235205 -3.135397107 0.002082296 ILMN_3238203 8.835610873 8.605197794 0.230413079 3.140205062 0.002143626 ILMN_2335302 6.442226039 6.341346992 0.100879047 3.120261874 0.002162367 ILMN_1659845 8.183671422 8.090991233 0.092680189 3.119107799 0.002167262 ILMN_1751463 6.528266497 6.626216861 -0.097950363 -3.108398521 0.002269345 ILMN_1736180 8.041903155 7.904947162 0.136955993 3.106361675 0.002302316 ILMN_1808568 8.548029189 8.451528374 0.096500815 3.10025944 0.002323699 ILMN_1745021 6.63074737 6.720072608 -0.089325238 -3.103415864 0.002356593 ILMN_1800634 8.406982102 8.601274539 -0.194292437 -3.098561409 0.0024031 ILMN_1763207 6.020122548 6.150162829 -0.130040281 -3.083260915 0.00244137 ILMN_3212007 6.193826759 6.302630731 -0.108803972 -3.086006302 0.002502543 ILMN_1711422 6.487538788 6.569794344 -0.082255557 -3.066151595 0.0025348 ILMN_1881526 7.60388875 7.458095047 0.145793704 3.067768694 0.002617751 ILMN_1907042 7.715272582 7.603252318 0.112020263 3.051110502 0.002663741 ILMN_2349600 8.104252763 8.020796628 0.083456135 3.057914411 0.002677127 ILMN_1778683 6.430762545 6.52685708 -0.096094535 -3.058661935 0.002718126 ILMN_1809957 11.99428275 12.09912102 -0.104838268 -3.05201349 0.002738308 ILMN_1736974 6.198445723 6.327408231 -0.128962508 -3.043171782 0.002817561 ILMN_3239965 6.824822631 6.998093084 -0.173270453 -3.036752132 0.002819746 ILMN_1701131 6.142736898 6.255814289 -0.113077391 -3.030702063 0.002834918 
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ILMN_1773295 6.8913882 7.097922608 -0.206534408 -3.030088456 0.002854367 ILMN_1652185 9.288653064 9.12346133 0.165191733 3.033043949 0.002956156 ILMN_1754988 6.360573242 6.436264377 -0.075691135 -3.015085478 0.003041118 ILMN_1795227 10.71115656 10.80534927 -0.094192704 -3.009096338 0.00316285 ILMN_2317739 6.439555901 6.365615312 0.073940589 2.996836155 0.00318506 ILMN_1695135 6.644942813 6.727214885 -0.082272073 -2.991096893 0.003236612 ILMN_1690583 6.359442883 6.258526275 0.100916608 2.9977457 0.003299172 ILMN_2155719 11.56942036 11.3474461 0.221974261 2.980554553 0.00335254 ILMN_1700268 6.127860376 6.253399592 -0.125539216 -2.990492218 0.003369159 ILMN_2318932 6.546827916 6.64498032 -0.098152404 -2.98168601 0.003374176 ILMN_1771048 8.300773109 8.193793257 0.106979852 2.979696834 0.003411351 ILMN_1656865 6.473674284 6.37278023 0.100894055 2.972648037 0.003437717 ILMN_2400661 5.996172365 6.131358431 -0.135186066 -2.979504157 0.003487986 ILMN_2396813 7.979348026 8.137892886 -0.158544861 -2.970406874 0.003502309 ILMN_1783443 6.681465427 6.783413081 -0.101947654 -2.972163556 0.003514373 ILMN_2383807 6.082012426 6.191621022 -0.109608596 -2.969865725 0.003516565 ILMN_1769218 6.429222793 6.334592529 0.094630264 2.960601412 0.00359169 ILMN_1901934 6.695287372 6.778664184 -0.083376812 -2.959325661 0.003595997 ILMN_1678618 5.89025309 6.041730279 -0.151477189 -2.954580814 0.003646645 ILMN_1823128 6.45736477 6.545355493 -0.087990723 -2.96054458 0.003662673 ILMN_1682938 8.562880832 8.412204273 0.150676559 2.949798078 0.003743708 ILMN_2276952 8.875829865 8.668529353 0.207300512 2.945868773 0.003749803 ILMN_1666494 7.187361991 7.097559993 0.089801998 2.94180534 0.003822288 ILMN_1746393 7.358333464 7.269206276 0.089127188 2.944382667 0.00383517 ILMN_1676555 6.514947266 6.598329543 -0.083382277 -2.928798065 0.003967364 ILMN_1780887 7.374668184 7.287982514 0.08668567 2.918761013 0.004073858 ILMN_1659761 7.234499947 7.136740101 0.097759846 2.916787528 0.004087017 ILMN_1801119 8.264105668 8.145010854 0.119094814 2.909344189 0.004259366 ILMN_1703337 7.225001542 7.58925515 -0.364253609 -2.881590022 0.004402704 ILMN_3236036 7.098170992 6.938551037 0.159619954 2.8992824 0.004486765 ILMN_1816092 6.411538803 6.517262983 -0.10572418 -2.894161105 0.004492545 ILMN_1845037 7.490330805 7.587454623 -0.097123818 -2.886354589 0.00449772 ILMN_1801584 10.73503953 10.54246062 0.192578908 2.880339033 0.004504384 ILMN_3304821 6.70221173 6.603237404 0.098974326 2.887543126 0.004562601 ILMN_2206716 11.71747453 11.80943345 -0.091958925 -2.884500747 0.004605835 ILMN_1911059 6.909579569 6.817404191 0.092175378 2.879598535 0.004618368 ILMN_2227573 10.60645849 10.72132233 -0.114863842 -2.880956391 0.004651241 ILMN_1656501 7.538403182 7.635318661 -0.096915479 -2.877067591 0.004669826 
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Appendix 5.  List of Blood-Informative Transcripts in The Norfolk Island Population 
 
Axis Probe Gene Axis 1 ILMN_2309245 BIN1  ILMN_2098616 C5ORF39  ILMN_1700628 DDX24  ILMN_1703565 GLTSCR2  ILMN_1733696 IMP3  ILMN_1708151 LAGE3  ILMN_2183687 LIME1  ILMN_1700306 OCIAD2  ILMN_1657204 SAE1  ILMN_2369785 SNRPD2 Axis 2 ILMN_1814397 EPB42  ILMN_1729487 GMPR  ILMN_1759155 IFIT1L  ILMN_1811927 OR2W3  ILMN_1784678 PBX1  ILMN_1680652 SELENBP1  ILMN_1772809 SLC4A1  ILMN_1704446 SLC6A10P  ILMN_1766165 SNCA  ILMN_1807919 TNS1 Axis 3 ILMN_1775235 AFF3  ILMN_1668277 BLK  ILMN_1782704 CD19  ILMN_1723004 CD72  ILMN_1734878 CD79A  ILMN_1778681 EBF1  ILMN_1664063 FAM129C  ILMN_1691071 FCRLA  ILMN_1811049 POU2AF1  ILMN_1700147 VPREB3 Axis 4 ILMN_2357272 BCLAF1  ILMN_2374293 DYRK1A  ILMN_2378048 HNRPK  ILMN_1792997 NPTN  ILMN_1681845 PAPD4  ILMN_1700834 SLK  ILMN_2312275 SRP54  ILMN_1682316 TRIM33  ILMN_1668417 WASPIP  ILMN_1795228 ZFAND5 Axis 5 ILMN_1662524 IL8RA  ILMN_1689836 C5AR1  ILMN_1666049 NUP214  ILMN_1715068 AQP9  ILMN_1808047 PHC2  ILMN_2372974 SIRPA  ILMN_2368292 TSEN34  ILMN_1722218 MBOAT7  ILMN_1791771 HCK  ILMN_1778723 AMICA1 Axis 6 ILMN_1680279 USP49  ILMN_1692145 ZNF14  ILMN_2054554 DTWD2  ILMN_2075794 NLRP8  ILMN_2106658 BLZF1  ILMN_2162367 DMC1  ILMN_2222101 N4BP2  ILMN_2313889 ZNF682  ILMN_2330495 OCIAD1  ILMN_2407851 IL17RD Axis 7 ILMN_1739428 IFIT2  ILMN_1729749 HERC5  ILMN_1657871 RSAD2  ILMN_2388547 EPSTI1  ILMN_1745397 OAS3 267  Chapter 10: Conclusions and Future Directions 
 
Axis Probe Gene  ILMN_2349061 IRF7  ILMN_1799467 SAMD9L  ILMN_1670305 SERPING1  ILMN_1662358 MX1  ILMN_1797001 DDX58 Axis 8 ILMN_2066348 HERPUD2  ILMN_1783852 CD164  ILMN_2379788 HIF1A  ILMN_2179397 TATDN1  ILMN_1713752 SERINC3  ILMN_1751816 MCTS1  ILMN_2044226 PPP3CA  ILMN_1742813 TMEM167A  ILMN_1739583 ROCK1  ILMN_2389844 SP3 Axis 9 ILMN_1674780 SF3B1  ILMN_2272074 TROVE2  ILMN_1748797 GRB2  ILMN_2340217 PTPRC  ILMN_1804148 TMED4  ILMN_1801984 VHL  ILMN_1653652 PTPRC  ILMN_1698323 PLEKHB2  ILMN_2291954 SLA  ILMN_1756806 MCL1 
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Appendix 6.  Gene ontology analysis.  A gene ontology analysis was carried out using DAVID.  In the table below the module colour, category of enrichment, term , gene count , gene percentage, raw p-value and Bonferroni corrected p-value are given.     
 Module Category Term Count % P-Value Bonferroni  
 Module Category Term Count % P-Value Bonferroni   ME1          GOTERM_BP_ALL metabolic process 35 56,5 6,2E-4 3,8E-1    GOTERM_BP_ALL primary metabolic process 31 50,0 4,8E-3 9,7E-1    GOTERM_BP_ALL biosynthetic process 20 32,3 4,9E-3 9,8E-1    GOTERM_BP_FAT hemopoiesis 5 8,1 5,5E-3 9,7E-1    GOTERM_BP_ALL hemopoiesis 5 8,1 5,6E-3 9,9E-1   ME2          GOTERM_CC_ALL intracellular 710 6,8 4,0E-29 2,0E-26    GOTERM_CC_ALL intracellular part 694 6,7 5,4E-29 2,7E-26    GOTERM_CC_ALL intracellular membrane-bounded organelle 551 5,3 2,7E-22 1,4E-19    GOTERM_CC_ALL membrane-bounded organelle 551 5,3 3,5E-22 1,7E-19    SP_PIR_KEYWORDS phosphoprotein 520 5,0 5,9E-21 2,8E-18    GOTERM_CC_ALL intracellular organelle 587 5,6 2,3E-18 1,1E-15    GOTERM_CC_ALL organelle 587 5,6 3,3E-18 1,6E-15    SP_PIR_KEYWORDS alternative splicing 511 4,9 2,1E-15 1,0E-12    SP_PIR_KEYWORDS acetylation 227 2,2 3,6E-15 1,8E-12    GOTERM_CC_ALL cytoplasm 491 4,7 7,4E-15 3,6E-12    UP_SEQ_FEATURE splice variant 509 4,9 9,0E-15 2,2E-11    GOTERM_BP_ALL primary metabolic process 477 4,6 1,0E-12 2,6E-9    GOTERM_BP_ALL metabolic process 515 4,9 1,5E-12 3,9E-9    GOTERM_BP_ALL cellular metabolic process 459 4,4 3,5E-12 8,9E-9  
269  Chapter 10: Conclusions and Future Directions 
 
 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT intracellular organelle lumen 154 1,5 7,1E-12 3,4E-9    GOTERM_CC_ALL nuclear part 161 1,5 1,0E-11 5,0E-9    GOTERM_CC_ALL intracellular organelle part 306 2,9 2,4E-11 1,2E-8    GOTERM_CC_FAT membrane-enclosed lumen 157 1,5 2,4E-11 1,2E-8    GOTERM_CC_FAT organelle lumen 154 1,5 4,2E-11 2,0E-8    GOTERM_CC_ALL cytoplasmic part 343 3,3 4,2E-11 2,1E-8    GOTERM_CC_ALL nucleus 353 3,4 4,5E-11 2,2E-8    GOTERM_CC_ALL organelle part 306 2,9 5,3E-11 2,6E-8    GOTERM_CC_ALL cell part 814 7,8 1,2E-10 5,9E-8    GOTERM_CC_ALL cell 814 7,8 1,2E-10 6,1E-8    GOTERM_CC_ALL intracellular organelle lumen 154 1,5 1,5E-10 7,7E-8    GOTERM_CC_ALL membrane-enclosed lumen 157 1,5 5,3E-10 2,6E-7    GOTERM_CC_ALL organelle lumen 154 1,5 8,3E-10 4,1E-7    GOTERM_BP_ALL nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 261 2,5 9,2E-10 2,4E-6    GOTERM_BP_ALL macromolecule metabolic process 396 3,8 9,3E-10 2,4E-6    SP_PIR_KEYWORDS nucleus 304 2,9 1,1E-9 5,2E-7    GOTERM_BP_ALL cellular macromolecule metabolic process 367 3,5 1,3E-9 3,4E-6    GOTERM_BP_ALL cellular nitrogen compound metabolic process 276 2,6 1,4E-9 3,6E-6    GOTERM_BP_ALL cellular process 648 6,2 1,5E-9 3,9E-6    GOTERM_BP_ALL nitrogen compound metabolic process 281 2,7 3,0E-9 7,7E-6    GOTERM_CC_FAT nuclear lumen 124 1,2 3,4E-9 1,6E-6    GOTERM_CC_ALL nuclear lumen 124 1,2 3,2E-8 1,6E-5    GOTERM_CC_FAT mitochondrion 96 0,9 7,2E-8 3,4E-5    GOTERM_MF_ALL catalytic activity 353 3,4 1,2E-7 1,1E-4    SP_PIR_KEYWORDS zinc-finger 139 1,3 1,4E-7 6,7E-5  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_BP_ALL RNA metabolic process 90 0,9 2,2E-7 5,6E-4    GOTERM_CC_ALL mitochondrion 96 0,9 3,8E-7 1,9E-4    SP_PIR_KEYWORDS zinc 165 1,6 7,5E-7 3,6E-4    GOTERM_BP_ALL gene expression 221 2,1 8,8E-7 2,3E-3    GOTERM_MF_ALL transferase activity 141 1,4 1,1E-6 1,0E-3    SP_PIR_KEYWORDS metal-binding 211 2,0 1,2E-6 5,5E-4    GOTERM_BP_ALL biosynthetic process 253 2,4 1,2E-6 3,1E-3    GOTERM_BP_ALL cellular biosynthetic process 247 2,4 1,2E-6 3,1E-3    SP_PIR_KEYWORDS atp-binding 108 1,0 3,4E-6 1,6E-3    SP_PIR_KEYWORDS wd repeat 34 0,3 7,8E-6 3,7E-3    GOTERM_MF_ALL ligase activity, forming carbon-nitrogen bonds 31 0,3 8,1E-6 7,7E-3    GOTERM_MF_FAT ligase activity, forming carbon-nitrogen bonds 31 0,3 9,9E-6 8,8E-3    GOTERM_CC_FAT nucleolus 63 0,6 1,0E-5 4,8E-3    GOTERM_CC_FAT nucleoplasm 75 0,7 1,0E-5 4,9E-3    GOTERM_MF_ALL binding 724 6,9 1,5E-5 1,4E-2    SP_PIR_KEYWORDS mitochondrion 73 0,7 1,6E-5 7,6E-3    INTERPRO WD40 repeat, conserved site 34 0,3 1,7E-5 2,3E-2    GOTERM_BP_FAT RNA processing 55 0,5 1,7E-5 4,2E-2    GOTERM_MF_ALL ligase activity 43 0,4 1,7E-5 1,7E-2    SP_PIR_KEYWORDS transferase 109 1,0 1,9E-5 9,0E-3    UP_SEQ_FEATURE repeat:WD 1 33 0,3 1,9E-5 4,5E-2    UP_SEQ_FEATURE repeat:WD 2 33 0,3 1,9E-5 4,5E-2    GOTERM_BP_ALL RNA processing 55 0,5 2,0E-5 5,0E-2    SP_PIR_KEYWORDS s-adenosyl-l-methionine 18 0,2 2,2E-5 1,1E-2    GOTERM_MF_ALL zinc ion binding 169 1,6 2,5E-5 2,3E-2  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_ALL nucleolus 63 0,6 2,8E-5 1,4E-2    GOTERM_CC_ALL nucleoplasm 75 0,7 3,3E-5 1,6E-2    INTERPRO WD40/YVTN repeat-like 35 0,3 3,5E-5 4,8E-2    GOTERM_MF_FAT zinc ion binding 169 1,6 3,8E-5 3,3E-2    GOTERM_MF_ALL methyltransferase activity 24 0,2 4,7E-5 4,4E-2    GOTERM_CC_FAT endomembrane system 66 0,6 4,9E-5 2,3E-2    SP_PIR_KEYWORDS Transcription 148 1,4 5,2E-5 2,4E-2    SP_PIR_KEYWORDS ligase 34 0,3 6,1E-5 2,9E-2    GOTERM_BP_FAT intracellular transport 61 0,6 6,1E-5 1,4E-1    GOTERM_MF_ALL ATP binding 115 1,1 6,1E-5 5,7E-2    SMART WD40 31 0,3 6,2E-5 1,5E-2    UP_SEQ_FEATURE repeat:WD 3 31 0,3 6,2E-5 1,4E-1    GOTERM_MF_ALL transferase activity, transferring one-carbon groups 24 0,2 6,3E-5 5,8E-2    GOTERM_BP_ALL intracellular transport 61 0,6 6,9E-5 1,6E-1    GOTERM_MF_ALL adenyl ribonucleotide binding 116 1,1 6,9E-5 6,4E-2    GOTERM_MF_ALL adenyl nucleotide binding 121 1,2 7,1E-5 6,6E-2    GOTERM_CC_FAT organelle membrane 85 0,8 7,3E-5 3,4E-2    BIOCARTA Ceramide Signaling Pathway 8 0,1 8,5E-5 1,4E-2    GOTERM_MF_FAT ATP binding 115 1,1 8,6E-5 7,5E-2    GOTERM_MF_FAT adenyl ribonucleotide binding 116 1,1 9,5E-5 8,1E-2    GOTERM_MF_FAT adenyl nucleotide binding 121 1,2 1,0E-4 8,6E-2    SP_PIR_KEYWORDS Apoptosis 39 0,4 1,0E-4 4,7E-2    INTERPRO WD40 repeat 31 0,3 1,1E-4 1,4E-1    GOTERM_MF_ALL nucleoside binding 122 1,2 1,2E-4 1,1E-1    GOTERM_CC_ALL endomembrane system 66 0,6 1,3E-4 6,1E-2  
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 Module Category Term Count % P-Value Bonferroni    UP_SEQ_FEATURE compositionally biased region:Pro-rich 78 0,7 1,3E-4 2,7E-1    GOTERM_BP_ALL organelle organization 105 1,0 1,3E-4 2,9E-1    GOTERM_MF_ALL purine nucleoside binding 121 1,2 1,3E-4 1,2E-1    GOTERM_BP_ALL cellular macromolecule biosynthetic process 196 1,9 1,6E-4 3,3E-1    GOTERM_MF_ALL S-adenosylmethionine-dependent methyltransferase activity 15 0,1 1,6E-4 1,4E-1    GOTERM_MF_FAT nucleoside binding 122 1,2 1,7E-4 1,4E-1    GOTERM_BP_ALL macromolecule biosynthetic process 197 1,9 1,7E-4 3,6E-1    GOTERM_MF_ALL RNA binding 63 0,6 1,9E-4 1,6E-1    GOTERM_MF_FAT purine nucleoside binding 121 1,2 1,9E-4 1,6E-1    SP_PIR_KEYWORDS methyltransferase 20 0,2 2,1E-4 9,6E-2    GOTERM_CC_ALL organelle membrane 85 0,8 2,2E-4 1,0E-1    GOTERM_MF_FAT RNA binding 63 0,6 2,4E-4 2,0E-1    GOTERM_CC_ALL macromolecular complex 206 2,0 2,4E-4 1,1E-1    GOTERM_BP_ALL establishment of localization in cell 72 0,7 2,7E-4 4,9E-1    GOTERM_MF_ALL transition metal ion binding 191 1,8 2,8E-4 2,3E-1    INTERPRO WD40 repeat, subgroup 28 0,3 2,8E-4 3,2E-1    GOTERM_CC_ALL protein complex 173 1,7 3,1E-4 1,4E-1    SP_PIR_KEYWORDS transit peptide 44 0,4 3,3E-4 1,5E-1    GOTERM_BP_FAT transcription 150 1,4 3,4E-4 5,6E-1    GOTERM_MF_ALL protein binding 491 4,7 3,6E-4 2,9E-1    GOTERM_CC_FAT endoplasmic reticulum part 34 0,3 3,8E-4 1,6E-1    BIOCARTA Signaling of Hepatocyte Growth Factor Receptor 9 0,1 3,9E-4 6,5E-2    GOTERM_MF_FAT transition metal ion binding 191 1,8 4,1E-4 3,1E-1    GOTERM_BP_ALL transcription 150 1,4 4,6E-4 6,9E-1    UP_SEQ_FEATURE transit peptide:Mitochondrion 43 0,4 4,8E-4 6,8E-1  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_MF_ALL nucleotide binding 157 1,5 4,9E-4 3,7E-1    BIOCARTA Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling 8 0,1 4,9E-4 8,1E-2    GOTERM_BP_FAT chromatin modification 30 0,3 5,0E-4 7,1E-1    SP_PIR_KEYWORDS nucleotide-binding 119 1,1 5,3E-4 2,2E-1    GOTERM_BP_ALL chromatin modification 30 0,3 5,5E-4 7,6E-1    GOTERM_BP_FAT ncRNA processing 23 0,2 5,7E-4 7,5E-1    SP_PIR_KEYWORDS hydrolase 111 1,1 5,8E-4 2,4E-1    GOTERM_MF_ALL acid-amino acid ligase activity 24 0,2 5,8E-4 4,3E-1    GOTERM_BP_ALL macromolecule localization 85 0,8 6,1E-4 7,9E-1    GOTERM_BP_ALL ncRNA processing 23 0,2 6,1E-4 7,9E-1    GOTERM_CC_ALL endoplasmic reticulum part 34 0,3 6,4E-4 2,7E-1    GOTERM_MF_FAT acid-amino acid ligase activity 24 0,2 6,7E-4 4,5E-1    GOTERM_MF_FAT nucleotide binding 157 1,5 7,0E-4 4,7E-1    GOTERM_BP_ALL cellular localization 75 0,7 7,2E-4 8,4E-1    UP_SEQ_FEATURE repeat:WD 4 27 0,3 7,4E-4 8,3E-1    SP_PIR_KEYWORDS transcription regulation 138 1,3 7,8E-4 3,1E-1    SP_PIR_KEYWORDS protein transport 43 0,4 9,1E-4 3,5E-1    GOTERM_BP_FAT regulation of gene expression, epigenetic 13 0,1 9,1E-4 8,9E-1    GOTERM_BP_ALL regulation of gene expression, epigenetic 13 0,1 9,5E-4 9,1E-1  
 ME3  Term Count % P-Value Bonferroni    SP_PIR_KEYWORDS acetylation  27 36,0 1,1E-6 1,6E-4    GOTERM_CC_FAT membrane-enclosed lumen 17 22,7 3,3E-3 3,7E-1    GOTERM_CC_FAT mitochondrial part 9 12,0 3,3E-3 3,7E-1    SP_PIR_KEYWORDS mitochondrion 10 13,3 3,4E-3 4,0E-1  
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 Module Category Term Count % P-Value Bonferroni    SP_PIR_KEYWORDS DNA damage  5 15,6 3,1E-4 3,3E-2    GOTERM_MF_FAT endodeoxyribonuclease activity 3 9,4 4,6E-4 4,6E-2    GOTERM_BP_FAT DNA repair 5 15,6 7,1E-4 2,7E-1  
 ME5   Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  24 35,8 8,5E-6 1,4E-3    SP_PIR_KEYWORDS phosphoprotein 43 64,2 1,0E-5 1,6E-3    SP_PIR_KEYWORDS cytoplasm 24 35,8 3,6E-4 5,6E-2  
 ME6  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS phosphoprotein  23 74,2 8,1E-5 8,4E-3    GOTERM_CC_FAT nucleoplasm 9 29,0 9,6E-5 1,1E-2    GOTERM_CC_FAT nucleoplasm part 7 22,6 3,5E-4 3,9E-2  
 ME7  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS phosphoprotein  209 58,7 1,0E-17 3,6E-15    UP_SEQ_FEATURE mutagenesis site 76 21,3 1,7E-9 1,7E-6    GOTERM_BP_FAT defense response 38 10,7 3,2E-9 6,2E-6    GOTERM_BP_FAT intracellular signaling cascade 58 16,3 5,4E-9 1,0E-5    GOTERM_BP_FAT immune response 39 11,0 2,1E-8 4,1E-5    SP_PIR_KEYWORDS membrane 161 45,2 5,8E-8 2,0E-5    SP_PIR_KEYWORDS kinase 34 9,6 3,3E-7 1,1E-4    GOTERM_BP_FAT phosphate metabolic process 44 12,4 1,2E-6 2,2E-3    GOTERM_BP_FAT phosphorus metabolic process 44 12,4 1,2E-6 2,2E-3    GOTERM_BP_FAT regulation of Ras protein signal transduction 18 5,1 1,4E-6 2,7E-3    GOTERM_BP_FAT protein kinase cascade 24 6,7 2,1E-6 4,1E-3    GOTERM_BP_FAT phosphorylation 38 10,7 2,5E-6 4,7E-3    GOTERM_BP_FAT membrane invagination 18 5,1 2,7E-6 5,2E-3  
275  Chapter 10: Conclusions and Future Directions 
 
 Module Category Term Count % P-Value Bonferroni    GOTERM_BP_FAT endocytosis 18 5,1 2,7E-6 5,2E-3    GOTERM_BP_FAT regulation of small GTPase mediated signal transduction 19 5,3 4,2E-6 8,0E-3    SP_PIR_KEYWORDS host-virus interaction 19 5,3 4,5E-6 1,5E-3    GOTERM_MF_FAT enzyme activator activity 22 6,2 5,5E-6 3,1E-3    GOTERM_BP_FAT regulation of hydrolase activity 22 6,2 5,8E-6 1,1E-2    KEGG_PATHWAY Fc gamma R-mediated phagocytosis 13 3,7 6,3E-6 6,7E-4    SP_PIR_KEYWORDS sh3 domain 16 4,5 6,5E-6 2,2E-3    GOTERM_BP_FAT leukocyte activation during immune response 8 2,2 6,9E-6 1,3E-2    GOTERM_BP_FAT cell activation during immune response 8 2,2 6,9E-6 1,3E-2    KEGG_PATHWAY Chemokine signaling pathway 18 5,1 7,1E-6 7,6E-4    SP_PIR_KEYWORDS cytoplasm 93 26,1 9,0E-6 3,1E-3  
 ME8   Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  150 39,7 3,6E-37 1,4E-34    SP_PIR_KEYWORDS phosphoprotein 254 67,2 6,0E-33 2,3E-30    SP_PIR_KEYWORDS cytoplasm 125 33,1 3,3E-14 1,3E-11    SP_PIR_KEYWORDS Spliceosome 19 5,0 1,7E-11 6,5E-9    GOTERM_CC_FAT nuclear lumen 72 19,0 3,3E-10 1,3E-7    GOTERM_CC_FAT intracellular organelle lumen 82 21,7 4,4E-10 1,7E-7    SP_PIR_KEYWORDS mrna splicing 22 5,8 7,9E-10 3,0E-7    SP_PIR_KEYWORDS alternative splicing 203 53,7 9,9E-10 3,7E-7    GOTERM_CC_FAT spliceosome 19 5,0 1,3E-9 5,0E-7    GOTERM_CC_FAT organelle lumen 82 21,7 1,3E-9 5,3E-7    GOTERM_CC_FAT membrane-enclosed lumen 82 21,7 3,4E-9 1,3E-6    UP_SEQ_FEATURE splice variant 200 52,9 6,1E-9 8,3E-6    SP_PIR_KEYWORDS nucleus 131 34,7 1,2E-8 4,5E-6  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT cytosol 64 16,9 1,6E-8 6,2E-6    SP_PIR_KEYWORDS mrna processing 22 5,8 3,9E-8 1,5E-5    GOTERM_CC_FAT nucleoplasm 48 12,7 4,8E-8 1,9E-5    GOTERM_BP_FAT RNA splicing 25 6,6 5,5E-8 1,0E-4    SP_PIR_KEYWORDS rna-binding 32 8,5 7,5E-8 2,8E-5    GOTERM_MF_FAT nucleotide binding 86 22,8 3,2E-7 1,7E-4    INTERPRO Nucleotide-binding, alpha-beta plait 19 5,0 6,1E-7 4,8E-4    GOTERM_BP_FAT glucose catabolic process 11 2,9 8,1E-7 1,5E-3    GOTERM_BP_FAT mRNA processing 24 6,3 1,9E-6 3,5E-3    GOTERM_BP_FAT mRNA metabolic process 26 6,9 2,0E-6 3,6E-3    INTERPRO RNA recognition motif, RNP-1 18 4,8 2,4E-6 1,9E-3    KEGG_PATHWAY Spliceosome 16 4,2 3,4E-6 4,3E-4    GOTERM_BP_FAT hexose catabolic process 11 2,9 4,2E-6 7,7E-3    GOTERM_CC_FAT nucleoplasm part 32 8,5 4,5E-6 1,8E-3    GOTERM_BP_FAT monosaccharide catabolic process 11 2,9 5,5E-6 1,0E-2    SMART RRM 18 4,8 6,9E-6 1,2E-3    GOTERM_CC_FAT membrane-bounded vesicle 32 8,5 7,2E-6 2,8E-3    GOTERM_CC_FAT ribonucleoprotein complex 30 7,9 7,9E-6 3,1E-3  
 ME9  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  143 30,4 8,7E-23 3,3E-20    SP_PIR_KEYWORDS phosphoprotein 259 55,0 3,5E-17 1,4E-14    GOTERM_MF_FAT RNA binding 53 11,3 3,5E-11 2,2E-8    GOTERM_CC_FAT intracellular organelle lumen 87 18,5 1,2E-10 4,7E-8    GOTERM_CC_FAT organelle lumen 88 18,7 1,7E-10 6,3E-8    GOTERM_CC_FAT nucleoplasm 55 11,7 2,5E-10 9,4E-8  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT membrane-enclosed lumen 88 18,7 4,6E-10 1,7E-7    SP_PIR_KEYWORDS rna-binding 40 8,5 6,3E-10 2,4E-7    GOTERM_CC_FAT nuclear lumen 74 15,7 8,4E-10 3,2E-7    GOTERM_CC_FAT cytosol 69 14,6 2,0E-9 7,7E-7    SP_PIR_KEYWORDS cytoplasm 130 27,6 2,2E-9 8,2E-7    GOTERM_CC_FAT ribonucleoprotein complex 37 7,9 1,2E-8 4,6E-6    SP_PIR_KEYWORDS nucleus 148 31,4 3,3E-7 1,3E-4    GOTERM_CC_FAT nuclear body 18 3,8 7,4E-7 2,8E-4    GOTERM_CC_FAT nuclear speck 14 3,0 1,3E-6 4,8E-4    GOTERM_CC_FAT nucleoplasm part 34 7,2 2,1E-6 7,8E-4    GOTERM_BP_FAT protein transport 43 9,1 4,6E-6 8,6E-3  
 ME9  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS mitochondrion  18 12,4 1,3E-4 2,6E-2    GOTERM_CC_FAT mitochondrion 21 14,5 2,1E-4 3,6E-2    GOTERM_CC_FAT mitochondrial part 14 9,7 6,6E-4 1,1E-1  
 ME9  Term  Count %  P-Value  Bonferroni     GOTERM_CC_FAT organelle membrane  19 15,8 3,2E-5 6,0E-3    INTERPRO Pyruvate carboxyltransferase 3 2,5 1,2E-4 3,5E-2    GOTERM_CC_FAT organelle envelope 13 10,8 1,9E-4 3,4E-2    GOTERM_CC_FAT envelope 13 10,8 1,9E-4 3,5E-2    GOTERM_CC_FAT mitochondrion 17 14,2 3,4E-4 6,2E-2    GOTERM_CC_FAT mitochondrial membrane 10 8,3 3,9E-4 7,1E-2    SP_PIR_KEYWORDS mitochondrion 15 12,5 4,1E-4 7,4E-2    GOTERM_CC_FAT mitochondrial part 12 10,0 5,2E-4 9,3E-2  
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 Module Category Term Count % P-Value Bonferroni    SP_PIR_KEYWORDS blood group antigen  7 2,8 1,4E-6 4,3E-4    GOTERM_CC_FAT hemoglobin complex 5 2,0 9,1E-6 2,4E-3    GOTERM_CC_FAT cortical cytoskeleton 7 2,8 2,4E-5 6,5E-3    BIOCARTA Hemoglobin's Chaperone 5 2,0 5,9E-5 3,9E-3    SP_PIR_KEYWORDS phosphoprotein 115 45,6 4,6E-4 1,3E-1    SP_PIR_KEYWORDS heme biosynthesis 4 1,6 4,7E-4 1,3E-1    GOTERM_CC_FAT cell cortex part 7 2,8 4,7E-4 1,2E-1  
 ME13  Term  Count %  P-Value  Bonferroni     GOTERM_CC_FAT secretory granule  4 22,2 7,1E-4 5,4E-2    GOTERM_CC_FAT platelet alpha granule 3 16,7 1,4E-3 1,1E-1  
 Dark Turquoise  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  279 31,0 9,0E-52 4,2E-49    SP_PIR_KEYWORDS phosphoprotein 462 51,4 2,0E-28 9,5E-26    SP_PIR_KEYWORDS cytoplasm 236 26,3 1,7E-16 1,0E-13    GOTERM_CC_FAT membrane-enclosed lumen 155 17,2 3,3E-14 1,5E-11    SP_PIR_KEYWORDS nucleus 275 30,6 3,9E-14 1,8E-11    GOTERM_CC_FAT intracellular organelle lumen 150 16,7 4,8E-14 2,2E-11    GOTERM_CC_FAT organelle lumen 150 16,7 3,1E-13 1,4E-10    GOTERM_CC_FAT nuclear lumen 125 13,9 3,0E-12 1,4E-9    GOTERM_MF_FAT RNA binding 75 8,3 3,8E-11 3,1E-8    GOTERM_BP_FAT cellular macromolecule catabolic process 76 8,5 5,0E-11 1,3E-7    SP_PIR_KEYWORDS rna-binding 59 6,6 9,0E-11 4,2E-8    GOTERM_CC_FAT cytosol 112 12,5 2,5E-10 1,2E-7    GOTERM_BP_FAT macromolecule catabolic process 78 8,7 2,6E-10 6,7E-7    GOTERM_BP_FAT RNA processing 60 6,7 1,4E-9 3,5E-6  
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 Module Category Term Count % P-Value Bonferroni    SP_PIR_KEYWORDS protein biosynthesis 30 3,3 1,8E-9 8,3E-7    GOTERM_CC_FAT nucleoplasm 81 9,0 3,1E-9 1,4E-6    GOTERM_BP_FAT translation 42 4,7 1,1E-8 2,7E-5    GOTERM_CC_FAT ribonucleoprotein complex 55 6,1 1,2E-8 5,7E-6    SP_PIR_KEYWORDS Initiation factor 15 1,7 2,3E-8 1,0E-5    UP_SEQ_FEATURE mutagenesis site 139 15,5 2,8E-8 5,5E-5    GOTERM_BP_FAT proteolysis involved in cellular protein catabolic process 59 6,6 1,0E-7 2,6E-4    SP_PIR_KEYWORDS ribonucleoprotein 34 3,8 1,2E-7 5,4E-5    GOTERM_BP_FAT cellular protein catabolic process 59 6,6 1,2E-7 3,1E-4    GOTERM_BP_FAT modification-dependent protein catabolic process 57 6,3 1,3E-7 3,2E-4    GOTERM_BP_FAT modification-dependent macromolecule catabolic process 57 6,3 1,3E-7 3,2E-4    GOTERM_BP_FAT protein catabolic process 60 6,7 1,5E-7 3,8E-4    SMART RRM 28 3,1 1,5E-7 3,0E-5    GOTERM_CC_FAT non-membrane-bounded organelle 171 19,0 2,9E-7 1,4E-4    GOTERM_CC_FAT intracellular non-membrane-bounded organelle 171 19,0 2,9E-7 1,4E-4    GOTERM_MF_FAT translation initiation factor activity 15 1,7 5,0E-7 4,1E-4    SP_PIR_KEYWORDS transit peptide 46 5,1 5,1E-7 2,4E-4    GOTERM_CC_FAT nucleoplasm part 53 5,9 8,4E-7 3,9E-4    INTERPRO RNA recognition motif, RNP-1 28 3,1 1,1E-6 1,2E-3    GOTERM_MF_FAT nucleotide binding 149 16,6 1,5E-6 1,2E-3    GOTERM_CC_FAT nucleolus 61 6,8 2,1E-6 9,7E-4    INTERPRO Nucleotide-binding, alpha-beta plait 27 3,0 4,1E-6 4,7E-3    UP_SEQ_FEATURE transit peptide:Mitochondrion 43 4,8 4,7E-6 9,4E-3    SP_PIR_KEYWORDS ribosomal protein 24 2,7 5,4E-6 2,5E-3    SP_PIR_KEYWORDS mitochondrion 64 7,1 6,8E-6 3,2E-3  
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 Module Category Term Count % P-Value Bonferroni    SP_PIR_KEYWORDS ubl conjugation pathway 45 5,0 7,1E-6 3,3E-3    GOTERM_CC_FAT organelle envelope 54 6,0 9,9E-6 4,6E-3    GOTERM_BP_FAT generation of precursor metabolites and energy 34 3,8 1,1E-5 2,7E-2    GOTERM_CC_FAT envelope 54 6,0 1,1E-5 5,0E-3    GOTERM_BP_FAT ribonucleoprotein complex biogenesis 24 2,7 1,1E-5 2,8E-2    GOTERM_BP_FAT ribosome biogenesis 19 2,1 1,4E-5 3,5E-2    GOTERM_BP_FAT rRNA processing 16 1,8 2,2E-5 5,3E-2    GOTERM_CC_FAT organelle membrane 81 9,0 2,3E-5 1,1E-2    GOTERM_BP_FAT aerobic respiration 10 1,1 2,4E-5 5,8E-2    GOTERM_CC_FAT mitochondrion 80 8,9 3,0E-5 1,4E-2    GOTERM_BP_FAT translational initiation 11 1,2 3,3E-5 8,1E-2    GOTERM_BP_FAT rRNA metabolic process 16 1,8 3,6E-5 8,8E-2    GOTERM_MF_FAT translation factor activity, nucleic acid binding 16 1,8 3,9E-5 3,1E-2    GOTERM_BP_FAT cellular respiration 16 1,8 4,1E-5 9,9E-2  
 ME15  Term  Count %  P-Value  Bonferroni     UP_SEQ_FEATURE domain:KRAB 7 7,1 1,7E-3 3,3E-1    INTERPRO Krueppel-associated box 7 7,1 2,0E-3 2,5E-1    SMART KRAB 7 7,1 2,1E-3 7,2E-2  
 ME16  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS phosphoprotein  129 50,4 7,2E-6 1,7E-3    GOTERM_CC_FAT nuclear matrix 6 2,3 5,4E-4 1,3E-1    GOTERM_CC_FAT nuclear periphery 6 2,3 8,0E-4 1,8E-1  
 ME17   Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  100 26,1 2,3E-11 6,6E-9    SP_PIR_KEYWORDS phosphoprotein 186 48,6 1,4E-6 4,0E-4  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_MF_FAT RNA binding 35 9,1 1,5E-6 7,2E-4    SMART HELICc 11 2,9 2,5E-5 2,9E-3    SMART DEXDc 11 2,9 3,2E-5 3,7E-3    UP_SEQ_FEATURE domain:Helicase C-terminal 11 2,9 3,8E-5 3,6E-2    INTERPRO DNA/RNA helicase, C-terminal 11 2,9 5,3E-5 3,0E-2    SP_PIR_KEYWORDS rna-binding 26 6,8 5,6E-5 1,6E-2    SP_PIR_KEYWORDS nucleus 116 30,3 6,0E-5 1,7E-2    INTERPRO DEAD-like helicase, N-terminal 11 2,9 6,3E-5 3,5E-2    SP_PIR_KEYWORDS protein transport 23 6,0 2,1E-4 5,8E-2    INTERPRO Helicase, superfamily 1 and 2, ATP-binding 10 2,6 2,8E-4 1,5E-1    SP_PIR_KEYWORDS helicase 11 2,9 2,8E-4 7,8E-2  
 ME18  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS acetylation  170 37,8 2,9E-39 9,3E-37    SP_PIR_KEYWORDS ribonucleoprotein 54 12,0 2,2E-33 6,9E-31    SP_PIR_KEYWORDS ribosomal protein 46 10,2 4,5E-33 1,4E-30    GOTERM_CC_FAT ribonucleoprotein complex 70 15,6 5,6E-32 1,8E-29    GOTERM_MF_FAT structural constituent of ribosome 43 9,6 6,8E-31 2,8E-28    GOTERM_CC_FAT ribosome 47 10,4 2,5E-30 8,2E-28    GOTERM_BP_FAT translational elongation 35 7,8 6,4E-30 9,4E-27    GOTERM_CC_FAT ribosomal subunit 37 8,2 2,2E-28 7,4E-26    KEGG_PATHWAY Ribosome 34 7,6 3,5E-28 4,3E-26    GOTERM_BP_FAT translation 53 11,8 1,6E-27 2,3E-24    SP_PIR_KEYWORDS ribosome 28 6,2 6,2E-26 2,0E-23    GOTERM_CC_FAT cytosolic ribosome 26 5,8 4,0E-21 1,3E-18    SP_PIR_KEYWORDS protein biosynthesis 33 7,3 4,8E-19 1,5E-16  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT cytosolic part 30 6,7 5,5E-18 1,8E-15    GOTERM_CC_FAT small ribosomal subunit 20 4,4 4,0E-16 1,5E-13    GOTERM_CC_FAT cytosolic small ribosomal subunit 16 3,6 1,4E-14 4,5E-12    SP_PIR_KEYWORDS mitochondrion 56 12,4 1,4E-12 4,4E-10    GOTERM_CC_FAT cytosol 77 17,1 1,6E-12 5,3E-10    GOTERM_CC_FAT large ribosomal subunit 17 3,8 5,0E-12 1,7E-9    GOTERM_MF_FAT structural molecule activity 47 10,4 2,9E-11 1,2E-8    GOTERM_CC_FAT mitochondrion 64 14,2 1,2E-10 3,9E-8    GOTERM_CC_FAT mitochondrial membrane part 20 4,4 2,3E-10 7,5E-8    GOTERM_CC_FAT mitochondrial part 42 9,3 2,6E-9 8,5E-7    GOTERM_CC_FAT non-membrane-bounded organelle 109 24,2 5,0E-9 1,6E-6    GOTERM_CC_FAT intracellular non-membrane-bounded organelle 109 24,2 5,0E-9 1,6E-6    KEGG_PATHWAY Oxidative phosphorylation 20 4,4 1,8E-8 2,2E-6    GOTERM_BP_FAT ribonucleoprotein complex biogenesis 20 4,4 9,3E-8 1,4E-4    SP_PIR_KEYWORDS mitochondrion inner membrane 20 4,4 1,0E-7 3,3E-5    GOTERM_MF_FAT RNA binding 43 9,6 1,3E-7 5,4E-5    KEGG_PATHWAY Alzheimer's disease 21 4,7 1,5E-7 1,9E-5    KEGG_PATHWAY Huntington's disease 22 4,9 1,8E-7 2,2E-5    GOTERM_CC_FAT intracellular organelle lumen 79 17,6 2,0E-7 6,4E-5    GOTERM_BP_FAT RNA processing 36 8,0 2,1E-7 3,1E-4    GOTERM_CC_FAT cytosolic large ribosomal subunit 10 2,2 2,7E-7 9,0E-5    SP_PIR_KEYWORDS mrna splicing 20 4,4 3,6E-7 1,1E-4    SMART Sm 7 1,6 4,3E-7 5,8E-5    GOTERM_BP_FAT mRNA metabolic process 28 6,2 4,4E-7 6,5E-4    KEGG_PATHWAY Parkinson's disease 18 4,0 4,5E-7 5,5E-5  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT organelle lumen 79 17,6 5,0E-7 1,6E-4    GOTERM_BP_FAT RNA splicing 24 5,3 5,4E-7 8,0E-4    GOTERM_CC_FAT membrane-enclosed lumen 80 17,8 5,5E-7 1,8E-4    SP_PIR_KEYWORDS respiratory chain 12 2,7 5,9E-7 1,9E-4    GOTERM_BP_FAT oxidative phosphorylation 14 3,1 7,6E-7 1,1E-3    GOTERM_BP_FAT generation of precursor metabolites and energy 25 5,6 8,3E-7 1,2E-3    GOTERM_CC_FAT mitochondrial membrane 28 6,2 1,8E-6 5,9E-4    GOTERM_CC_FAT mitochondrial envelope 29 6,4 1,9E-6 6,1E-4    INTERPRO Like-Sm ribonucleoprotein, eukaryotic and archaea-type, core 7 1,6 1,9E-6 1,4E-3    GOTERM_CC_FAT mitochondrial ribosome 10 2,2 2,3E-6 7,4E-4    GOTERM_CC_FAT organellar ribosome 10 2,2 2,3E-6 7,4E-4    GOTERM_CC_FAT organelle inner membrane 25 5,6 2,3E-6 7,7E-4    SP_PIR_KEYWORDS mrna processing 21 4,7 2,5E-6 7,9E-4    INTERPRO Like-Sm ribonucleoprotein, core 7 1,6 4,0E-6 2,9E-3    GOTERM_BP_FAT mRNA processing 24 5,3 4,4E-6 6,5E-3    GOTERM_BP_FAT RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 16 3,6 5,4E-6 7,9E-3    GOTERM_BP_FAT RNA splicing, via transesterification reactions 16 3,6 5,4E-6 7,9E-3    GOTERM_BP_FAT nuclear mRNA splicing, via spliceosome 16 3,6 5,4E-6 7,9E-3    SP_PIR_KEYWORDS phosphoprotein 212 47,1 6,6E-6 2,1E-3    GOTERM_MF_FAT hydrogen ion transmembrane transporter activity 12 2,7 1,2E-5 4,9E-3    UP_SEQ_FEATURE transit peptide:Mitochondrion 28 6,2 1,2E-5 1,3E-2    GOTERM_CC_FAT respiratory chain 11 2,4 1,5E-5 5,0E-3    SP_PIR_KEYWORDS transit peptide 28 6,2 1,6E-5 5,0E-3    SP_PIR_KEYWORDS electron transport 12 2,7 1,8E-5 5,7E-3  
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 Module Category Term Count % P-Value Bonferroni    GOTERM_CC_FAT mitochondrial inner membrane 22 4,9 2,5E-5 8,3E-3    GOTERM_CC_FAT mitochondrial respiratory chain 10 2,2 2,6E-5 8,6E-3    GOTERM_CC_FAT organelle membrane 50 11,1 3,5E-5 1,2E-2    GOTERM_CC_FAT mitochondrial proton-transporting ATP synthase complex, coupling factor F(o) 5 1,1 4,2E-5 1,4E-2    GOTERM_BP_FAT ribonucleoprotein complex assembly 10 2,2 4,5E-5 6,4E-2    GOTERM_MF_FAT monovalent inorganic cation transmembrane transporter activity 12 2,7 4,7E-5 1,9E-2    GOTERM_CC_FAT organelle envelope 33 7,3 7,0E-5 2,3E-2    GOTERM_CC_FAT envelope 33 7,3 7,5E-5 2,4E-2    GOTERM_CC_FAT nuclear lumen 60 13,3 7,9E-5 2,6E-2    GOTERM_CC_FAT mitochondrial proton-transporting ATP synthase complex 6 1,3 7,9E-5 2,6E-2  
 ME19  Term  Count %  P-Value  Bonferroni     SP_PIR_KEYWORDS ribonucleoprotein  13 17,6 4,9E-10 7,3E-8    GOTERM_MF_FAT structural constituent of ribosome 10 13,5 8,9E-9 1,4E-6    SP_PIR_KEYWORDS ribosomal protein 10 13,5 3,4E-8 5,0E-6    GOTERM_CC_FAT ribonucleoprotein complex 14 18,9 1,5E-7 2,0E-5    GOTERM_CC_FAT ribosome 10 13,5 2,5E-7 3,3E-5    GOTERM_BP_FAT translation 11 14,9 6,2E-7 4,0E-4    GOTERM_CC_FAT cytosol 20 27,0 9,7E-7 1,3E-4    GOTERM_CC_FAT ribosomal subunit 8 10,8 1,0E-6 1,4E-4    GOTERM_BP_FAT translational elongation 7 9,5 2,9E-6 1,8E-3    SP_PIR_KEYWORDS acetylation 26 35,1 5,2E-6 7,8E-4    SP_PIR_KEYWORDS ribosome 6 8,1 7,9E-6 1,2E-3    GOTERM_CC_FAT cytosolic ribosome 6 8,1 2,2E-5 2,9E-3    GOTERM_CC_FAT cytosolic part 7 9,5 4,1E-5 5,4E-3  
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 Module Category Term Count % P-Value Bonferroni    KEGG_PATHWAY Ribosome 6 8,1 9,4E-5 6,2E-3    GOTERM_CC_FAT large ribosomal subunit 5 6,8 1,8E-4 2,3E-2    GOTERM_MF_FAT structural molecule activity 10 13,5 4,5E-4 6,7E-2                   
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Appendix 7. ME1 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this network. No significant gene ontology was detected in this network.  Genes ATP5D (ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Delta Subunit) and TAF10, an RNA Polymerase are representing hub genes as they have the bigger number of connections. ATP5D produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain.. 
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Appendix 8. ME2 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkGene ontology analysis suggest the that this cluster is mainly composed by intracellular proteins (P-value=2,0 x 10-26) playing a role in alternative splicing (p-value=1,0 x 10-12).           
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Appendix 9. ME3 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThe main function enriched by genes in this network correspond to acetylation (p-value=1.6 x 10-4).  NHP2, the main hub gene, is a ribonucleoprotein required for ribosome biogenesis and telomere maintenance.. It is also part of the H/ACA small nucleolar ribonucleoprotein (H/ACA snoRNP) complex, which catalyzes pseudouridylation of rRNA.           
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Appendix 10. ME4 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThis network is modestly associated with DNA damage (p-value=3.3 x 10-2) and endodeoxyribonuclease activity (p-value=4.6 x 10-2).  The ME4 module showed a poor correlation between Module Membership values and Intramodular connectivity.  That is reflected in the fact that many of the proteins are not connected to a main core.            
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Appendix 11. ME5 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThe biological role of genes in this module are acetylation processes (p-value=1.4 x 10-3)  carried out by phosproteins (p-value=8.1 x 10-4).  The Small Ubiquitin-Like Modifier 2 (SUMO2) gene is a  ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction.  
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Appendix 12. ME6 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThis cluster is enriched by genes enconding  phosphoproteins (p-value=8.3 x 10-3)   from the nucleoplasm (p-value=1.1 x 10-2) .   
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Appendix 13. ME7 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this network Multiple terms were enriched in this cluster.  The majority of proteins seem to be phosphoproteins (p-value=3.6 x 10-15).  Among the functions are defense response (p-value=6.2 x 10-6) and endocytosis (p-value=6.5 x 10-4).  This is one of the most well correlated cluster detected in the Norfolk Island population  
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Appendix 14. ME8 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkGenes in this cluster are mainly proteins involved in mRNA splicing (p-value=6. x 10-8) with acetylation (p-value=1.4  x 10-34)   and phosphorylation activities (p-value=1.1  x 10-30).   
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Appendix 15. ME9 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThe biological activities in this cluster includes acetylation (P-value=3.3  x 10-20).  and RNA binding (p-value=2.2  x 10-8).  .  The gene ontology analysis also suggest that the location of this proteins is in the nuclear lumen (p-value=3.1  x 10-8).   
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Appendix 16. ME9 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkAlthough no specific function was identified for this module, these proteins seem to be localize in the mitochondria (p-value=2.6  x 10-2).   
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Appendix 17. ME9 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkSimilar to the ME9 network, proteins in this module also localize at the mitochondria.  It is important to note that this module had a high correlated to the grey cluster , where all genes that could not be assigned to any of the clusters group together.   
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Appendix 18. ME12 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this network Gene ontology analysis indicates the presence of blood group antigens (p-value=4.3  x 10-4) and haemoglobin complex (P-value=2.4  x 10-3).   proteins in this cluster.   
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Appendix 19. ME14 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this network Acetylation (P-value=4.2  x 10-49)  and phosphoprotein (p-value=4.7  x 10-26) protein activities enriched in this cluster.  Additionally  RNA binding (p-value=3.1  x 10-8) and processing (P-value=1.2  x 10-6) are part of the biological functions of this group of genes.   
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Appendix 20. ME15 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkThis cluster did not present any significant results after the gene ontology analysis  
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Appendix 21. ME16 Network. This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this network Only phosphoproteins showed to enriched this cluster  The ATP-Binding Cassette Sub-Family E (ABCE1) gene, clearly a hub gene, antagonizes the binding of 2-5A (5'-phosphorylated 2',5'-linked oligoadenylates) by RNase L through direct interaction with RNase L and therefore inhibits its endoribonuclease activity. It may play a central role in the regulation of mRNA turnover.  Another hub gene in this network is the Proteasome (Prosome, Macropain) Subunit, Alpha Type, 2 (PSMA2) gene which have a potential regulatory effect on the proteasome complex through tyrosine phosphorylation. 
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Appendix 22. ME18 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkGenes in this network are structural constituent of the ribosome (p-value=2.8  x 10-28) therefore the functional biological role is the protein translation (p-value=2.3  x 10-24) 
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Appendix 23. ME19 Network.  This figure summarizes the network of predicted associations for a particular group of proteins. The network nodes are proteins and their predicted structure is shown in the middle of each node. A confidence view where stronger associations are represented by thicker lines is presented in this networkProteins in this module are similar to the proteins in the ME18 cluster, which is not surprising as in the eigengene clustering tree they are next to each other, indicating similarities in patterns of expression.  Ribonucleoprotein (p-value=7.3  x 10-8) and structural constituent of ribosome (p-value=1.4  x 10-6) are the most significant outputs from the gene ontology analysis.       
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